 
A Multi -Center, Phase III, Randomized Trial of Reduced Intensity (RIC) 
Conditioning and Transplantation of Double Unrelated Umbilical Cord 
Blood (dUCB) versus HLA -Haploidentical Related Bone Marrow (Haplo) for 
Patients with Hematologic Malignancies  
 
(Posted on clinincaltrials.gov as [STUDY_ID_REMOVED])  
EudraCT 2013- 004536- 28 
 
BMT CTN PROTOCOL 1101  
VERSION 8.0 
 
Study Chairpersons  
Ephraim Fuchs, M.D.1; Paul O’Donnell, M.D., Ph.D.2; Claudio Brunstein, M.D.3 
 
Protocol Team  
Omar Aljitawi, M.D.4  
Joseph Antin, M.D.5 
Karen Ballen, M.D.6  
Kate B ickett7 
Achintya Jaitly7 
Luciano Costa, M.D.8  
Corey Cutler, M.D., M.P.H.5 
Peter Dawson , Ph.D.7 
Steven Devine, M.D.9 
Nahed El Kasser, M.D., Ph.D.15 Mary Eapen, M.D.10 
Mary Horowitz, M.D., M.S.10 
Javier Bolaños Meade, M.D.1  
Adam Mendizabal, Ph.D. 7  
Chatchada Karanes, M.D.11 
Brent Logan, Ph.D.10 
Rachel Salit, M.D.14 
Elizabeth Shima Rich, M.D., Ph.D.12 
John Wingard, M.D.13 
Jamie Garrison, M.S.7 
 
Sponsored by the National Institutes of Health  
National Heart, Lung, and Blood Institute  
National Cancer Institute  
 
_________________________________________   ___________________________________________   
Approval Signature (Protocol Chair/Officer)    Approval Signature (Protocol Chair/Officer ) 
1 Johns Hopkins University  
2 Massachusetts General Hospital Cancer Center  
3 University of Minnesota  
4 University of Rochester Medical Center  
5 Dana Farber Cancer Institute  
6 University of Virginia 
7 The Emmes  Corporation  8 University of Alabama at Birmingham  
9 Ohio State University  
10 CIBMTR, Medical College of Wisconsin  
11 City of Hope National Medical Center  
12 Astellas Pharma Global Development  
 13 University of Florida College of Medicine  
14  Fred Hutchinson Cancer Research Center  
 15 National Heart, Lung and Blood Institute  

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
i Core Study Participants : Affiliate  Study Participants : 
Blood & Marrow Transplant Program at 
Northside Hospital  
Case Western Reserve University Consortium  
   - University Hospitals of Cleveland/Case   
        Western  
   - Cleveland Clinic  
   - West Virginia University  
City of Hope National Medical Center  
Dana Farber Cancer Institute 
   - Brigham & Women’s Hospital  
   - Massachusetts General Hospital  
Duke University Medical Center  
Fred Hutchinson Cancer Research Center  
Johns Hopkins University Ohio State Consortium  
   - Ohio State/Arthur G. James Cancer    
        Hospital  
   - Roswell Park  
   - University of North Carolina  
   - Virginia Commonwealth University, MCV    
        Hospital  
Stanford Hospital and Clinics  
University of Florida Consortium  
   - University of Flori da College of Medicine  
   - Emory University  
University of Michigan Consortium  
   - University of Michigan Medical  Center  
   - Mayo Clinic, Rochester  
   - Mount Sinai   
University of Minnesota  
University of Nebraska Consortium  
   - University of Kansas  
University of Pennsylvania  
University of Texas, MD Anderson Cancer 
Center  
 Florida Hospital Cancer Institute  
Jewish Hospital  
Karmanos Cancer Center  
Penn State College of Medicine  
Spectrum Health/West Michigan  
Stony Brook Medical Center   
University of Alab ama at Birmingham  
University of California, Los Angeles  
University of Oklahoma  
University of Rochester Medical Center  
University of Virginia  
Weill Cornell Medical College  
  
 
 
 
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
ii PROTOCOL SYNOPSIS – BMT CTN 1101 
 
A M ulti-Center, Phase III, Randomized Trial of Reduced Intensity  (RIC) Conditioning and 
Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA -
Haploidentical Related Bone Marrow  (haplo -BM)  for Patients with Hematologic 
Malignancies  
 
 
Principal Investigators : Ephraim Fuchs, M.D., Paul O’Donnell, M.D., Ph.D., Claudio 
Brunstein, M.D.  
 Study Design:  This study is a multi -center, Phase III, ran domized trial of reduced 
intensity conditioning followed by transplantation of two unrelated cord blood units with calcineurin inhibitor and mycophenolate mofetil (MMF) for GVHD prophylaxis versus HLA -haploidentical 
related bone marrow with posttransplant cyclophosphamide, calcineurin inhibitor , and MMF for GVHD prophylaxis in patients 
with: 1) Acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia,  dendritic cell leukemias, natural killer cell 
malignancies  or Burkitt’s lymphoma in remission.  
2) Lymphoma, including marginal zone lymphoma, follicular 
lymphoma, or chemotherapy -sensitive large -cell, Hodgkin or 
mantle cell lymphoma , enteropathy -associated T cell 
lymphoma, or hepatosplenic gammadelta T cell lymphoma .  
 
Primary Objective:   The primary objective is to compare progression- free-survival at 2 
years post -randomization between patients who receive unrelated 
double cord blood unit transplantation versus HLA -haploidentical 
related bone marrow transplantation . 
 
Secondary Objectives : Patients enr olled in this study will also be followed for the 
following endpoints: neutrophil recovery, graft failure, platelet 
recovery, donor cell e ngraftment, acute graft -versus -host-disease 
(GVHD) and chronic GVHD, overall survival, treatment -related  
mortality, in fections, hospital admission and length of stay, health 
related quality of life, relapse/progression, and cost effectiveness 
(see companion 1101 study document for ancillary cost effectiveness protocol) .   
 
Accrual Objective:   The target sample size is 410 patients.  
 Accrual Period : The target accrual period is 4 years.   
 
Eligibility Criteria : Patients  > 18 and ≤ 70 years of age with a diagnosis of a 
hematologic malignancy with two partially HLA -matched UCB 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
iii units , each with a minimum of 1.5 x 107/kg pre -cryopreserved total 
nucleated cell dose ( for non-red blood cell depleted units, the 
minimum cryopreserved total nucleated cell dose of each unit must 
be at least 2.0  x 107/kg), and a partially HLA -mismatched related 
donor.   
 
Adequate organ functio n defined as: 1) left ventricular ejection 
fraction ≥ 40%; 2) DLCO, FEV 1, FVC > 50% predicted; 3) total 
bilirubin ≤ 2.5 mg/d L except for patients with Gilbert’s syndrome  
or hemolysis , and ALT,  AST, and alkaline phosphatase all < 5 x 
upper limit of normal ( ULN); 4) serum creatinine within normal 
range, or if serum creatinine outside normal range, must have measured or estimated creatinine clearance > 40 mL/min/1.73m
2; 
5) Karnofsky performance score ≥ 70; and 6) if applicable, > 6 
months since a previous autologous transplant.  
 Treatment Description:  Eligible patients will be randomized to dUCB or haplo- BM 
transplantation:  
The preparative regimen for haplo -BM transplantation will consist 
of:  
- Fludarabine 30 mg/m
2 IV Days –6, –5, –4, –3, – 2 
- Cyclophosphamide (Cy) 14.5 mg/kg IV Days –6, –5 
- Total body irradiation (TBI) 200cGy Day –1  
- Day 0 will be the day of infusion of non- T-cell depleted bone 
marrow  
The GVHD prophylaxis regimen for haplo- BM transplantation will 
consist of:  
- Cy 50 mg/kg IV Days 3, 4 
- Tacrolimus (IV or po) beginning Day 5 with dose adjusted to 
maintain a  trough level of 5 -15 ng/mL .  Cyclosporine ( trough  
level of  200-400 ng/ mL) may be substituted for tacrolimus if 
the patient is intolerant of tacrolimus or per in stitutional 
practice.  
- Mycophenolate mofetil (MMF) 15 mg/kg po TID , maximum 
dose 1 g po TID beginning Day  5 until Day 35  
Supportive care for haplo -BM transplantation includes:  
- Filgrastim (G -CSF) 5 mcg/kg/day beginning Day 5 until 
ANC >1500/mm3 for 3 consecutive measurements on at least 
two different days  
The preparative regimen for dUCB transplantation will consist of:  
- Fludarabine 40 mg/m2 IV Days –6, –5, –4, –3, – 2 
- Cyclophosphamide 50 mg/kg IV Day –6  
- Total Body Irradiation (TBI)  
- 200 c Gy Day –1 for p atients who have received cytotoxic  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
iv chemotherapy with in the last 3 months  or an  autologous 
transplant within 24 months  of enrollment   
- 300 cGY Day - 1 for patients who have not received 
cytotoxic chemotherapy within 3 months of enrollment or  an 
autologous transplant  within 24 months of enrollment  
- Day 0 will be the day of the double UCB transplant  
The GVHD prophylaxis regimen for dUCB transplantation will 
consist of:  
- Cyclosporine beginning Day –3 with dose adjusted to 
maintain a  trough level of 200- 400 ng/mL .  Tacrolimus 
(trough level of 5 -15 ng/mL) may be substituted for 
cyclosporine if the patient is intolerant of cyclosporin e or per 
institutional practice.  
- Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum 
dose 1 g po TID beginni ng Day -3 until Day 35.  
Supportive care for dUCB transplantation includes:  
- Filgrastim (G -CSF) 5 mcg/kg/day beginning Day 1 until 
ANC >1500/mm3 for 3 consecutive measurements on at least 
two different days  
 Study Duration : Patients will be followed for three  years after transplantation .  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
v TREATMENT SCHEMA  
 
 
  Patient ≥ 18 and ≤70 yrs.  
Acute leukemia or lymphoma  
Available both  
1) 4-6/6 HLA -matched 
UCB units  
2) 4-6/8 HLA matched 
related donor  
Adequate organ function  
Performance score ≥70  
Double UCB  Haplo -BM Randomization  
Stratified by Transplant Center  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
vi TABLE OF CONTENTS  
 
1. BACKGROUND AND RATIO NALE  ............................................................................ 1 
1.1. Background  ....................................................................................................................... 1 
2. STUDY DESIGN ............................................................................................................ 2-1 
2.1. Study Overview  .............................................................................................................. 2-1 
2.1.1.  Hypotheses and Specific Objectives  ................................................................................ 2-1 
2.1.1.1.  Hypotheses  ................................................................................................................ 2-1 
2.1.1.2.  Study Objectives  ....................................................................................................... 2-1 
2.2. Eligibility Criteria for Enrollment and Randomization ............................................. 2-1 
2.2.1.  Patient Inclusion Criteria  ................................................................................................. 2-1 
2.2.2.  Patient Exclusion Criteria  ................................................................................................ 2-3 
2.3. Additional Patient Eligibility Criteria for Conditioning  ............................................ 2-3 
2.3.1.  Patients with Adequate Physical Function as Measured by ............................................. 2-3 
2.3.2.  Additional Patient Inclusion Criteria for Patients Assigned to Haploidentical BM Arm  2-4 
2.3.3.  Additional Patient Inclusion Criteria for Patients Assigned to Double Umbilical Cord 
Blood Arm  ....................................................................................................................... 2-4 
2.3.4.  Additional Patient Exclusion Criteria  .............................................................................. 2-4 
2.4. Donor Selection for Haploidentical -BM ...................................................................... 2-5 
2.4.1.  Donor Inclusion Criteria  .................................................................................................. 2-5 
2.4.2.  Donor Prioritization Schema ............................................................................................ 2-5 
2.5. Graft Selection for Double Umbilical Cord Units  ....................................................... 2-5 
2.6. Treatment Plans  ............................................................................................................. 2-6 
2.6.1.  Treatment Plan for Patients Randomized to Haplo -BM .................................................. 2-6 
2.6.1.1.  Fludarabine  ............................................................................................................... 2-7 
2.6.1.2.  Pre-transplantation cyclophosphamide  ..................................................................... 2-7 
2.6.1.3.  Total body irradiation (TBI)  ..................................................................................... 2-7 
2.6.1.4.  Transplantation of haplo- BM ................................................................................... 2-7 
2.6.1.5.  Post-transplantation cyclophosphamide  ................................................................... 2-8 
2.6.1.6.  Immunosuppressive therapy  ..................................................................................... 2-8 
2.6.1.7.  Tacrolimus  ................................................................................................................ 2-8 
2.6.1.8.  Mycophenolate mofetil (MMF)  ................................................................................ 2-8 
2.6.1.9.  Growth factor support  ............................................................................................... 2-9 
2.6.2.  Treatment Plan Selection for Patients Randomized to dUCB  ......................................... 2-9 
2.6.2.1.  Fludarabine  ............................................................................................................. 2-10 
2.6.2.2.  Cyclophosphamide  ................................................................................................. 2-10 
2.6.2.3.  Total body irradiation (TBI)  ................................................................................... 2-10 
2.6.2.4.  Cyclosporine A  ....................................................................................................... 2-11 
2.6.2.5.  Mycophenolate mofetil (MMF)  .............................................................................. 2-11 
2.6.2.6.  UCB infusion .......................................................................................................... 2-11 
2.6.2.7.  Growth factor support  ............................................................................................. 2-12 
2.7. Additional Supportive Care  ........................................................................................ 2-13 
2.7.1.  Post Transplant Maintenance Therapy  ........................................................................... 2-13 
2.7.2.  Infection Prophylaxis  ..................................................................................................... 2-13 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
vii 2.7.3.  Transfusion Support  ....................................................................................................... 2-13 
2.7.4.  Indwelling Central Venous Catheter  .............................................................................. 2-13 
2.7.5.  Pre-infusion Medication and Hydration Regimen  ......................................................... 2-13 
2.7.6.  Anti-Ovulatory Treatment  ............................................................................................. 2-13 
2.7.7.  Management of Slow Engraftment and Graft Failure .................................................... 2-13 
2.8. Risks and Toxicities  ..................................................................................................... 2-14 
2.9. Health -Related Quality of Life Assessments  ............................................................. 2-15 
2.9.1.  Instruments  ..................................................................................................................... 2-15 
2.9.2.  Administration  ............................................................................................................... 2-16 
3. STUDY ENDPOINTS  .................................................................................................... 3-1 
3.1. Primary  Endpoint  .......................................................................................................... 3-1 
3.2. Secondary Endpoints  ..................................................................................................... 3-1 
3.2.1.  Neutrophil Recovery  ........................................................................................................ 3-1 
3.2.2.  Primary Graft Failure  ....................................................................................................... 3-1 
3.2.3.  Secondary Graft Failure  ................................................................................................... 3-1 
3.2.4.  Platelet Recovery  ............................................................................................................. 3-1 
3.2.5.  Donor Cell Engraftment  ................................................................................................... 3-1 
3.2.6.  Acute GVHD  ................................................................................................................... 3-2 
3.2.7.  Chronic  GVHD  ................................................................................................................ 3-2 
3.2.8.  Overall Survival  ............................................................................................................... 3-2 
3.2.9.  Treatment -Related Mortality (TRM)  ............................................................................... 3-2 
3.2.10.  Infections .......................................................................................................................... 3-2 
3.2.11.  Hospital Admission and Length of Stay  .......................................................................... 3-2 
3.2.12.  Health -Related Quality of Life (HQL)  ............................................................................ 3-2 
3.2.13.  Relapse, Residual Disease and Disease Progression  ....................................................... 3-3 
3.2.14.  Cost-effectiveness Analysis  ............................................................................................. 3-5 
4. PATIENT ENROLLMENT A ND EVALUATION .................................................... 4-1 
4.1. Enrollment Procedures  .................................................................................................. 4-1 
4.1.1.  Screening and Eligibility Procedures  ............................................................................... 4-1 
4.2. Study Monitoring and Data Submission ...................................................................... 4-1 
4.2.1.  Follow -up Schedule  ......................................................................................................... 4-1 
4.2.2.  Criteria for Forms Submission  ......................................................................................... 4-2 
4.2.2.1.  Electronic Case Report Forms (eCRFs)  ................................................................... 4-2 
4.2.2.2.  Access to Data  .......................................................................................................... 4-3 
4.2.2.3.  Record Retention  ...................................................................................................... 4-3 
4.2.3.  Study Monitoring ............................................................................................................. 4-3 
4.2.4.  Adverse Events  ................................................................................................................ 4-4 
4.2.4.1.  Adverse Event Reporting .......................................................................................... 4-4 
4.2.4.2.  Adverse Event Monitoring ....................................................................................... 4-5 
4.2.4.3.  Adverse Event Definitions  ........................................................................................ 4-8 
4.2.5.  Patient Assessments  ......................................................................................................... 4-9 
4.2.5.1.  Pre-transplant evaluations  ......................................................................................... 4-9 
4.2.5.2.  Post-transplant evaluations  ..................................................................................... 4-11 
5. STATISTICAL CONSIDERATIONS  ......................................................................... 5-1 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
viii 5.1. Study Design and Objectives ......................................................................................... 5-1 
5.1.1.  Accrual  ............................................................................................................................. 5-1 
5.1.2.  Randomization  ................................................................................................................. 5-1 
5.1.3.  Primary Endpoint  ............................................................................................................. 5-1 
5.1.4.  Primary Hypothesis  .......................................................................................................... 5-1 
5.2. Sample Size and Power Considerations  ....................................................................... 5-1 
5.3. Interim Analysis and Stopping Guidelines  .................................................................. 5-2 
5.3.1.  Interim Analysis for Efficacy and Futility  ....................................................................... 5-2 
5.3.2.  Guidelines for Safety Monitoring .................................................................................... 5-5 
5.4. Demographic and Baseline Characteristics  ................................................................. 5-6 
5.5. Analysis Plan  .................................................................................................................. 5-6 
5.5.1.  Analysis of the Primary Endpoint  .................................................................................... 5-6 
5.5.2.  Analysis of Secondary Endpoints  .................................................................................... 5-7 
5.5.2.1.  Secondary analysis of PFS ........................................................................................ 5-7 
5.5.2.2.  Overall survival  ........................................................................................................ 5-7 
5.5.2.3.  Treatment -related mortality  ...................................................................................... 5-7 
5.5.2.4.  Relapse/progression  .................................................................................................. 5-8 
5.5.2.5.  Hematologic recovery  ............................................................................................... 5-8 
5.5.2.6.  Donor cell engraftment  ............................................................................................. 5-8 
5.5.2.7.  Acute GVHD of grades II -IV and III -IV .................................................................. 5-8 
5.5.2.8.  Chronic GVHD  ......................................................................................................... 5-8 
5.5.2.9.  Incidence of prim ary graft failure  ............................................................................. 5-8 
5.5.2.10.  Incidence of secondary graft failure  ......................................................................... 5-9 
5.5.2.11.  Incidence of toxicities grade ≥  3 per CTCAE version 4.0 ........................................ 5-9 
5.5.2.12.  Incidence of infections  .............................................................................................. 5-9 
5.5.2.13.  Hospital admission and length of stay  ...................................................................... 5-9 
5.5.2.14.  Health -Related Quality of life  .................................................................................. 5-9 
5.6. Subgroup Analysis  ......................................................................................................... 5-9 
6. ETHICS AND REGULATORY  ................................................................................... 6-1 
6.1. Good Clinical Practice Guidelines  ................................................................................ 6-1 
6.1.1.  Patient Consent  ................................................................................................................ 6-1 
6.1.2.  Patient Withdrawal........................................................................................................... 6-1 
6.1.2.1.  Patient withdrawal from intervention  ....................................................................... 6-1 
6.1.2.2.  Patient withdrawal from data collection  ................................................................... 6-1 
6.1.2.3.  Patient Removal From Study  .................................................................................... 6-1 
6.1.3.  Confidentiality  ................................................................................................................. 6-2 
6.1.4.  Participation of Women and Minorities  ........................................................................... 6-2 
6.2. Protocol Amendments  ................................................................................................... 6-2 
6.3. Protocol Deviations  ........................................................................................................ 6-3 
6.4. Premature Termination of the Trial  ............................................................................ 6-3 
6.5. Publication Policy ........................................................................................................... 6-3 
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
ix LIST OF APPENDICES  
 
APPENDIX A  ABBREVIATIONS  
APPENDIX B  INFORMED CONSENTS  AND DONOR ASSENT  
APPENDIX C  LABORATORY PROCEDURES  
APPENDIX D  APPROVED CYTOTOXIC CHEMOTHERAPY REGIME NS 
APPENDIX E  REFERENCES  
 
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-1 CHAPTER 1  
 
 
1. BACKGROUND AND RATIO NALE  
 1.1. Background  
 
Reduced intensity conditioning ( RIC) blood or marrow transplantation (BMT) has allowed older 
and less clinically fit patients to recei ve potentially curative treatment with allogeneic BMT for 
high risk or advanced hematological  malignancies .
1, 2, 3, 4
, 5  Patients lacking an HLA -matched 
sibling may receive a graft from a suitably HLA -matched unrelated donor.  However, up to a 
third of patients will not have an HLA -matched sibling  or a suitably  matched adult unrelated 
donor (i.e., no more than a mismatch at a single locus).  Even when a suitably matched unrelated 
donor is identified, data from the National Marrow Donor Program (NMDP) indicate that a 
median of four months is required to complete searches that result in transplantation ; thus, some 
number of patients succumb to their disease while awaiting identification and evaluation of a 
suitably matched adult unrelated donor.6  
 Single or dual  center studies have shown that partially HLA -mismatched related bone marrow 
(haplo- BM) and unrelated double umbilical cord blood (dUCB) are valuable sources of donor 
cells for RIC  BMT, thus extending this treatment moda lity to patients who lack other  donors.
7, 8, 
9, 10, 11, 12  In order to study the reproducibility, and thus, the wider applicability of these two 
alternative donor strategies, The Blood and Marrow Transplantation Clinical Trials Network (BMT CTN) conducted tw o parallel multicenter prospective phase II clinical trials.  These two 
studies evaluated the safety and efficacy of related haplo -BM ( BMT CTN 0603) and dUCB 
(BMT CTN 0604) 
transplantation after RIC .  
Eligibility criteria for the two trials were the same and included patients up to 70 years with: poor -risk acute 
leukemia or Burkitt lymphoma in remission, Hodgkin lymphoma, mantle cell lymphoma, or aggressive non-Hodgkin lymphoma in sensitive relapse, or multiply relapsed marginal zone or follicular lymphoma .  The 
target accrual of 50 patients per trial was achieved  in just 
20 months (16 months faster than expected).  The primary 
objective was to determine overall survival (OS) 180 days after BMT, with examination of : 
neutrophil and platelet recovery, graft failure, acute GVHD, chronic GVHD, incidence of 
 
Figure 1.  Schemas for non- myeloablative conditioning and transplantation 
of either double unrelated umbilical cord blood (A) or HLA -haploidentical 
related d onor bone marrow (B).  

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-2 infection, treatment- related mortality (TRM), time to relapse/progression, and current 
progression- free survival (PFS).  
 
Figure 1 shows the schemata for re duced i ntensity  conditioning ( RIC) and transplantation of 
either dUCB or haplo- BM grafts .  Recipients of dUCB grafts were conditioned with fludarabine 
(Flu) 40 mg/m2/day intravenously (IV) from Days -6 to - 2 (total dose of 200 mg/m2), 
cyclophosphamide (Cy)  50mg/kg IV on D ay -6, and 2 Gy total body irradiation (TBI) in a single 
fraction on D ay -1 (Figure 1A).  Graft -versus -host disease (GVHD) prophylaxis included 
mycophenolate mofetil (MMF) and cyclosporine A (CsA), with tacrolimus as an acceptable 
substitut ion for CsA.  Filgrastim 5 mcg /kg/day  was initiated on D ay 1 and continued until the 
absolute neutrophil count 
(ANC) was ≥2,000/ µL for 3 
consecutive days.  
 
Recipients of haplo- BM were 
conditioned with Flu 30 
mg/m2/day IV daily from D ays 
-6 to - 2 (total dose of 150 
mg/m2), Cy 14.5 mg/kg IV on 
Day -6 and - 5, and 2 Gy TBI in 
a single fraction on D ay -1 
(Figure 1B).  GVHD prophylaxis consisted of Cy 50 mg/kg IV on D ays 3 and 4 
followed by MMF and tacrolimus beginning on Day 5, 
with CsA as an acceptable subst itution for tacrolimus.  
Filgrastim 5 mcg /kg/day  was 
initiated on post -transplantation 
Day 5 and continued until the 
ANC was ≥ 1000/ µL for three 
consecutive days.  
 
Patient and graft characteristics   
 
Characteristics of the patients enrolled in the two trials are summarized in Table 1  (BMT CTN 
0603 and 0604) .  Fifty -four patients were registered on the dUCB trial but  4 of these patients  
were not treated according to protocol and excluded from the analysis; one withdrew consent, and three had  disease relapsed/progression.  Accrual occurred between January 2009 and March 
2010.  Among recipients of dUCB transplantation the  median combined nucleated cell dose at 
the time of cryopreservation was 5.0 x  10
7/kg and at infusion, 4.2 X 107/kg.  Donor -recipient 
HLA disparity was assigned based on the more highly mismatched of the two dUCB unit s; 
33 donor -recipient pairs were categorized as  4/6 matches , 14 pairs  as 5/6, and 3 pairs  as 
6/6 HLA -matched.  Matching criteria used intermediate resolution typing at HLA -A and  B with 

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-3 high resolution typing at HLA -DRB1.  Cord blood units for  35 donor -recipient pairs (70%) were 
mismatched to each other at two HLA loci.  
 
Fifty -five patients were registered on the haplo -BM trial, but five were not treated according to 
the protocol  and excluded from the analysis; one withdrew consent, two were found to have 
disease relapsed/progression, and two were not eligible for the protocol.  Accrual occurred between December 2008 and May 2010.  Seventeen donors were siblings of the recipient, 15  
were parents and 18 were children.  More than three quarters of the HLA -haploidentical related 
donors were mismatched for four or more HLA loci using high- resolution typing (HLA -A, -B, -
C, -DRB1, and – DQB1) in both the graft -versus -host and host -versus -graft directions (not 
shown).   Hematopoietic Recovery and Chimerism  
 
After dUCB transplantation, the cumulative incidence of neutrophil recovery >500/µL at Day 56 
was 94% (95%CI, 87- 100%) with a 
median time to recovery of 15 days (range, 4 -47).  The cumulative 
incidence of platelet recovery, ≥ 
20,000/µL at Day 100 was 82% 
(95%CI, 71- 93%) with a median time to 
recovery of  38 days (range, 3- 87).  The 
corresponding probability for platelets ≥ 50,000/µL was 59% (95%CI, 44 -73%) 
with a median time to recovery of 43 
days (range, 29- 323).  There were five 
cases of primary graft failure and one secondary graft failure.  Three graf t 
failure patients died at D ays 23, 28, and 
193 (after second dUCB transplant).  
Two patients had autologous reconstitution and died of relapse at Day 99 and 117.  The patient with 
secondary graft failure was determined to have lost chimerism at D ay 183, had 
leukemia relapse at D ay 330, and died 
at Day 347.  Median donor chimerism in marrow or peripheral blood was 92% (range, 0- 100%) 
on Day 28 and 100% (range, 25 -100%) on D ay 56 after transplantation (not shown).  In BMT 
CTN 0604, we only enrolled patients who had received immune suppressive chemotherapy within 3 months of enrollment .  Earlier pilot data suggested that for patients who had not 
received chemotherapy within 4 months of a planned dUCB transplant with a regimen of similar 
intensity as described in BMT CTN 0604, graft failure rates were as  high as 35% (University of 
Minnesota, unpublished data) .  
  
Figure 2.  Acute (A,C) or chronic (B,D) g raft-
versus -host disease after RIC and transplantation of 
dUCB (A ,B) or Haplo -marrow (C,D ) 
 

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-4 Recent data from the Fred Hutchinson Cancer Research Center ( FHCRC)  demonstrated that 300 
cGy, instead of 200 cGy, is able to overcome this engraftment barrier with no obvious adverse 
effect on other outcomes .13,14 
 
After haplo- BM the cumulative incidence of neutrophil recovery >500/µL at Day 56 was 96% 
(95%CI, 90- 100%) wit h a median time to recovery of 16 days (range, 12 -83).  The cumulative 
incidence of platelet recovery ≥ 20,000/ µL at Day 100 was 98% (95%CI, 93- 100%) with a 
median time to recovery of 24 days (range, 1- 92).  The corresponding probability for platelets  
≥ 50,000/µL was 76% (95%CI, 64- 88%) with a median time to recovery of 26 days (range, 1-
126).  There was one case of primary graft failure.  This patient did not receive a second 
transplant and died on Day 67.  Median donor chimerism in marrow or peripheral blood was 
100% (range 72- 100%) on Day 28 and 100% (range 0- 100%) on D ay 56 after transplantation 
(not shown).  
 Graft -versus -host disease  
 After dUCB transplantation, the cumulative incidences of grade II -IV and III -IV acute GVHD at 
Day +100 were 40% (95% C I, 26 -54%) and 21% (95% CI, 6 -37%), respectively (Figure 2A).  
The cumulative incidence of chronic GVHD at 1 year was 25% (95% CI, 12- 39%; Figure 2B).   
 After haplo -BM transplantation , the cumulative incidence of grade II -IV acute GVHD at Day 
+100 were 32% (95% CI, 19 -45%; Figure 2C).  There were no reported cases of grade III -IV 
acute GVHD.  The cumulative incidence of chronic GVHD at 1 year was 13% (95% CI, 3- 23%; 
Figure 2D).  
 Treatment -Related -Mortality, Relapse, and Survival  
 After dUCB transplantation, the median follow -up of surviving patients was 365 days (range, 56-
411 days).  The 1- year cumulative incidence of TRM  was 24% (95% CI, 11- 36%) and of 
relapse/progression was 31% (95% CI, 17- 44%; Figure 3A).  Twenty -one patients (42%) have 
died: 10 from relapse, 4 from acute or chronic GVHD, 3 from graft failure, 1 from infection, and 3 from other causes.  Six-month survival, which was the primary endpoint, was 74% (95% CI, 
59-84%).  The 1 -year probability of progression- free surv ival was 46% (95% CI, 31- 60%) and 
overall survival 54% (95% CI, 38 -67%; Figure 4B).  
 After haplo -BM, the median follow -up of surviving patients was 357 days (range 103- 441).  The 
1-year cumulative incidence of TRM  was 7% (95% CI, 0 -15%) and of relapse/prog ression was 
45% (95% CI, 30- 61%; Figure 4C).  Sixteen patients have died: 13 from relapse, 2 from 
infection, and 1 from graft failure.  Six-month survival, which was the primary endpoint, was 
84% (95%CI, 70- 92%).  The 1 -year probability of progression- free survival was 48% (95% CI, 
32-62%) and overall survival 62% (95% CI, 44- 76%; Figure 4D).  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-5 These early res ults of the RIC 
followed by haploidentical related 
(0603) or double UCB (0604)  
transplantation in multicenter 
Phase II t rials are quite 
encouraging.  Importantly, in this 
cooperative  group setting (17 
different centers entered patients 
on the haploidentical trial and 16 
on the UCB trial), both of these 
alternative donor approaches 
produced early results similar to that reported with unrelated donor , and even HLA -matched 
sibling, BMT 1.  These data 
demonstrate not only the efficacy of both of these approaches, but also that both can be safely exported  from the single center 
settin g.  Both  haplo- BM and  
dUCB grafts can be obtained rapidly for >90% of patients 
lacking an HLA -matched donor.  
The BMT CTN dUCB results (0604) are quite similar to those reported for a single institution trial in a similar group of patients .9  The BMT CTN haplo- BM results (0603) may even be a 
little better than those initially reported by Johns Hopkins and Fred Hutchinson,
12 probably 
because of inclusion of somewhat better -risk patients  in the BMT CTN trial.  When comparing 
0603 and 0604, engraftment, especially of platelets, appeared slower wit h UCB .  There also 
appeared to be a higher rate of TRM in the BMT CTN UCB trial (0604) .  Recently, we updated 
the results of the phase II trials.  The 3 -year probabilities of progression -free survival after haplo -
identical related (0603) and double UCB (0604) were 35% (95% CI 21% -48%) and 36% (95% 
CI 23% -49%).15  Consis tent with our earlier observation, the pattern of treatment failure varied 
by donor source.  For recipients of haploidentica l related transplantation, relap se was the 
predominant cause of trea tment failure and for recipients of double UCB transplantation, TRM 
was the predominant cause of treatment failure.  Recent data also suggest that delayed immune 
recovery leading to increased serious infections may be an issue with UCB transplantation  in 
older adults; because of thymic dysfunction, immune reconstitution after BMT in older patients appears to primarily arise from memory lymphocytes whose numbers are very low in UCB  
units .
16, 17, 18  However, the numbers of patients in the two BMT CTN trials ar e relatively small, 
assignment was not randomized, and longer follow -ups are needed.  Moreover, some concern has 
been raised about the durability of remissions, especially in myeloid malignancies, after  RIC 
haploidentical  BMT.  Thus, carefully controlled clinical trials are required to determine the best 
graft source for adult patients requiring alternative donor BMT.  
 Accordingly, this protocol describes a Phase  III, randomized, open label, multicenter, 
prospective, comparative trial of double UCB versus  related haplo -BMT transplantation after  
Figure 3.  Relapse, NRM (A,C), overall survival, and event -
free survival (B,D) after RIC and transplantation of dUCB (A,B) 
or Haplo- marrow (C,D).  

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
1-6 RIC in patients with hematologic malignancies.  Confirming the safet y and efficacy of UCB 
and/or haploidentical related BMT would allow access to BMT for essentially all patients in 
need.  Moreover, a successful MUD  search takes a median of 3 -4 months ,19 a time -frame that is 
too long for many patients with aggressive diseases.  UCB, and haploidentical related donors, 
can usually be identified as quickly as HLA -matched  sibling donors, again allowing many 
patients whose  disease currently will not remain quiescent long enough for a MUD search, the 
option of BMT.  
 
The central hypothesis of this trial is that progression -free survival (PFS) at two years after RIC 
haplo- BM transplantation is similar  to the PFS after RIC d UCB transplantation.  Accordingly, 
the primary endpoint of the trial will be two year PFS, with secondary endpoints of T RM, 
progression/relapse, overall survival, hematopoietic recovery, acute and chronic GVHD, 
infections, hospital admissions , and health -related quality of life ( HQL ). 
 
Extended Family Members as Haploidentical Donors  
   
Preliminary data (Fuchs E, et al., unpublished) in which 10 patients  with high -risk 
hematologic malignancies received HLA -haploidentical 
transplants from extended family donors (aunt, uncle, niece, nephew, cousin, grandchild) showed no negative impact on transplant outcom es compared to 
results using first degree family donors.  Use of extended family members as potential donors when a suitable first degree relative is unavailable or unsuitable is supported by another Johns Hopkins study which used the 
1101 haploidentical t ransplantation protocol for recipients of grafts from 20 heavily HLA -
mismatched unrelated donors (Kasamon Y, et al. presented at ASH 2015 and submitted for publication)  where genetic heterogeneity would be expected to be much greater between donor 
and reci pient than in transplants using family donors .  In this study, there was a median of 2 
HLA mismatches and included three 7/10 matches, one 6/10 match and one 5/10 match.  Full CD3 chimerism was 93% at day 60 and there was no grade 3 acute GVHD. The cumulat ive 
incidences of grade 2 acute GVHD and any chronic GVHD were 19% and 7%, respectively.  Data from both extended family donors and HLA -mismatched unrelated donors showed high 
rates of engraftment and acceptably low incidences of acute or chronic GVHD and non- relapse 
mortality.    
Figure 4 .  Data from HLA- mismatched unrelated donors showing low 
incidences of acute or chronic GVHD (A), and non -relapse mortality (B).  

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-1 CHAPTER 2  
 
 
2. STUDY DESIGN 
 2.1. Study Overview  
 
This is a Phase III randomized, open label, multicenter trial to compare PFS  at 2 years post -
randomization between patients who receive RIC followed by a dUCB  transplant versus  a related 
haplo- BM transplant for hematologic malignancy.   
 2.1.1. Hypotheses and Specific Objectives  
 2.1.1.1. Hypotheses  
 Primary Hypothesis: Two year PFS is similar  after related haplo -BM donor transplantation or  
after dUCB transplantation.  Secondary Hypotheses:   TRM is significantly lower but relapse is significantly higher after 
haplo- BM versus dUCB transplantation. 
 2.1.1.2. Study Objectives  
 The primary objective is to compare PFS at 2 years post -randomization between patients who 
receive a dUCB  transplant with patients who receive a  related haplo -BM transplant.  Secondary 
objectives include comparing neutrophil recovery, primary and secondary graft failure, platelet 
recovery, donor cell engraftment, acute GVHD, chronic GVHD, overall survival, TRM , 
relapse/progression, hospital admission and length of stay, health -related  quality of life , and cost -
effectiveness .  
 
2.2. Eligibility  Criteria  for Enrollment and Randomization  
 
2.2.1. Patient Inclusion Criteria  
 Patients will be  enrolled regardless of gender.  Patients fulfilling the following criteria are 
eligible for enrollment:  
1. Age: Subjects ≥  18 and ≤ 70 years old  
2. Patients must have available both:  
a. One or more potential related mismatched donors (biologic parent (s ) or siblings (full 
or half), children or other extended family members). At least  low resolution DNA 
based  typing at HLA -A, -B and – DRB1  is required  pre-randomization for potential 
haplo- identical donors other than biological parents and children.   
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-2 b. At least two potential umbilical cord blood units identified.   
i. Each unit must have a minimum of 1.5 x 107/kg pre -cryopreserved total 
nucleated cell dose.  For non- red blood cell depleted units, the minimum pre -
cryopreserved total nucleated cell dose of each unit must be at least 
2.0 x  107/kg.  
ii. Units must be HLA matched at a minimum of 4/6 to the recipient at HLA -A, 
HLA -B (at low resolution using DNA based typing ) and HLA -DRB1 ( at high 
resolution using  DNA based typing ). Confirmatory typing is not required for  
randomization.  
3. Acute Leukemias (includes T lymphoblastic lymphoma) : 
a. Acute Lymphoblastic Leukemia (ALL) in first complete remission ( CR1) (see 
remission definition in Chapter 3)  that is NOT considered favorable -risk as defined 
by the presence of at least one of the following:  
i. Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other MLL 
rearrangements,  
ii. White blood cell counts of greater than 30,000/mcL  (B-ALL) or greater than 
100,000/mcL (T -ALL)  at diagnosis,  
iii. Recipient age older than 30 years at diagnosis , 
iv. Time to CR greater than 4 weeks  
b. Acute Myelogeneous Leukemia (AML) in first complete remission ( CR1) (see 
remission definition in Chapter 3)  that is NOT  considered as favorable -risk.  
i. Favorable risk is defined as having one of the followingt (8,21) without CKIT 
mutation  
ii. inv(16) without CKIT mutation or t(16;16)  
iii. FLT3 ITD and TKD mutations without concurrent mutations in NPM1 or core 
binding factors (inv(16) and t(8:21)).  
iv. Normal karyotype with double mutated CEBPA  
v. APL in first molecular remission at end of consolidation 
Please consult with the protocol chairs for patients meeting one of the above criteria   but with additional features that may be considered high risk.  
c. Acute Leukemias in 2
nd or subsequent CR (see remission definition in C hapter 3).  
d. Biphenotypic/Undifferentiated/Prolymphocytic /Dendritic Cell Leukemias  and Natural 
Killer Cell  Malignancies  in first or subsequent CR , adult T -cell leukemia/lymphoma 
in first or subsequent CR  
4. Burkitt’s lymphoma: second or subsequent CR. 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-3 5. High risk lymphomas in first CR, including, enteropathy -associated T cell lymphoma, or 
hepatosplenic gammadelta T cell lymphoma.  
6. Chemotherapy -sensitive ( at least stable disease; see response criteria in Chapter 3) 
lymphomas that have failed at least 1 prior regimen of multi- agent chemotherapy and are 
INELIGIBLE for an autologous transplant. Patients with CLL are not eligible regardless 
of disease status.  
7. Performance status: Karnofsky score ≥  70%.  
 
2.2.2. Patient Exclusion Criteria  
 
Patients fulfilling the following criteria are ineligible for registration onto this study:  
1. Patients with suitably matched related or unrelated donor , as defined per institutional 
practice.  
An unrelated donor search is not required for a patient to be eli gible for this protocol , or a 
search and donor mobilization may be abandoned, if the clinical situation dictates an 
urgent transplant.  Clinical urgency is defined as 6- 8 weeks from referral to transplant or 
a low -likelihood of finding a matched, unrelated donor . 
2. Recipients of prior autologous hematopoietic stem cell transplantatio n are ineligible if 
disease recurrence occurred < 6 months from their autologous hematopoietic stem cell transplant. 
3. Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or  radiologic findings).  
4. Prior allogeneic hematopoietic stem cell transplant.  
5. Patients with history of primary idiopathic myelofibrosis or any severe marrow fibrosis.  
6. Planned use of prophylactic donor lymphocyte infusion ( DLI) therapy.  
7. Anti-donor HLA antibodies.   Positive anti- donor HLA antibody is defined as a positive 
crossmatch test of any titer (by complement -dependent cytotoxicity or flow cytometric 
testing) or the presence of anti -donor HLA antibody  to the high expression loci HLA -A,  
-B, -C, or – DRB1  with mean fluorescence intensity >1000 by solid phase immunoassay .   
8. Fertile men or women unwilling to use  2 effective forms of birth control or abstinence.  
 
2.3. Additional Patient Eligibility Criteria for Conditioning  
 
2.3.1. Patients with A dequate P hysical Function as M easured by  
a. Cardiac: Left ventricular ejection fraction at rest must be ≥  40%, or shortening 
fraction > 25%.  
b. Hepatic:   
i. Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert’s syndrome or 
hemolysis;  
ii. ALT, AST, and Alkaline Phosphatase < 5 x ULN.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-4 c. Renal: Serum creatinine within normal range, or if serum creatinine outside normal 
range, then renal function (measured or estimat ed creatinine clearance or GFR)  > 40 
mL/min/1.73m2. 
d. Pulmonary: DLCO (corrected for hemoglobin), FEV 1, and FVC > 50% predicted. 
 2.3.2. Additional Patient Inclusion Criteria for Patients Assigned  to Haploidentical BM Arm  
Patients must be HLA typed at high resolution using DNA based typing at the following HLA -
loci: HLA -A, -B, -C and DRB1  and have available:  
A related hapl oidentical BM donor with 2, 3, or 4 HLA -mismatches.  A unidirectional 
mismatch in either the graft versus host or host versus graft direction is considered a mismatch.  The donor and recipient must be HLA i dentical for at least one antigen 
(using high resolution DNA based typing) at  the following genetic  loci: HLA -A, 
HLA -B, HLA -C, and HLA -DRB 1.  Fulfillment of this criterion shall be considered 
sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.  See Section 2.4  for donor selection 
criteria.   
 2.3.3. Additional Patient Inc lusion Criteria for Patients Assigned  to Double Umbilical Cord
 Blood Arm  
1. Patients must have available two UCB units fulfilling the following criteria: 
a. Each unit must have a minimum of 1.5 x 10
7/kg pre -cryopreserved total nucleated cell 
dose.  For non- red b lood cell depleted units, the minimum pre -cryopreserved total 
nucleated cell dose of each unit must be at least 2.0  x 107/kg.  
b. Units must be HLA matched at a minimum of 4/6 to the recipient at HLA -A, HLA -B 
(at low resolution using DNA based typing) , and HL A-DRB1 (at high resolution 
using DNA based typing).  
c. See Section 2. 5 for graft selection criteria.   
2. Patients must have received at least one cycle of the cytotoxic chemotherapy regimens 
(or regimen of similar intensity) listed in Appendix D within 3 months of enrollment (measured from the start date of chemotherapy) OR have had an autologous transplant 
within 24 months of  enrollment OR  receive 300 cGy as part of the preparative regimen .  
 
2.3.4. Additional Patient Exclusion Criteria  
 Patients fulfilling the following criteria are ineligible to proceed to transplant:  
1. Pregnancy or breast -feeding.  
2. Evidence of HIV infection or known HIV positive serology.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-5 2.4. Donor Selection for Haploidentical -BM 
 
2.4.1. Donor Inclusion Criteria  
1. Donors must be HLA -haploidentical relatives of the patient.  Eligible donors include 
biological parents, sibling s (full or half), children or extended family members.  
2. For d onors <  18 years, the maximum recipient weight ( ideal body weight  in kg ) should 
not exceed 1.25 times the donor weight ( actual body weight  in kg ). 
 2.4.2. Donor Prioritization Schema  
 In the event that two  or more eligible donors are identified, the following order of priority  is 
suggested but NOT mandated:  
1. For cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor  
2. Red blood cell compatibility  
a. RBC cross -match compatible  
b. Minor ABO incompatibility  
c. Major ABO incompatibility  
 
2.5. Graft Selection for Double Umbilical Cord Units  
1.
 Unit selection is based on pre -cryopreserved total nucleated cell dose & HLA -A, -B, and 
-DRB1 .  See S ection 2.2.1 for HLA typing criteria . 
2. After attaining the  minimum total nucleated cell dose  threshold of  1.5 x 107/kg (or 2.0 x 
107/kg for units that were not red cell -depleted), it is recommended HLA -match take 
priority for unit selection.  However, within the best available HLA match grade (e.g. 
5/6), units with the largest total nucleated cell dose per kg recipient body weight should 
be chosen.  
3. It is recommended two mismatches at a single HLA -locus be avoided if possibl e.   
4. Matching the two units is recommended but NOT mandated.  The recommendation is that units  be HLA matched at a minimum of 4/6 to each other but not necessarily at the same 
HLA -loci as with the recipient.  
 
For additional guidance on graft or donor s election, pl ease contact the study chairs  or protocol 
officer via the EMMES protocol coordinator.   
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-6 2.6.Treatment Plans  
 
Dose Adjustment Formulas  
 
Estimated creatinine clearance determined by the Cockcroft Formula:  
 
  CCr = (140 – age) x ideal body weight (IBW) (kg)    x   0.85 (for female)  
                         P Cr x 72 
 
Ideal Body Weight (IBW) Formulas:  
 
Males IBW = 50 kg + 2.3 kg/ 2.5 cm over 1.52  meters  
 
Females IBW = 45.5 kg + 2.3 kg/ 2.5 cm over 1.52   meters  
 
Adjusted Ideal Body Weight Formula:  
 
 AIBW = IBW + [(0.25) x (ABW -  IBW)]  
 
2.6.1. Treatment Plan for Patients Randomized to Haplo -BM 
 
All patients randomized to the haplo- BM arm will receive preparative therapy as shown in Table 
2.6.1.  
TABLE 2. 6.1 - HAPLO PREPARATIVE REGIMEN  
 
Day –6, -5 Fludarabine 30 mg/ m2 IV over 30 -60 minutes , then  
Cyclophosphamide 14.5 mg/kg IV over 1 -2 hours* 
Day –4→ -2 Fludarabine 30 mg/ m2 IV over 30 -60 minutes  
Day –1 TBI 200 cGy 
Day   0  Non-T-cell depleted bone marrow  
Days 3,  4 Cyclophopshamide 50 mg/kg IV  
Mesna 40 mg/kg IV* 
Day   5  Begin tacrolimus  (or cyclosporine) , mycophenolate 
mofetil, and G -CSF 
*Uroprophylaxis  may be altered  per institutional preference (see below)  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-7 2.6.1.1. Fludarabine  
 
Fludarabine 30 mg/m2/day will be administered over 30 -60 minutes intravenous infusion on 
Days –6 through –2 for a total dose of 150 mg/m2.  Fludarabine will be dosed according to the 
recipient’s actual body weight.  For patients who have a n estimated or measured  creatinine 
clearance < 70 mL/min/1.73 m2, or either  prior CNS disease, prior brain radiation, or prior 
intrathecal chemotherapy, the fludarabine dose should be reduced by 20%.   Fludarabine dosing is 
based on the last creatinine clearance prior to the start of conditioning .  The fludarabine dose 
should be the same on D ays -6 to - 2, even if the patient’s creatinine changes.   
 Fludarabine must be administered before cyclophosphamide on Days - 6 and -5. 
 2.6.1.2. Pre -transplantation cyclophosphamide  
 Hydration prior to cyclophosphamide may be given according to institutional standards.  A recommended approach is as follows: Patients are instructed to increase fluids overnight before 
cyclophosphamide administration.  Hydration with normal saline at 3 mL /kg/hr IV will be started 
2 hours prior to cyclophosphamide, then the rate will be reduced to 2 mL /kg/hr for 1 hour pre -
cyclophosphamide and continued at 2 mL /kg/hr for 8 hours post -cyclophosphamide. 
 Mesna may be administered per institutional standards.  Mesna dose will be based on the cyclophosphamide dose being given.  A suggested approach is as follows: divided doses IV 30 min pre - and at 3, 6, and 8 hours post -Cy.  The total daily dose of mesna must be ≥ 80% of the 
total daily dose of Cy.   
 Cyclophosphamide  14.5 mg/kg/day will be administered as a 1 -2 hour intravenous infusion on 
Days –6 and –5.  Cyclophosphamide  will be dosed according to the recipient’s ideal body weight 
(IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed 
according to the adjusted IBW (AIBW; see above for formulas). If the recipient’s actual body 
weight (ABW) is less than the ideal body weight (IBW) and in the best interest of the recipient, the cyclophosphamide dosing can be based on the ABW . Uropr otection can be administered 
according to institutional guidelines.  Mesna is  recommended to accompany pre -transplantation 
Cy, but is not required.  
 2.6.1.3. Total body irradiation (TBI)  
 
200 cGy TBI will be administered in a single fraction on Day – 1.  Radiation sources and dose 
rates will be defined by the institution.  TBI may be delive red from either linear accelerator or 
Cobalt sources.  Graft may be infused on the same day as TBI administration as long as there is 
4-6 hours between administration of TBI and infusion of bone marrow.  
 2.6.1.4. Transplantation of haplo -BM 
 On Day 0, patients wil l receive unprocessed marrow unless there is a major ABO 
incompatibility, in which case red blood cells will be depleted from the donor marrow using institutional practices.  Institutional practices will determine if there will be processing for minor 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-8 ABO incompatibilities.  Donor bone marrow will be harvested with a target yield of 4 x 108 
nucleated cells/kg recipient IBW , and a recommended minimum yield of 2.5 x 108 nucleated 
cells/kg of recipient IBW .  We recommend taking no more than 10 mL  per aspirate.   In addition 
to calculating the total nucleated cell dose /kg, a s ample of the product to be infused will be sent 
for flow cytometry to determine the content of CD34+cells.   The use of cryopreserved marrow is 
not pe rmitted.   
 
2.6.1.5. Post -transplantation cyclop hosphamide  
 Hydration and uroprotection may be given according to institutional standards.  See Section 2.6.1.2 for a recommended strategy.  
 Cyclophos phamide  50mg/kg will be given as an IV infusion over 1- 2 hours  (depending on 
volume)  on Days 3 post -transplant (between 60 and 72 hours after marrow infusion) and on Day 
4 post -transplant (approximately 24 hours after Day 3 cyclophosphamide).  Cy clophosphamide  
will be dose d according to the recipient’s ideal body weight (IBW), unless the patient wei ghs 
more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW (AIBW; see Section 2.6) . If the recipient’s actual body weight (ABW) is less than the ideal body 
weight (IBW) and in the best interest of the recipient, the cyclophosphamide dosing can be based on the ABW . 
 2.6.1.6. Immunosuppressive therapy  
 
Corticosteroids may not be used as an anti -emetic agent and should not be administered 
until 24 hours after the completion of post -transplantation cyclophosphamide, unless used 
for ad renal support or during a medical emergency (e.g. treatment of anaphylaxis). 
 
2.6.1.7. Tacrolimus  
 Tacrolimus will be given at a dose of 1 mg IV qd or 1 mg PO  bid, and then will be changed to a 
PO dosing schedule once a therapeutic level is achieved or as per inst itutional standards.  
Tacrolimus prophylaxis will begin on Day 5 post -transplant.  Serum levels of tacrolimus will be 
measured around Day 7 and then should be checked weekly thereafter and the dose adjusted 
accordingly to maintain a trough level of 5 -15 ng/mL.  Tacrolimus will be discontinued after the 
last dose around Day 180, or may be continued if active GVHD is present.    Cyclosporine ( trough level of 200- 400 ng/ mL) may be substituted for tacrolimus if the patient is 
intolerant of tacrolimus or  per institutional practice ( see Section 2.6.2.4) .   
 2.6.1.8. Mycophenolate mofetil (MMF)  
 MMF will be given at a dose of 15 mg/kg PO  or IV  TID (based upon actual body weight) with 
the maximum total daily dose not to exceed 3 grams (1 g PO TID).  MMF prophylaxis will be gin 
on Day 5 post -transplant and will be  discontinued after the last dose on Day 35, or may be 
continued if active GVHD is present.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-9 2.6.1.9. Growth f actor s upport  
 
G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial 
dose is allowed), until absolute neutrophil count (ANC) is ≥ 1,500/mm3 for three consecutive 
measurements on two different days .  G-CSF may be restarted to maintain ANC > 1,000/mm3.  
G-CSF may be given by IV or subcutaneously.  
 2.6.2. Treatment Plan Selection f or Patients Randomized to dUCB  
 All patients  who are  randomized to the double umbilical cord blood transplant arm and who have 
received cytotoxic chemotherapy within 3 months of enrollment or  an aut o HSCT within 24 
months of enrollment (see Appendix D) will receive preparative therapy as shown in Table 2. 6.2. 
 
TABLE 2. 6.2a -  dUCB PREPARATIVE REGIMEN FOR PATIENTS WHO HAVE 
RECEIVED CYTOTOXIC CHEMOTHERAPY WITHIN 3 MONTHS OF 
ENROLLMENT OR AUTO HSCT WITHIN 24 MONTHS OF ENROLLMENT  
 
Day –6 Fludarabine 40 m g/m2 IV over 30 -60 minutes , 
then Cyclophosphamide 50 mg/kg IV over 2 hours 
Day –5→ -2 Fludarabine 40 m g/m2 IV over 30 -60 minutes  
Day –3 Begin cyclosporine (or tacrolimus) and MMF  
Day –1 TBI 200 cGY  
Day 0  UCB Transplant  
Day 1  Begin G -CSF 
 
All patients who are randomized to the double umbilical cord blood transplant arm and who have NOT  received cytotoxic chemotherapy within 3 months of enrollment or an auto HSCT within 
24 months of enrollment (see appendix D) will receive preparative therap y as shown in Table 
2.6.2b.  
TABLE 2.6.2b -  dUCB PREPARATIVE REGIMEN FOR PATIENTS WHO HAVE NOT  
RECEIVED CYTOTOXIC CHEMOTHERAPY1 WITHIN 3 MONTHS OF 
ENROLLMENT OR AUTO HSCT WITHIN 24 MONTHS OF ENROLLMENT  
 
Day –6 Fludarabine 40 mg/m2 IV over 30 -60 minutes, 
then Cyclophosphamide 50 mg/kg IV over 2 hours 
Day –5→ -2 Fludarabine 40 mg/m2 IV over 30 -60 minutes  
Day –3 Begin cyclosporine (or tacrolimus) and MMF  
Day –1 TBI 300 cGY  
Day 0  UCB Transplant  
Day 1  Begin G -CSF 
1See Appendix D for list of approved cytotoxic chemotherapy regimens  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-10 2.6.2.1. Fludarabine  
 
Fludarabine 40 mg/m2/day will be administered over 30 -60 minut es intravenous infusion on 
Days -6 through -2 for a total dose of 200 mg/m2.  Fludarabine will be dosed according to the 
recipient’s actual body weight.  For patients who have a estimated or measured creatinine 
clearance < 70 mL/min/1.73 m2, or prior CNS disease, or prior brain radiation, or prior 
intrathecal chemotherapy, the fluda rabine dose should be reduced by 20%.   Fludarabine dosing is 
based on the last creatinine clearance prior to the start of conditioning.  The fludarabine dose should be the same on Days -6 to - 2, even if the patient’s creatinine changes.   
 Fludarabine must  be administered before cyclophosphamide on D ay -6. 
 2.6.2.2. Cyclophosphamide  
 Hydration prior to cyclophosphamide may be given according to institutional standards.  A recommended approach is as follows: Patients are instructed to increase fluids overnight befo re 
Cy administration.  Hydration with normal saline at 3 mL /kg/hr IV will be started 2 hours prior 
to Cy, then the rate will be reduced to 2 mL /kg/hr for 1 hour pre -cyclophosphamide and 
continued at 2 mL /kg/hr for 8 hours post -cyclophosphamide. 
 Mesna may be administered per institutional standards.  Mesna dose will be based on the 
cyclophosphamide dose being given.  A suggested approach is as follows: divided doses IV 30 min pre - and at 3, 6, and 8 hours post -cyclophosphamide.  The total daily dose of mesna must be 
≥ 80% of the total daily dose of cyclophosphamide.    Cyclophosphamide 50mg/kg x 1 day to be administered on Day - 6.  Cyclophosphamide will be 
dosed according to the recipient’s ideal body weight (IBW), unless the patient weighs more than 
125% of  IBW, in which case the drug will be dosed according to the adjusted IBW (AIBW; see 
Section 2.6) . If the recipient’s actual body weight (ABW) is less than the ideal body weight 
(IBW) and in the best interest of the recipient, the cyclophosphamide dosing ca n be based on the 
ABW . 
 2.6.2.3. Total body irradiation (TBI)  
 
200 cGy TBI will be administered in a single fraction on Day – 1 for patients who have received 
cytotoxic chemotherapy within 3 months of enrollment or an auto HSCT within 24 months of enrollment .  300 cGY TBI will be administered in a single fraction on Day –1 for patients who 
have NOT received cytotoxic chemotherapy within 3 months of enrollment or an auto HSCT 
within 24 months of enrollment.  Radiation sources and dose rates will also be defined b y the 
institution.  TBI may be delivered from either linear accelerator or Cobalt sources.  Graft may be infused on the same day as TBI administration as long as there is 4- 6 hours between 
administration of TBI and infusion of the umbilical cord blood unit s. 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-11 2.6.2.4. Cyclosporine A  
 Cyclosporine  will be administered  IV beginning on Day –3 and doses will be adjusted to 
maintain a trough level of 200- 400 ng/mL by HPLC or 250- 500 ng/mL by TDX method (or 100-
250 ng/mL by Tandem MS or equivalent level for other CSA t esting methods) or within 
therapeutic level per institutional standard testing.  Dose adjustments will be made on the basis of toxicity or low cyclosporine  levels (trough level of < 200 ng/mL ).  Once the patient can 
tolerate oral medications and has a norm al gastro -intestinal transit time, cyclosporine  will be 
converted to an oral form at 2 -3x the current IV dose.  Cyclosporine  dosing will be monitored 
and altered as clinically appropriate.  Patients will receive cyclosporine  until Day +100.  In the 
absence  of GVHD, the dose will be tapered 10% per week beginning on Day 101, to be 
discontinued approximately Day 180- 200. 
 Tacrolimus ( trough level  of 5-15 ng/mL) may be substituted for cyclosporine if the patient is 
intolerant of cyclosporine or per institutional practice ( see S ection 2.6.1.7) .   
 2.6.2.5. Mycophenolate mofetil (MMF)  
 MMF will be given at a dose of 15 mg/kg PO  or IV  TID (based upon actual body weight) with 
the maximum total daily dose not to exceed 3 grams (1 g PO TID)  beginning on the morning of  
Day -3.  MMF prophylaxis will be discontinued after the last dose on Day 35, or may be 
continued if active GVHD is present.  
 2.6.2.6. U CB infusion 
 
Following the administration of the preparative therapy, all subjects  randomized to the UCB arm  
will undergo UCB transplantation.  Under NO  circumstances should the  cord blood units  be 
irradiated.  No in- line leukocyte filter should be used and no medications or fluids should be 
given piggyback through the catheter lumen that is being used for the cord blood unit infusion.  
The graft MUST be infused through a central line.  Vital signs should be monitored before 
beginning the infusion and periodically during administration.  The two units for dUCB transplantation are infused one after the other with an interval between unit  infusion no longer 
than 6h .  It is recommend ed a minimum interval of 30 min between the infusion of the two unit s 
in order to observe and manage any acute infusional toxicity related to the infusion of the first unit.  The order of infusion of the units w ill follow institutional practice.   Infusion should be 
initiated as soon as possible after thaw.  
 The cord blood should be thawed, diluted with or without wash per validated institutional or supplying cord blood bank procedures with the exception that bedside thawing and direct infusion is not allowed.  Bedside thaws are not allowed because of the inab ility to rescue the 
product if there is loss of integrity of the UCB bag on thaw at the bedside and because of the instabilit y of the cells in 10% DMSO post -thaw.   Contingency plans for UCB units which cannot 
be infused due for example loss of integrity of  the bag with contamination or poor viability, will 
follow institutional policies.    
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-12 All transplant centers/cellular therapy laboratories must be familiar with thawing of cord blood 
units.  They must have validated procedures and maintain competency in the thaw process.  The cord blood unit must be thawed in a qualified laboratory by trained personnel.  Generally the cryopreserved unit is removed from the protective cassette, placed in a zippered plastic  bag (e.g. 
Ziplock
TM or equivalent)  and thawed rapidl y in a 37◦C waterbath.  The zippered plastic  bag 
allows for recovery of cells if the cryopreservation bag cracks or leaks during the thawing process, a rare but possible event.  Once the contents of the bag reach a slushy consistency, the cells can be dilu ted in dextran/albumin, a hypertonic solution that buffers against the intracellular 
hypertonicity created by DMSO.  Cell suspensions can subsequently be washed to remove DMSO, free hemoglobin and other cellular debris allowing for resuspension in a volume  
appropriate for the size of the patient to be transplanted.   
 
Based on the NMD P Cord Blood Advisory Board Group the following recommendations are 
relevant, particularly for larger volume units (e.g. RBC replete or “whole blood” untis) which 
have been , on rare occasion,  associated with transient cardiomyopathy (Takotsubo syndrome).  
These recommendation s are not intended to supersede manufacturer’s instructions or preclude 
the use or development of validated thawing and infusion procedures . 
1. If a product is  washed, after unit is spun and supernatant is removed, resuspend in a 
minimum of 50 mL  of reconstitution solution.  
2. Filter the product with standard 170 -  260 micron blood filter . 
3. Thaw units independently, with preference toward thawing the second unit aft er the first 
unit was infused successfully.  
4. Infuse unit independently.  Should a reaction occur, appropriately manage the reaction before the second unit is thawed for infusion. 
5.  Time from initiation of thaw to completion of infusion should be minimized.  Preferably this should be less than 2 hours, but data show stem cell integrity is maintained for longer periods. 
6. Infusion rate should not exceed 250 mL/h or 5 mL/min.  The order of infusion of the units will follow institutional practice.   
 Benadryl, epinephrine, and hydrocortisone should be a vailable for emergency use if necessary.  
Oxygen with nasal prongs for standby use should be present in the room.  
 2.6.2.7. Growth f actor  support  
 G-CSF will be given beginning on Day 1 at a dose of 5 mcg/kg/day (rounding to the nearest vial 
dose is allowed), until absolute neutrophil count (ANC) is ≥ 1,500/mm
3 for three consecutive 
measurements on two different days .  G-CSF may be restarted  to maintain ANC > 1,000/mm3.  
G-CSF may be giv en by IV or subcutaneously.  
    
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-13 2.7. Additional Supportive Care  
 
2.7.1. Post Transplant Maintenance Therapy  
 
Plans for the use of post transplant maintenance therapy must be disclosed prior to randomization, and must be used irrespective of the outcome of the random ization. 
 
 2.7.2. Infection Prophylaxis  
 Patients will receive infection prophylaxis and nutritional support according to institutional guidelines.  Infection prophylaxis should include, but is not limited to, agents or strategies (e.g., PCR screening and preemptive therapy) to reduce the risk of  bacterial , herpes simplex, CMV , 
HHV- 6, EBV, P neumocystis j iroveci , and fungal infections.   
 2.7.3. Transfusion Support  
 Transfusion thresholds for blood product support will be  according to standard institutional 
guidelines.  All blood products will be irradiat ed. 
 2.7.4. Indwelling Central Venous Catheter  
 Placement of a double or triple lumen central venous catheter will be required for the transplantation procedure and administration of IV medications and transfusion of blood 
products.  This catheter may be removed and replaced as clinically indicated.  However, the graft 
MUST  be infused through a central line. 
 2.7.5. Pre-infusion Medication and Hydration Regimen  
 The pre -medication and hydration regimen prior to blood products transfusion and 
transplantation will be given following institutional guidelines.  
 
2.7.6. Anti-Ovulatory Treatment  
 Females of childbearing potential should be started on an anti -ovulatory agent prior to the 
initiation of the preparative regimen  per institutional practice . 
 2.7.7. Mana gement of Slow Engraftment and Graft Failure  
 Slow engraftment or graft failure shall be managed according to institutional practices, and may include the administration of colony stimulating factors and prophylactic antibiotics.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-14 2.8.Risks and Toxicities  
 
Cyclophosphamide:  
 Cyclophosphamide side effects include: nausea/vomiting, cardiomyopathy, skin rash, mucositis, stomatitis, sterility, diarrhea, hemorrhagic cystitis, fluid weight gain/edema, alopecia , and 
hemolytic/anemia.  
 Fludarabine:  
a. Neurotoxicity: Agitation or confusion, blurred vision, loss of hearing, peripheral neuropathy or weakness have been reported.  Severe neurologic effects, including blindness, coma, and death are seen in 36% of patients treated with doses approximately four times greater than recommended; severe CNS toxicity is rarely seen with doses in 
the recommended range for nontransplant therapy of hematologic malignancies.  Effect of chronic use on the CNS is unknown, although patients have received recommended doses f or up to 15 courses.  The dose used in this study is approximately 1.5 times the 
usual one -course dose given in non- transplant settings.  Doses and schedules such as 
those used in this study have been used in adult and pediatric patients and increased neurotoxicity has not been observed.  
b. Anemia: Life -threatening and sometimes fatal autoimmune hemolytic anemia has been 
reported after one or more cycles of therapy in patients with or without a previous history of autoimmune hemolytic anemia or a positive Coombs’ test and who may or may not be in remission; no mechanisms for development of this complication have been identified.  Corticosteroids may or may not be effective in controlling these episodes.  The majority 
of patients re -challenged developed a recur rence of the hemolytic process.  
c. Cardiovascular: Deep venous thrombosis, phlebitis, transient ischemic attack, and aneurysm (1%) are reported.    
d. Fever: 60% of patients develop fever.  
e. Skin Rash: 15% of patients develop a skin rash, which may be pruritic.  
f. Digestive: Gastrointestinal side effects include: nausea/vomiting (36%), diarrhea (15%), stomatitis (9%), anorexia (7%), GI bleeding and esophagitis (3%), mucositis (2%), liver failure, abnormal liver function test, constipation, dysphagia (1%) , and mouth sores.  
g. Some other effects are: Chills (11%), peripheral edema (8%), myalgia (4%), osteoporosis (2%), pancytopenia, arthralgia (1%), dysuria (4%), urinary tract infection and hematuria (2%); renal failure, abnormal renal function test, and proteinuria (1%) ; and, very rarely, 
hemorrhagic cystitis and pulmonary toxicity.  
 Total Body Irradiation:  
 TBI can cause: nausea and vomiting, diarrhea, parotitis (rapid onset within 24- 48 hours, usually 
self-limited), generalized mild erythema, hyperpigmentation, fever,  mucositis, and alopecia.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-15 Late effects include: possible growth retardation, vertebral deformities, cataracts, probable 
increased risk of secondary malignant neoplasms, sterility, nephropathy, interstitial pneumonitis and veno- occlusive disease.   
 Mycophe nolate Mofetil:  
 Side effects include: pancytopenia, nausea, vomiting, diarrhea, hypertension, headache, dizziness, insomnia, hyperglycemia, electrolyte imbalances, rash, and leg cramps/bone pain.  
 Tacrolimus and Cyclosporine -A: 
 Side effects include: reversible renal insufficiency, hypertension, hyperglycemia, hypomagnesemia, hypokalemia, and neurologic toxicity.   
 
2.9. Health -Related Quality of Life Assessments  
 
2.9.1. Instruments  
 FACT -BMT: The Functional Assessment of Cancer Therapy – Bone Marrow Transplant 
subscale version 4.0 instrument is a 37 item scale comprised of a general core questionnaire, the FACT -G, that evaluates the health -related quality of life (HQL) of patients receiving treatment 
for cancer, and a specific module, BMT Concerns, that addresses disease and treatment -related 
questions specific to bone marrow transplant.  The FACT -G consists of four subscales developed 
and normed in cancer patients: Physical Well- being, Social/Family Well- being, Emotional Well -
being, and Func tional Well- being.  Each subscale is positively scored, with higher scores 
indicating better functioning.  The FACT -BMT Trial Outcome Index, comprised of the physical 
well being scale, the functional well being scale and the BMT specific items, will be use d as the 
outcome measure in summarizing the FACT -BMT data.  The FACT -BMT takes 6 minutes to 
complete, and is being used to collect HQL data in BMT CTN 0201, 0801 and 0901.  MOS SF -36: The Medical Outcomes Study Short Form 36 is a 36 item general assessment of 
health quality of life with eight components: Physical Functioning, Role Physical, Pain Index, General Health Perceptions, Vitality, Social Functioning, Role Emotional, and Mental Health Index.  Each domain is positively scored, indicating that higher scores are associated with positive outcome.  This scale has been widely applied in a variety of outcome studies and is being used in this protocol as a generic measure of quality of life.  To facilitate comparison of the results with published norms, the Physical Component Summary (PCS) and Mental Component Summary (MCS) will be used as the outcome measures in summarizing the SF -36 
data.  These summary scores are derived by multiplying the z -score for each scale by its 
respective physical or mental factor score coefficient and summing the products.  Resulting scores are then transformed into T -scores (mean=50; standard deviation=10).  The SF -36 takes 6 
minutes to complete, an d is being used to collect HQL data in BMT CTN protocols 0801 and 
0901.  Global HQL: Four standard questions will assess patient self -assessed Karnofsky performance 
status, overall health and overall quality of life, (excellent, very good, good, fair, poor ) and a 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
2-16 rating scale for overall quality of life (where 0 equals death and 100 equals perfect quality of 
life).  In addition, the presence and severity of chronic GVHD will be assessed (mild, moderate, severe).  These questions take 1 minute to complete an d are being collected for BMT CTN 
protocols 0201, 0801, and 0901.  Occupational Functioning: Occupational functioning will be measured using 6 items that assess 
current job status, type of work (will be captured using Hollingshead categories), number of hours of paid and unpaid work, school, importance of work and change in work goals.  The same 
scale has been used in NHLBI -sponsored HCT studies and BMT CTN protocol 0201 and 0901. 
 EQ-5D: The EQ -5D will collect data that may be used to calculate patient -reported utilities for 
cost-utility analyses.  The EQ-5D contains a five item survey with three  response levels per item 
measuring mobility, self -care, usual activities, pain/discomfort and anxiety/depression.  The EQ -
5D takes appr oximately 1 minute to comple te (Agency for Healthcare Research and Quality, 
2005).  2.9.2. Administration  
 The self report questionnaires will be completed prior to transplantation and subsequently at  12 
months , and 24 months from randomization or until death.  Only patients able to read an d speak 
in English or Spanish are eligible to participate in the HQL component of this trial.  Surveys are 
completed by participants using self -completed instruments as a first choice.  If this method of 
data collection is not possible, then surveys and re sponse options may be read verbatim to 
participants, either in person or over the phone, to collect data.  The method of survey 
completion, the date, and the language will be recorded in the database.  Surveys may not be 
completed by surrogates.  
 
TABLE: 2.9 REQUIRED PATIENT -REPORTED OUTCOMES DATA COLLECTION  
Instrument  N 
items  Pre-
transplant  12 mos  24 mos  
Socio -demographics  8 X   
Global quality of life  4 X X X 
FACT -BMT  37 X X X 
MOS SF -36 36 X X X 
Occupational functioning  6 X X X 
EQ-5D 5 X X X 
Alternative contacts  2 X X X 
TOTAL N ITEMS   98 92 92 
ANTICIPATED TIME   30 min 30 min 30 min 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
3-1 CHAPTER 3  
 
 
3. STUDY ENDPOINTS  
 3.1. Primary Endpoint  
 
The primary endpoint is PFS at 2-years from  the date of randomization.  PFS is defined as the 
time interval from date of randomization and time to relapse/progression , to death or to last 
follow -up. 
 
3.2. Secondary Endpoints  
 
3.2.1. Neutrophil Recovery  
 Neutrophil recovery is defined as achieving an ANC ≥ 500/mm
3 for three consecutive 
meas urements on three different days.  The first of the three days will be designated the day of 
neutrophil recovery.  The only competing event for neutrophil recovery is death without neutrophil recovery.   
 3.2.2. Primary G raft Failure  
 Primary graft failure is defined as < 5% donor chimerism on all measurements  up to and 
including D ay 56 .   
 3.2.3. Secondary G raft Failure  
 Secondary graft failure is defined as initial whole blood or marrow donor chimerism ≥  5% 
declining to <  5% on subsequent measurements.   
 3.2.4. Platelet R ecovery  
 Platelet recovery is defined by two different metrics as the first day of a sustained platelet count > 20,000/mm
3 or > 50,000/mm3 with no platelet transfusions in the preceding seven days.  The 
first day of the sustained platelet count will be designated the day of platelet engraftment.  
 3.2.5. Donor Cell Engraftment   
 
Donor cell engraftment is defined as donor chimerism ≥  5% on Day ≥  56 after transplantation.  
Chimerism may be evaluated in whole blood or blood cell fraction s, including CD3 and CD33 or 
CD15 fraction s).  The actual measurement dates may be within +/ - 7 days of the above 
recommended time points. 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
3-2 3.2.6. Acute GVHD  
 
The cumulative in cidences of grade II – IV and III – IV acute GVHD will be determined.  Acute 
GVHD will be graded according to the BMT CTN MOP.  The time to onset of acute grades II -IV 
GVHD and grades III -IV GVHD will be recorded, as well as the maximum grade achieved.   
 3.2.7. Chronic GVHD  
 The cumulative incidence of cGVHD will be determined.   Data will be  collected directly from 
providers and chart review according to the recommendations of the NIH Consensus Conference.   
Eight organs will be  scored on a 0 -3 scale to reflect degree of chronic GVHD involvement.  
Liver function and pulmonary function results  will  also be recorded.  These data will allow 
calculation of the NIH global severity scores of mild, moderate , and severe chronic GVHD, 
which has been associated with transplant related mortality  and overall survival .
20   
 3.2.8. Overall Survival  
 Overall survival is defined as the time interval between date of randomization and death from 
any cause or for surviving patients, to last follow -up.  The time interval between date of 
transplant and death from any cause or for surviving patients, to last follow -up will also be 
analyzed.   
 3.2.9. Treatment -Related Mortality (TRM)  
 The cumulative incidence of TRM will be estimated at Days 100, 180, and at 1 and 2 years after 
transplantation.  An event for this endpoint is death without evidence of disease progression or 
recurrence.   
 3.2.10. Infections  
 All Grade 2 and 3 infections will be reported according to the BMT CTN MOP.  Grade 1 CMV 
infections through Day 56 will also be reported.   
 3.2.11. Hospital Admission and Length of Stay  
 The total number of hospital admissions within the first six months after transplantation, indication for admission, and length of stay per hospital admi ssion will be captured.  
 3.2.12. Health -Related  Quality of Life (HQL)  
 The instruments will be scored according to the recommendations of the developers.  See Section 2.9.1 for detailed descriptions of the instruments.  The FACT -BMT instrument will be 
summarized by the Trial Outcome Index, comprised of the physical, functional and BMT -
specific items.  The MOS SF -36 will be summarized by the Physical Component Summary 
(PCS) and Mental Component Summary (MCS).  The EQ -5D utility score will be calculated.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
3-3 HQL will b e described and compared between the two treatment arms over time.  The self report 
questionnaires will be completed prior to transplantation and subsequently at  12 and 24 months 
from randomization or until death.  Only pa tients able to read and speak in E nglish  or Spanish  
are eligible to participate in the HQL component of this trial.  
 
3.2.13. Relapse, Residual Disease and Disease Progression  
 Relapse of Malignancy  – Testing for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relaps e after transplantation.  For the purpose of this study, relapse is 
defined by either morphological or cytogenetic evidence of acute leukemia consistent with pre -
transplant features, or radiologic evidence (including the recurrence of fluoro- deoxyglucose 
[FDG] -avid lesions on PET scan) of progressive lymphoma.  When in doubt, the diagnosis of 
recurrent or progressive lymphoma should be documented by tissue biopsy.    Minimal Residual Disease – Minimal residual disease is defined by the sole evidence of 
malignant cells by flow cytometry, or fluorescent in situ hybridization (FISH), or Southern blot, or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of morphological or cytogenetic evidence of disease in blood or marrow.  Sinc e the frequency of 
testing for minimal residual disease is highly variable among centers, and the sensitivity is highly variable among laboratory techniques, evidence of minimal residual disease alone will not be sufficient to meet the definition of relaps e in the context of this trial.  However, minimal residual 
disease that progresses (see above) will be considered as relapse and the date of relapse will be 
the date of detection of minimal residual disease that prompted an intervention by the treating 
physician.  Data on tapering immunosuppression, administering chemotherapy or biological 
agents to in response to detection of minimal residual disease will be captured in the case report 
forms.  
 Acute Leukemia  – Relapse will be diagnosed when there is:  
1. The r eappearance of leukemia blast cells in the peripheral blood; or,  
2. > 5% blasts in the marrow, not attributable to another cause (e.g., bone marrow regeneration); or , 
3. The appearance of new dysplastic changes within the bone marrow; or,  
4. The development of extramedullary leukemia or leukemic cel ls in the cerebral spinal 
fluid ; or, 
5. The reappearance of cytogenetic abnormalities present prior to transplantation. 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
3-4 Lymphoma  – Relapse will be diagnosed when there is:  
1. Appearance of any new lesion more than 1.5 cm in any axis during or at the end of 
therapy, even if other lesions are decreasing in size.  Increased FDG uptake in a previously unaffected site should only be considered relapsed or progressive disease after confirmation with other modalities.  In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT are mostly benign.  Thus, a therapeutic 
decision should not be made solely on the basis of the PET without histologic confirmation.  
2. At least a 50% increase from nadir in the s um of the product diameters (SPD) of any 
previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).  To be considered progressive disease, a lymph node with a 
diameter of the short axis of less  than 1.0 cm must increase by ≥  50% and to a size of 1.5 
x 1.5 cm or more than 1.5 cm in the long axis.  
 Lesions should be PET positive if observed in a typical FDG -avid lymphoma or the 
lesion was PET positive before therapy unless the lesion is too small  to be detected with 
current PET systems (<.1.5 cm in its long axis by CT).  
 
 Institution of any therapy to treat persistent, progressive or relapsed disease, 
including withdrawal of immunosuppressive therapy or DLI, will be considered evidence of relapse/ progression regardless of whether the criteria described above 
are met.  
 
TABLE 3.2 RESPONSE CRITERIA FOR LYMPHOMA  
From Cheson, B.D. et al.  Revised response criteria for malignant lymphoma.  J Clin Oncol  5:579- 586, 2007.  
 
 

BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
3-5 Response Criteria for Acute Leukemia  
 
Remission is defined as < 5% blasts with no morphological characteristics of acute leukemia 
(e.g., Auer Rods) in a bone marrow with > 20% cellularity, peripheral blood counts showing 
ANC >1000/ µl, including patients in CRp. 
 
Response Criteria for Lymphoma 
 
Response criteria for lymphoma are described in Table 3.2.  
 
3.2.14. Cost-effectiveness Analysis 
 
The primary endpoint for the CEA is the cost per QALY from the societal perspective with two time horizons: (1) within trial, and (2) lifetime using economic modeling.  
 The secondary endpoints for the CEA include costs from a narrower third party payer perspective and a separate analysis of the value of informal caregiving.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-1 CHAPTER 4  
 
 
4. PATIENT ENROLLMENT A ND EVALUATION 
 4.1. Enrollment Procedures  
 
4.1.1. Screening and Eligibility Procedures  
 Patients will be registered using the BMT CTN Electronic Data Capture System (AdvantageEDC
SM).  The following procedures should be followed:  
 
1. An authorized user at the transplant center enters the patient d emographics  and HLA 
typing results of the recipient, haplo donor, and both CBUs into Segment 0 in 
AdvantageEDC.  HLA match scores will be calculated to confirm eligibility prior to randomization.  Further review by the DCC will be triggered if the institutional match score disagrees with the calculated match score.  The DCC review must be completed prior to proceeding to Segment A.  The eligibility screening includes a question 
confirming that the patient (or legal guardian) signed the informed consent.   
2. Upon successful completion of the Segment 0 HLA forms, an authorized user at the 
transplant center will enter the remainder of the eligibility criteria required prior to randomization on the Segment A enrollment form .  In addition, the transplant center mus t 
commit to using or not using post transplant maintenance therapy, irrespective of the treatment assignment.  
 
3. If the patient is eligible, the patient will be randomized to the dUCB or Haploidentical transplant arm and the treatment assignment will be displayed along with the generated patient number .  Patients should be registered as close as possible to the initiation of the 
conditioning regimen.  
 
4. A visit schedule based on treatment start date is displayed for printing and is referred to as ‘Segment A  Follow -up.’ 
 
4.2. Study Monitoring  and Data Submission  
 
4.2.1. Follow -up Schedule  
 The follow -up schedule for scheduled study visits is outlined in Table 4.2.1.  A detailed 
description of each of the forms and the procedures required for forms completion and submiss ion can be found in the Data Management Handbook and User’s Guide. 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-2 TABLE 4.2.1:  FOLLOW -UP SCHEDULE  
 
Study Visit  Target Day Post -Transplant  
1 week   7 ± 3 days 
2 week  14 ± 3 days 
3 week  21 ± 3 days 
4 week  28 ± 3 days 
5 week  35 ± 3 days 
6 week  42 ± 3 days 
7 week  49 ± 3 days 
8 week  56 ± 3 days 
9 week  63 ± 3 days  
10 week  70 ± 3 days  
11 week  77 ± 3 days  
12 week  84 ± 3 days  
13 week  91 ± 3 days  
6 month  180 ± 45 days 
12 month  365 ± 45 days 
24 month  730 ± 60 days 
36 month              1095 ± 60 days 
 
4.2.2. Criteria for Forms Submission  
 
4.2.2.1. Electronic Case Report Forms (eCRFs)  
 
All data for patients  are recorded in the electronic Case Report Forms (eCRF) exclusively 
designed for the study.  The Principal Investigator at each of the participating center’s is 
responsible for complete, accurate and timely reporting of  data.   
 Criteria for timeliness of submission for all study forms are detailed in the Data Management Handbook and User’s Guide.  Forms that are not entered into AdvantageEDC (the electronic data entry system) within the specified time will be considered delinquen t and addressed with the 
delinquent center .  When data are unavailable because a measure has not been taken , a test not 
performed or data are unk nown, a form or field exception is requested by the center.   A form will 
continue to show as “missing ” either u ntil the form is entered into the AdvantageEDC  system  
and integrated into the Data and Coordinating Center’s (DCC) master database, or until an 
exception is granted and entered into the Missing Form Exception File, as detailed in the Data Management Handbook.  
 Corrections in the eCRF are to be conducted only by authorized personnel and may require 
authorization prior to implantation of corrections . However, a ll earlier entires are retrievable 
despite corrections . All corrections are recorded automatically concerning date, time point and 
person. Plausibility and completeness of the eCRF are verified by personnel at the Data 
Coordinaring Center.   
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-3 At all times, the Principal  Investigator s at the participating centers  have full  responsibility for 
ensuring  accuracy and authenticity of all clinical and laboratory data entered on the e CRFs.  
 
Reporting Patient Deaths:   Recipient death information must  be entered into AdvantageEDC 
within 24 hours of knowledge of the patient’s death.  If the cause of death is unknown at that 
time, it need not be recorded at that time.  However, once the cause of death is determined, the form must be updated in AdvantageEDC.  
 CIBMTR Data Reporting:  Centers participating in BMT CTN trials must register pre - and 
post-transplant outcomes on all consecutive hematopoietic stem cell transplants done at their 
institution during their time of participation to the Center for International Blood and Marrow Transplant Research (CIBMTR).  Registration is done using procedures and forms of the Stem Cell Transplant Outcomes Database (SCTOD).  (Note: Federal legislation requires submission of these forms for all US allotransplant recipients.)  Enrollment of BMT CTN # 1101 must be 
indicated on the SCTOD pre -transplant registration form.  Additiona lly, CIBMTR pre - and post - 
transplant  Comprehensive Report Forms must also be submitted for all patients enrolled on this 
trial.  CIBMTR forms will be submitted directly to the CIBMTR at the times specified on the 
Form Submission Schedule.  GVHD Monitoring :  GVHD should be monitored in accordance with BMT CTN guidelines as 
specified in the Manual of Procedures.  Patients should be assessed weekly until Day 90 post-
transplant for GVHD.  After Day 90 patients will be assessed at each follow -up visit (Day 180,  
365, and 730) for the presence of GVHD.   
 
4.2.2.2. Access to Data  
 
Participating sites and their Principal Investigators must agree to allow trial- related on -site 
monitoring, including audits and regulatory inspections by  BMT CTN  DCC personnel such that 
the DCC has direct access to source data/documents as required.    
 
4.2.2.3. Record Retention  
 
Responsibilities of the Sponsor :  As required by law, all study documents must be stored by the 
sponsor for at least 10 years after the clinical t rial was finished or stopped.  
 Responsibilities of the Principal Investigator : The Investigator agrees to keep records, 
including the identity of all participating patients, all original signed informed consent forms, copies of all CRFs, source documents, detailed records of treatment disposition and other trial-related documents. The trial -related records should be retained by the Investigator for at least 10 
years or as specified by contract, whichever is longer.    
 4.2.3. Study Monitoring 
 
Monitoring and audits will be performed during the clinical study to ensure that the study meets the quality criteria.   
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-4 The investigator agrees that the monitor will visit the study center in appropriate intervals. 
During these visits, the monitor will check the quality of the data recording and ensure that the study center adheres to the timeframe as set in the study protocol. The investigators agree to provide any relevant information and documentation whenever requested by the monitor. This includes a ccess to all original study documents and source data including access to electronic 
source documents if necessary. Source data are checked and compar ed with entries in the data 
base. The pa rticipant has given consent to this procedure by signing the patient information and 
written informed consent form.  The monitor has the responsibility to treat all information confidentially and to safeguard the integrity and personal privacy of the study participants.  Following a monitoring visit, the Monitor will provide a report to the sponsor and the site, which will summarize the documents reviewed and a statement of findings, deviations, deficiencies, conclusions, actions taken and actions required. The Principal Investigator at  each site will be 
responsible for ensuring that monitoring findings are addressed (this may be delegated to an appropriate member of staff).  
 Details of monitoring activities will be included in the Site Monitoring Plan.  
 4.2.4. Adverse Event s 
 
4.2.4.1.Adverse Event Rep orting 
 
Adverse event reporting will be conducted according to the BMT CTN ’s manual of operating 
proceedures ( MOP ). 
Unexpected AE Reporting:   Unexpected, grade 3 -5 adverse events (AE) will be reported 
through an expedited AE reporting system via AdvantageEDC.  Unexpected, grade 4 -5 AEs  
must be reported within 24 hours of knowledge of the event.  Unexpected, grade 3 AEs must be reported within three business days of knowledge of the event.   
 The principal investigator is responsible for submitting  follow -up reports to the DCC for all 
Grade 3 -5 Unexpected AEs regarding the patient’s subsequent course until the Unexpected AE 
has resolved or until the patient’s condition stabilizes (in the case of persistent impairment), or the patient dies.  
 Expected  AE Reporting:   Expected AEs will be reported using NCI’s Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.0 at regular intervals as defined  on the Form 
Submission Schedule.  All fatal (Grade 5) expected adverse events will be reported in an expedited manner to the DCC.  Most protocol -specific life -threatening or disabling (Grade 4) and 
other non- fatal expected adverse events will be reported on study forms submitted on a defined 
forms submission schedule.  Grade 4 adverse events not c ollected on study forms should be 
reported in an expedited manner.  
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-5 4.2.4.2.Adverse Event Monitoring 
 
Unexpected Adverse Events:   Unexpected adverse events will be reported via a web -based 
adverse event ( AE) system.  The Adverse Event Coordinator will review dail y all submitted 
unexpected adverse events and forward the information to the Medical Monitor for review.  
 
All unexpected adverse events will be reviewed by the Medical Monitor within 2 business days of receiving the summary of the adverse event from the tr ansplant center.  If the Medical 
Monitor requires additional information to make his/her assessment, transplant centers will have 4 business days to respond to the request for additional information.  The Medical Monitor has medical expertise relevant to t he study protocol and may request the 
participant's treatment assignment when reviewing the adverse event.  A designated person at the  
DCC is responsible for notifying the Project Officer (National Heart Lung and Blood Insttiute  
[NHLBI] ) immediately of all Grade 3 -5 unexpected adverse events and of any concerns 
regarding the frequency or type of adverse event(s) on a study or study treatment arm.  The NHLBI Project Officer (or designee) is responsible for reviewing the adverse event materials to determine i f the materials are complete.  If there are any concerns regarding the type or 
frequency of the event, the NHLBI Project Officer will request that the Data Saftey Monitoring 
Board ( DSMB ) Executive Secretary notify the DSMB Chair.  The DSMB Chair will revie w the 
adverse event materials, determine if the information is complete, determine if additional DSMB review is required and make recommendations to the NHLBI concerning continuation of the study.  Full documentation of the procedures will be available at the DCC.  
 The Medical Monitor will review cumulative unexpected grades 3- 5 SAEs on a quarterly basis 
(data will be reported in a blinded fashion).  The Medical Monitor may seek additional guidance from one of the DCC Principal Investigators, based on the e xpertise required, for their 
assessments as long as the DCC Principal Investigator’s  institution is not participating in the 
protocol under consideration, and the DCC Principal Investigator is not considered to be otherwise in conflict by the NHLBI or by t he Steering Committee.  If there any concerns 
regarding safety, the NHLBI Program Directors will be notified immediately.  The Medical Monitor will provide a written summary of the safety concern.  
 The DCC will prepare semi -annual summary reports of all unexpected adverse events for the 
NHLBI Project Officer and DSMB Chair.  Semi -annual reports will be made available on a 
secure website and the NHLBI Project Officer and DSMB Chair will be notified by e -mail when 
the materials are posted.  
 Expected  Adverse Events:   The DCC will prepare semi -annual summary reports of all Grade 5 
expected adverse events for the NHLBI Project Officer and the DSMB Chair.  Semi -annual 
reports will be made available on a secure website and the NHLBI Project Officer and DSMB Chair will be notified by e -mail when the materials are posted.  Grade 3 -5 expected adverse 
events defined in the interim analysis plan will be reported as defined in the protocol.  Any concern regarding the type or frequency of a Grade 3- 5 expected adverse even t will be reported 
to the NHLBI Project Officer who will determine if referral to the DSMB is warranted.  If required, data materials will be provided by the DCC.  The DSMB Executive Secretary will 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-6 arrange for review by the DSMB Chair.  The Chair will determine if additional DSMB review is 
required and make recommendations to the NHLBI concerning continuation of the study.  The DCC will ensure that any additional reporting requirements defined by the NHLBI Project Officer, DSMB Chair and other oversight groups are identified and implemented. The DCC in collaboration with the NHLBI Project Officer will determine the exact content of these summary reports and the reporting schedule . 
 The Protocol Coordinator and Medical Monitor  will review the adverse events m onitored for 
stopping guidelines at least monthly.  
 Additionally, the Protocol Coordinator and Medical Monitor will review events reported on the protocol -specific toxicity form, the GVHD forms and the infection forms on a regular basis (at 
least semi -annually) to assess whether there are safety concerns that should be referred to the 
DSMB.  The Medical Monitor may seek additional guidance from one of the physicians at the DCC in these assessments as long as this physician’s  institution is not participatin g in the 
protocol under consideration.    
TABLE 4.2.4.1 REPORTING UNEXPECTED ADVERSE EVENTS ON A BMT CTN  
PHASE II OR III STUDY  
 
SEVERITY 
GRADE  ATTRIBUTION  TRANSPLANT CENTER  
REPORTING REQUIREMENTS  
5 - Fatal  
4 - Life-threatening  
     or Disabling  All attributions  
 Submit unexpected adverse event form to the DCC within 
24 hours of the event.  For Grade 5, also submit study 
death form to the DCC.  
Submit a summary of the adverse event to the DCC within 
4 working days.  For Grade 5, the summary should 
include potential contributing causes of death. 
Information reported for the adverse event must include: Name of adverse event, date of first onset, peak severity, 
relationship to study drug/device/treatment, resolution 
date, actions taken with respect to admi nistration of study 
drug/device/treatment, and other treatment for the adverse 
event.  
3 – Severe  
  All attributions  
    Definite  
Probable  
Possible  
  
 Submit unexpected adverse event form to the DCC within 
3 working days of the adverse event.   
Submit a summary of the adverse event to DCC within 4 working days  
Information reported for the adverse event must include:  
Name of adverse event, date of first o nset, peak severity, 
relationship to study drug/device/treatment, resolution 
date, actions taken with respect to administration of study drug/device/treatment, and other treatment for the adverse 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-7  
 
 Unlikely  
Unrelated  event.  
Multiple recurrences of the same adverse event shoul d be 
reported separately.  
Information reported for the adverse event must include: name of adverse event, date of first onset, peak severity, and relationship to the study drug/device/treatment.  
Multiple recurrences of the same adverse event should be 
reported together.   
Note: Any adverse event prompting a change in the 
administration of study drug/device/treatment must 
include resolution date, actions taken with respect to 
administration of study drug/device/treatment, and other 
treatment for the adverse event.  
 
TABLE 4.2.4.2  REPORTING EXPECTED ADVERSE EVENTS ON BMT CTN  
PHASE II OR III STUDIES  
 
SEVERITY 
GRADE  ATTRIBUTION  TRANSPLANT CENTER  
REPORTING REQUIREMENT  
5 – Fatal  
 All attributions  Submit study death form to the DCC within 24 hours of 
death.  
Submit death summaries and/or autopsy reports of the 
expected adverse event to DCC quarterly or as requested.  
The summaries should include potential contributing 
causes of death.  
4 – Life-threatening  
      or disabling All attributions  Submit study form(s) capturing data on the expected 
adverse event to the DCC at the form’s scheduled due 
date.  If the event is not captured on a study from, report using the AE system in an expedited manner.  
Note: Selected Grade 3 -5 events will be tracked and 
regularl y monitored by the DCC and DSMB as specified 
in protocol -specific monitoring plans.  
3 – Severe  
 All attributions  Submit study form(s) capturing data on the expected 
adverse event to the DCC at the form’s scheduled due 
date.  
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-8 4.2.4.3. Adverse Event Definitions  
 
Adverse Event  - Any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a medical treatment or 
procedure regardless of whether it is considered related to the medical treatm ent or procedure 
(attribution of definite, probable, possible, unlikely, or unrelated).  
 
Life-Threatening Adverse Event  - Any adverse event that places the participant, in view of the 
investigator, at immediate risk of death from the reaction.  
 
Serious Adverse Event (SAE)  - Any adverse event that results in any of the following outcomes: 
death, a life threatening adverse event, in -patient hospitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity, or a co ngenital anomaly/birth 
defect.  
 
Unexpected Adverse Event  - Any adverse event, the specificity or severity of which is NOT 
listed in the study protocol, product inserts or informed consent document. 
 
Attribution  - The determination of whether an adverse event is related to a medical treatment or 
procedure.  Attribution categories:  
 
Definite  The adverse event is clearly related  to the study drug/device/procedure/ 
treatment(s).  
 Probable  The adverse event is likely related  to the study drug/device/procedure/ 
treatment.  
For BMT CTN studies:  the adverse event is not likely to be caused by the subject’s underlying medical condition or other concomitant therapy, and the nature of the adverse event or the temporal relationship between the onset of the adverse event and study  drug/device/treatment administration lead the 
investigator to believe that there is a reasonable chance of causal relationship.  
 
Possible  The adverse event may be related  to the study drug/device/procedure/ 
treatment(s).  
For BMT CTN studies: the adverse event could be attributed to the subject’s 
underlying medical condition or other concomitant therapy, but the nature of the adverse event or the temporal relationship between the onset of the adverse event and study drug/device/treatment administration lead the investigator to believe that there could be a causal relationship.  
 
Unlikely  The adverse event is doubtfully related  to the study drug/device/ 
procedure/treatment(s).  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-9 Unrelated  The adverse event is clearly NOT related  to the study drug/device/proced ure/ 
treatment(s).  
For BMT CTN studies:  the adverse event is most plausibly explained by the 
subject’s underlying medical condition or other concomitant therapy, or the adverse event has no plausible biological relationship to study drug/device/ treatment .  
 
Common Terminology Criteria Adverse Events (CTCAE)  – a descriptive terminology developed 
by the National Cancer Institute (NCI) for use in reporting adverse events.  The CTCAE includes 
a grading (severity) scale for each adverse event term.  Exhibits 6 -1-1 and 6 -1-2 provide 
reporting requirements for BMT -related complex/multi- component events.  A copy of the current 
CTCAE guidelines is located at http://ctep.cancer.gov/reporting/ . 
 
Grade  – Severity of the adverse event.  Grades were developed using the following guidelines:  
 
 Grade  0 – No adverse event or within normal limits  
  1 – Mild adverse event  
  2 – Moderate adverse event  
  3 – Severe adverse event  
  4 – Life-threatening or disabling adverse event  
  5 – Fatal adverse event  
 4.2.5. Patient Assessments  
 Table 4.2.2 summarizes patient clinical assessments over the course of the study.  
 4.2.5.1. Pre -transplant evaluations  
 The following observations must be completed ≤  30 days  prior to patient enrollment : 
1. History, physi cal examination, height and weight.  
2. Karnofsky performance status.  
3. CBC with differential and platelet count and blood chemistries to include: serum 
creatinine, bilirubin, alkaline phosphatase, AST, and ALT, LDH, sodium, magnesium, potassium, and chloride .  
4. If not already performed, HLA typing of the recipient: At least low resolution DNA 
based typing at HLA -A and - B, high resolution at  HLA -DRB1 (see Section 2.2.1)  
5. If not already performed, HLA typing (DNA- based low or high resolution acceptable) of 
at least  one potential HLA -haploidentical first- degree relative (not required if potential 
haplo- donor is a biological parent or child) .  
6. Leukemia patients: Bone marrow aspirates for pathology and cytogenetics and/or biopsy.  
7. Serum sample for anti -donor HLA antibodies.  
8. Lymphomas: CT scans or Whole Body PET/CT.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-10 9. Declaration of post transplant maintenance therapy, if intended, and independent of the 
randomization assignment.   
The following observations are considered standard evaluations for transplant eligibility and must  be determined ≤  30 days prior to enrollment , OR ≤ 56 days  prior to the initiation of 
conditioning therapy .   
1. For patients randomized to the double umbilical cord blood arm, confirmatory HLA typing  (see Section 2.3.3) , if not already performed .   
2. For patients randomized to the HLA haplo -identical bone marrow arm, high resolution 
DNA- based typing (see Section 2.3.2)  of the recipient and donor , if not already 
performed . 
3. CMV antibody test, hepatitis panel (HepA Ab, HepB Sab, HepB Sag, HepB Core Ab, HepC Ab), herpes simplex, syphilis, HIV and HTLV1 I/II antibody, and varicella zoster virus. 
4. EKG.  
5. Left ventricular ejection fraction or shortening fraction. 
6. DLCO, FEV 1, and FVC.  
7. Chest imaging (Chest X -Ray or Chest CT).  
8. Peripheral  blood for pre -transplant chimerism, to establish a reference profile of host 
hematopoiesis. 
9. HQL questionnaires . 
10. Confidential Health Insurance Form and Caregivers Contact Information Form for t he 
Cost Effectiveness Ancillary study.  
 The following tests must be completed ≤  30 days prior to  the initiation of conditioning 
therapy .   
1. Recipient b lood sample for future research.  
2. Donor blood (from all Haplo- BM donors) and bone marrow (from donors ≥ 18 only) 
samples for future research.  Donor samples to be collected on Day 0.  
3. CBC with differential, and blood chemistries to include: serum creatinine, bilirubin , AST, 
and ALT .   
4. β-HCG serum pregnancy test for females of childbearing potential . 
5. Leukemia pat ients: bone marrow aspirate and/or biopsy for pathology.  THIS TEST 
DOES NOT NEED TO BE REPEATED  IF THE PRE- ENROLLMENT BONE 
MARROW WAS OBTAINED ≤ 30 DAYS PRIOR TO INITIATION OF 
CONDITIONING . 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-11 4.2.5.2. Post -transplant evaluations  
 
The following evaluations are considered standard evaluations for transplant recipients:  
1. Physical exam to assess GVHD and other morbidity weekly until Day 90 post-transplant, 
then at Days 180, 365, and 730 post-transplant.  GVHD evaluation and grading to be in 
keeping with  the BMT CTN MOP.  
2. Karnofsky performance status  on Days 56, 180, 365, and 730. 
3. CBC at least three times a week from Day 0 until ANC > 500 mm3 for 3 days after nadir 
reached.  Thereafter CBC twice per week until Day 28, then weekly until  Day 56 , then at 
Days 180, 365, an d 730 post -transplant. 
4. Creatinine, bilirubin, alkaline phosphatase, ALT, AST, LDH, sodium, magnesium, 
potassium, and chloride, twice a week until Day 28 (or four weeks) and then weekly until 
Day 56 , and then at Days 180, 365, and 730. 
5. Peripheral blood on Day s 28 and 56 for post -transplant chimerism assay.   Chimerism to  
be measured by standard molecular testing.  FISH may only be used with haplo sex mis -
matched transplants.   T cell chimerism is recommended.   Peripheral blood for chimerism 
assay recommended o n Day 180 if donor chimerism is less than 95% on Day 56.  For the 
dUCB arm, the chimerism of individual cord blood units should be re ported separately.  
6. dUCB Arm: Bone marrow aspirate and biopsy  with chimerism studies is required  at Day 
21 if WBC < 500.  If  there is zero donor chimerism on Day 21, repeat on Day 28.  At Day 
28, if the the marrow is < 5% cellular and or there is zero donor chimerism, consider management of graft failure per institutional guidelines.  
7. Haplo -BM Arm: if A NC is less than 500 on Da y 28, a bone marrow aspirate and biopsy 
with chimer ism studies  is required.  If zero donor chimerism is present at this time, 
consider management of graft failure per institutional guidelines.  
8. Toxicity assessments at Day s 28, 56, 180, 365, and 730.    
9. Disease status evaluation    
a. Leukemia Patients: Disease status evaluation with at minimum CBC with 
differential  is required at Day  730.  Abnormal counts should be followed up with 
bone marrow biopsy or aspirate.   
b. Lymphoma Patients – CT scans or Whole Body CT/PET scan on Day 730, per 
NCCN guidelines.  
10. Weekly CMV monitoring through Day 56.  
11.  HQL questionnaires  to be completed by the patient at Days 365, and 730.  
12.  Blood samples for future research on Days 28, 56, 180, and 365. 
BMT CLINICAL TRIALS NETWO RK  RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-12 TABLE 4.2. 2:  SUMMARY OF ASSESSMENTS  
 
Study Assessments/  
Testing  Baseline  Days after Transplantation  
7 14 21 28 35 42 49 56 63 70 77 84 91 180 365 730 109512 
History, ph ysical exam, height and weight  X                  
Karnofsky performance status  X        X      X X X  
HLA Typing  X                  
CBC1 differential, platelet count, and blood chemistries2 X X X X X X X X X      X X X  
Infectious disease titers3 X                  
CMV monitoring   X X X X X X X X          
EKG and LVEF or shortening fraction  X                  
DLCO, FEV1 and FEV  X                  
Bone marrow aspirate for pathology and cytogenetics 
and/or biopsy X*   X4 X4              
CT scans or Whole Body CT/PET5 X5                X5  
Chest x -ray or chest CT  X                  
ß-HCG serum pregnancy test (females only)  X                  
GVHD assessments6  X X X X X X X X X X X X X X X X  
Toxicity assessments      X    X      X X X  
Chimerism7 X    X    X      X7    
Anti-HLA antibody crossmatch test X                  
Blood samples for future research8 X8    X    X      X X   
Haplo donor blood and bone marrow sample for future 
research9 X9                  
Health -Related Quality of Life Assessments10 X               X X  
Confidential Health Insurance Form and Contact 
Information Form11  X                  
Comprehensive CIBMTR Forms               X X X X X 
Notes:  
1  CBC performed at least three times a week from Day 0 until ANC >500 mcL for three days after nadir.  CBC performed twice week ly until Day 28. CBC performed 
weekly after Day 28 until Day 56 . 
2  Blood chemistries  should include: serum creatinine, bilirubin, alkaline phosphatase, AST, and ALT, LDH, sodium, magnesium, potassium,  and chloride .  Blood 
chemistries performed twice weekly until Day 28.  Blood chemistries performed weekly after Day 28 until  Day 56.  
3  Infectious disease titers include: CMV, Hepatit is panel (HepA Ab, HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), herpes simplex virus, syphilis, HIV and HTLV 
I/II antibody, and varicella zoster.  
    *Baseline for leukemia patients only. 
4  For dUCB arm b one marrow biopsy and aspirates to pathology require d at Day 21 if WBC < 500.  For both dUCB arm and Haplo-BM arm Day 28 only to be done if 
slow neutrophil recovery to evaluate for graft failure.   
BMT CLINICAL TRIALS NETWO RK  RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
4-13 5  LYMPHOMA PATIENTS ONLY: CT scans or Whole Body CT/PET at Baseline and Day 730.   
  6  GVHD assessments performed weekly until Day 90 post-transplant, and then at Day 180, 365, and 730. 
7  Chimerism to be measured  by standard molecular testing  of a peripheral whole blood sample.   FISH may only be used with haplo sex mis -matched transplants  T cell  
chimerism is recommended.  Peripheral blood for chimerism assay recommended on Day 180 if donor chimerism is less than 95% on Day 56.  For the cord blood arm, 
chimerism of individual cord blood units should be re ported separately.  
8  Baseline blood samples for future research include samples from recipient and haplo donor .  See appendix C for details.  
9  Bone marrow sample for future research from Haplo -BM  donor s ≥18  only.  See appendix C for details.  
10 See Section 2. 9 for detailed descriptio n of HQL  assessments.  
11 See companion study document  for detailed description of Cost Effectiveness Ancillary study and Confidential Health Insurance and Contact Information form s. 
12 Day 1095 data to be obtained from the CIBMTR.  
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-1 CHAPTER 5  
 
 
5. STATISTICAL CONSIDERATIONS  
 
5.1. Study Design and Objectives  
 The study is designed as a Phase III, randomized, multicenter prospective comparative study of transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA -Haploidentical 
Related Bone Marrow (Haplo) using non- myeloablative conditioning for patients with 
hematologic malignancies .  The target enrollment is 410 patients, 205 for each arm.  
 5.1.1. Accrual  
 It is estimated that four years of accrual will be necessary to enroll the targeted sample size.  
 5.1.2. Randomization  
 Patients will be randomized at a ratio of 1:1 between the treatment arms using permuted blocks of random sizes.  Randomization will be stratified by center.  
 5.1.3. Primary Endpoint  
 
The primary endpoint is the probability of PFS at 2 years post randomization.  The primary 
analysis will be performed using the intent -to-treat principle so that all randomized p atients will 
be included in the analysis.  Death or progression will be considered failures for this endpoint.   
 5.1.4. Primary Hypothesis  
 The primary null hypothesis of the study is that there is no difference between the 2 year PFS probabilities for dUCB vs. haplo- BM. 
 
H
o: pdUCB  = p Haplo  
Ha: pdUCB  ≠ pHaplo 
 
5.2. Sample Size and Power Considerations  
 
The primary analysis will be done using a group sequential comparison of the 2 year PFS probabilities using the difference in Kaplan- Meier estimates
21; sequential monitoring is 
described further in S ection 5.3.  A pointwise comparison of PFS at 2 years is proposed for the 
primary analysis rather than a log -rank test because of the potential for crossing hazards.  Phase 
II data indicated potentially lowe r TRM and higher relapse rates for the haplo- BM arm, and 
differential timing between these two types of events would lead to nonproportional hazards.  
The logrank test would have poor power to detect a difference between these two groups if the 
hazards cro ss.  The time point of 2 years was chosen based on CIBMTR data which indicated 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-2 most events after UCB and haploidentical transplantation occur  by 2 years.  The final patient 
enrolled will be followed up for a minimum of 3 years, so that the targeted total s tudy duration is 
7 years (4 years accrual + 3 years follow -up on the last patient).   
 
The targeted sample size is 410 patients, 205 per treatment arm.  The baseline PFS at 2 years is 
assumed to be approximately 35 -40% based on CIBMTR data on RIC transplan tation using 
unrelated adult donors.  We allow for 5% censoring due to loss to follow -up by 2 years in 
addition to administrative censoring.  In addition, we anticipate up to 5% of patients will be 
randomized but do not make it to the assigned transplant, and for power calculations we assume that these patients will all progress or die within 6 months.  The targeted sample size of 205 
patients per group is sufficient to maintain type I error of 5% across all planned interim analyses (see below) while provid ing 80% statistical power for a two -sided test to detect a 15% increase 
in the PFS probability at 2 years.  Note that the targeted 15% increase in PFS is the effect attributable to the transplant type itself.  This translates to a slightly lower 14.25% inc rease in 
PFS in the Intention- to-Treat (ITT) populations after accounting for the 5% of patients who are 
randomized but do not make it to transplant.  We will monitor the proportion of patients who are randomized but do not receive a transplant, and if the  proportion is higher than the anticipated 
5%, we will re -evaluate the sample size to account for the resulting decrease in treatment effect 
for the ITT populations.  Details of this power calculation are found in the section on interim analyses for efficacy and futility.    
5.3. Interim Analysis and Stopping Guidelines  
 
Interim analysis for efficacy and futility will be conducted at times coincident with regularly scheduled meetings of the NHLBI -appointed Data and Safety Monitoring Board (DSMB) at 
approximatel y one year intervals.  Policies and composition of the DSMB are described in the 
BMT CTN’s Manual of Procedures.  The stopping guidelines serve as a trigger for consultation with the DSMB for additional review and are not formal “stopping rules” that would mandate 
automatic closure of study enrollment.   Toxicity, adverse events, and other safety endpoints will 
be monitored regularly and reported to the DSMB at each interim analysis.  5.3.1. Interim Analysis for Efficacy and F utility  
 Analyses will be performed as described below for the primary endpoint.  At the time of each 
interim analysis (tentatively planned at approximately 3, 4, 5, and 6 years), a two- sided test using 
the difference in Kaplan -Meier estimates of the PFS at 2 years  will be conducted.  These test 
statistics have independent increments as described in Gu et al.
21  All patients randomized prior 
to the time of the interim analyses will be used to compute the Kaplan -Meier estimate of PFS at 
2 years.  If the test statistic exceeds the critical value for efficacy, the DSMB will discuss the continuation of the trial.   
 
In order to preserve the overall Type I error rate at 5%, the critical value for the test statistic will 
be inflated above 1.96, the value that would be used if no repeated testing were used.  
Equivalently, the nominal p- value at which an observed difference is declared significant will be 
reduced belo w 0.05.  The actual critical values and nominal p- values will be computed using 
statistical methods for group sequential testing with O’Brien Fleming type boundaries.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-3 To permit necessary flexibility in scheduling interim analyses, the critical values will be 
recomputed to correspond to the actual available statistical information using the “use -function” 
approach of Lan and DeMets.  The error spending function α(t)=min(α,αt3) will be used to 
approximate the O -Brien -Fleming boundary with unequally spaced looks.22  Information is 
defined as the reciprocal of the variance of the difference in Kaplan -Meier estimates between the 
two treatments.  The final information at the end of the study reduces to the reciprocal of the 
variance of the difference in two binomi al proportions, assuming no censoring prior to 2 years, 
computed as 450.55.  Then the information fraction t is the ratio of the information at an interim analysis to the final information at the end of the study.  
 Interim analyses for futility will start when accrual is complete, so that these analyses do not 
impact power for secondary endpoints.  The main benefit of these interim analyses for futility is potentially shortening of the time until the study conclusions regarding two year survival are reached, since they allow for stopping prior to the completion of the two year follow -up for the 
last patient enrolled.  The stopping rule for futility will be triggered when the conditional power to reject the null hypothesis at the observed effect size is less  than 10%. 
 Phase II data on dUCB and haplo transplants as well as longer -term CIBMTR data on unrelated 
adult donor transplants with RIC indicate PFS probabilities at 6 months, 1 year, and 2 years of 65%, 47%, and 35%.  We also assume that 5% of patients w ill be randomized but not make it to 
the assigned transplant, and that all of these patients will progress or die by 6 months, so that the anticipated PFS curves in the ITT population are 62%, 45%, and 33%.  We also target a difference in 2 year PFS due to  transplant type of 15%, which translates to a 14.25% difference 
in PFS at 2 years in the ITT population.    Table 5.3.1a  shows the information accumulated, the critical values for efficacy and futility, and 
the nominal significance levels for tests conducted at interim analyses at 3, 4, 5, and 6 years from the start of the study.  The information calculations assume uniform  accrual of patients over 4 
years with 2 years of follow -up on the final patient enrolled.  The information fraction at each 
interim analysis comes from the reciprocal of the variance of the Kaplan -Meier estimate, which 
is approximated  using a piecewise co nstant hazard function assuming PFS probabilities  as 
described above.   Interim analyses for futility are planned to start at 4 years when accrual is 
completed.  
 Table 5.3.1b shows the cumulative probability of stopping for efficacy or futility at each inte rim 
analysis from a simulation study under various scenarios, including two null hypothesis scenarios (PFS at two years of 35% in each treated group or 40% in each treated  group) and 
under various alternative hypotheses (i mprovements in 2 year PFS of  10%, 15%, or  20% over 
baseline PFS of either 35% or 40% , corresponding to improvements in ITT population of 9.5%, 
14.25%, or 19% ).  Simulations used 10000 Monte Carlo samples, and generated baseline 
survival curves from the piecewise constant hazard model as de scribed previously .   
A proportional hazards model was used with hazard ratio chosen to induce the targeted increase in PFS in the ITT population for each scenario.  However, note that the proportional hazards 
model used in the simulation has minimum impac t on the operating characteristics because all 
analyses are based on the pointwise comparison of the 2 year PFS probabilities.  In addition to administrative censoring induced by the accrual distribution and end of study time, the 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-4 simulations also accounte d for additional drop out using independent exponential censoring with 
5% probability of censoring by 2 years.  The results indicate that there is >  50% power to detect 
a 15% improvement in 2 year PFS by the interim analysis at 4 years and 80% power to det ect the 
same improvement by the final analysis.  When there is no difference in two year survival there 
is a 76% chance of stopping for futility by the interim analysis at 4 years.  
 
TABLE 5. 3.1a CRITICAL VALUES AT E ACH INTERIM ANALYSIS  
Calendar time 
since study 
start (years)  Information 
Fraction  Critical 
Value  for 
Efficacy  Nominal 
Type I 
Error   Critical 
value for 
Futility  
3 0.48 3.0103  0.0013  - 
4 0.74 2.4534  0.0071  1.2057  
5 0.94 2.1092  0.0175  1.6881  
6 (Final)  1.00 2.0551  0.0199  2.0551  
  
TABLE 5.3. 1b CUMULATIVE PROBABILITIES OF STOPPING FOR EITHER 
EFFICACY OR FUTILITY BY EACH INTERIM ANALYSIS UNDER VARIOUS NULL 
AND ALTERNATIVE SCENARIOS, FROM A SIMULATION STUDY WITH 10,000 
REPLICATES  
   Cumulative probability of stopping and 
reaching conclusion by interim analysis at x 
years  
2 year PFS  in 
treated pop 
(ITT pop)  Diff in 
treated pop 
(ITT pop)  Conclusion  x=3 4 5 6 (Power)  
35%,35%  0%  Efficacy  0.004  0.019  0.044  0.051  
(33.2%,33.2%)  (0%)  Futility   0.765  0.914   
40%,40%  0%  Efficacy  0.003  0.017  0.041  0.048  
(38%,38%)  (0%)  Futility  - 0.767  0.911   
35%,45%  10%  Efficacy  0.056  0.232  0.430  0.479  
(33.2%,43.7%)  (9.5%)  Futility  - 0.300  0.442   
40%,50%  10%  Efficacy  0.058  0.239  0.431  0.472  
(38%,47.5%)  (9.5%)  Futility  - 0.300  0.438   
35%,50%  15%  Efficacy  0.171  0.534  0.765  0.802  
(33.2%,47.5%)  (14.25%)  Futility  - 0.098  0.151   
40%,55%  15%  Efficacy  0.188  0.551  0.770  0.802  
(38%,52.2%)  (14.25%)  Futility  - 0.087  0.142   
35%,55%  20%  Efficacy  0.390  0.823  0.952  0.967  
(33.2%,52.2%)  (19%)  Futility  - 0.014  0.023   
40%,60%  20%  Efficacy  0.432  0.838  0.953  0.964  
(38%,57%)  (19%)  Futility  - 0.011  0.021   
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-5 5.3.2. Guidelines for Safety Monitoring 
 
Monitoring of TRM, a key safety endpoint will be conducted monthly, and if rates significantly exceed pre- set thresholds, the NHLBI will be notified in order that the DSMB can be advised.  
Policies and composition of the DSMB are described in the BMT CTN's Manual of Procedures .  
The stopping guidelines serve as a trigger for consultation with the DSMB for additional review.  
The key safety endpoint to be monitored is the cumulative incidence of transplant -related 
mortality at D ay 100.  This outcome will be monitored using a Sequential Probability Ratio Test 
(SPRT) for binary data as described below.  The SPRT conserves type I error at 5% across all of the monthly examinations.  No additional control of the type I error across multiple treatment groups will be used.  
 The cumulati ve incidence of TRM  at Day 100 will be monitored separately for each arm.  Each 
month, the null hypothesis that the cumulative incidence  of TRM at D ay 100 is ≤ 15% will be 
tested against the alternative that it is > 1 5%.  This null hypothesis value comes f rom CIBMTR 
data on RIC  unrelated adult donor transplants, in which Day 100 TRM is 11% (95% confidence 
interval 6% -17%) for 7/8 HLA -matched unrelated peripheral blood stem cell transplants  and 9% 
(95% confidence interval 5% -14%) for double cord blood transplants.  Day 100 TRM will be 
monitored using  a SPRT for binary outcomes.  T he SPRT can be represented graphically.  At 
each interim analysis, the total number of patients enrolled is plotted against the total number of patients who have experienced t ranspla nt-related mortality .  The continuation region of the 
SPRT is defined by two decision boundaries.  Only the upper boundary will be used for monitoring the study to protect against high incidences of TRM .  If the graph falls above the 
upper boundary, the SP RT rejects the null hypothesis, and concludes that the TRM incidence is 
higher than predicted by the observed number of patients enrolled on study.  Otherwise, the 
SPRT continues until enrollment reaches the target goal.  The SPRT for TRM was developed from the following SPRT: 
A SPRT contrasting 15% versus 25% 100- day incidence, which results in decision boundaries 
with a common slope of 0.197 and an upper intercept of 4.258, with nominal type I and II errors of 6% and 10%, respectively.  
 The actual operating characteristics of this truncated test, shown in Table 5.3.2, were determined in a simulation study that assumed uniform accrual of 205 individuals over a four -year time 
period.    
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-6 TABLE 5.3. 2:  OPERATING CHARACTERISTICS OF SEQUENTIAL TESTING 
PROCEDURE FOR 100 DAY TRM FROM A SIMULATION STUDY WITH 10,000 
REPLICATIONS  
True 100- Day Incidence  15% 20% 25% 
Probability Reject Null  0.052 0.464  0.933 
Mean Month Stopped 49.6 38.7 21.7 
Mean # Endpoints in 100 Days  29.6 30.2 19.9 
Mean # Patients Enrolled  197.9 151.3 79.3 
 
For example, the testing procedure for a treatment which continues into Phase III testing rejects the null hypothesis in favor of the alternative 5% of the time when the true 100 -day TRM 
incidence is 15%, and 93% of the time when the rate is 25%.  This cor responds to a type I error 
rate of α = 0.05 and a type II error rate of β = 0.07.  When the true 100- day TRM incidence is 
25%, on average, the DSMB will be consulted 22 months after opening, when 20 events have 
been observed in 79 patients.   
 
5.4. Demographic  and Baseline Characteristics  
 
Demographics and baseline characteristics will be summarized for all patients.  Characteristics to 
be examined are: age, gender, race/ethnicity, performance status, primary disease, risk status  
(Leukemia in CR1 vs. CR2+, Lymphoma in CR vs. PR) , CMV status, HCT -comorbidity index, 
time from diagnosis to transplantation, cytogenetic at diagnosis (AML and ALL), HLA 
matching, prior autologous transplant, number of regimens prior to transplant (lymphoma only), 
cell dose/kg, and hapl o donor relationship.  Between group comparisons will be performed for 
continuous variables via a Kruskal -Wallis test and for categorical variables, via the chi -square 
test.  A secondary analysis of all outcomes will adjust for age, performance status, pri mary 
disease, risk status, and CMV status, in addition to any other demographic and baseline 
characteristics which are statistically different between treatment arms (p<0.1).      
5.5. Analysis Plan  
 
5.5.1. Analysis of the Primary Endpoint  
 
The primary outcome of the trial is PFS at 2 years after randomization.  The primary null hypothesis of the study is that there is no difference in PFS between the treatment arms at 2 years.  In the primary analysis, the intention- to-treat principle will b e used.  The primary analysis 
will be performed using the difference in Kaplan -Meier estimates for PFS at 2 years.  A 95% 
confidence interval for the difference in PFS at 2 years will also be constructed.    
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-7 5.5.2. Analysis of Secondary Endpoints  
 
5.5.2.1. Secondary anal ysis of PFS  
 Several secondary analyses of PFS will be conducted.  In addition to a point -wise comparison at 
2 years, Kaplan -Meier curves will be constructed for each treatment arm.  Additional analyses to 
be performed will depend on an assessment of the original assumption of nonproportional hazards assumed in the study design.  A Cox proportional hazards model will be fit to PFS and graphical diagnostics and time -dependent covariates will be used to assess the presence of  
nonproportional hazards between t reatment groups.  If there is no evidence of nonproportional 
hazards, a relative risk will be estimated from the Cox model both unadjusted and adjusted for other covariates.  If there appears to be nonproportional hazards, several analyses will be conducte d.  First, confidence bands for the difference in PFS will be constructed.  Second, a 
comparison of PFS post 2 years will be conducted using the linear combination test proposed by Logan et al.
23  This method  directly compares the PFS curves starting at 2 y ears, and accounts 
for patients enrolled early in the study having additional follow -up past 2 years.  Finally, an 
adjusted analysis of PFS at 2 years will be conducted using the adjusted PFS probabilities proposed by Zhang et al.
24.  The adjusted PFS probabilities are estimated using a Cox 
proportional hazards model, stratified on treatment.  Age, performance score, d isease, disease 
risk, CMV status, and any other covariates which are significantly different between the 
treatments ( p<0.1) will be used in any adjusted analyses.   Finally, PFS will also be described in 
each arm from the time of transplant.  
 5.5.2.2. Overall survival  
 Overall survival curves will be estimated using the Kaplan -Meier estimator.  Overall survival at 
2 years will be  compared between treatment arms using the difference in Kaplan -Meier 
estimators.  A secondary analysis of survival will be performed by assessing proportional 
hazards and performing subsequent analysis based on the results of that assessment, using the same methods as those described in Section 5.5.2.1.  Overall survival will also be described in 
each arm from the time of transplant.  
 5.5.2.3. Treatment -related mortality  
 Incidence of TRM will be estimated using the cumulative incidence function, treating relapse/progression as a competing risk.  Incidence of TRM will be compared between the treatment arms using Gray’s test.
25  In a secondary analysis, TRM will be compared between 
arms using a Cox proportional hazards model with treatment as the main effect.  Age, performance score, disease, disease risk, CMV status, and any other baseline characteristics which are significantly different between arms will be included as covariates in the Cox model to adjust for potential imbalances .  TRM will also be described in e ach arm from the time of 
transplant.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-8 5.5.2.4. Relapse/progression  
 
Incidence of relapse/progression will be estimated using cumulative incidence function, treating death in remission as a competing risk.  Incidence of relapse/progression will be compared between the treatment arms using Gray’s test.  In a secondary analysis, relapse/progression rates 
will be compared using a Cox proportional hazards model with treatment as the main effect.  Age, performance score, disease, disease risk, CMV status, and any other s ignificantly 
imbalanced characteristics will be adjusted for.   Relapse/progression will also be described in 
each arm from the time of transplant.  
 5.5.2.5.Hematologic recovery  
 Incidence of neutrophil and platelet engraftment from the time of transplant will be e stimated 
using the cumulative incidence function with death prior to engraftment as the competing risk.  Incidence of neutrophil engraftment at 56 days and incidence of platelet engraftment at 100 days will be compared between the treatment arms using a po intwise comparison of the cumulative 
incidence probabilities.     5.5.2.6. Donor cell engraftment  
 Donor chimerism at Days 28  and 56 after transplantation in each treatment arm will be described 
numerically as median and range for those evaluable as well as accord ing to proportions with full 
(> 95%), mixed (5- 95% donor cells), graft rejection (<  5%), or death prior to assessment of 
donor chimerism.  The proportions alive with ≥ 5% donor chimerism will be compared between 
the two groups using the chi -square test.   
 5.5.2.7. Acute GVHD of grades II -IV and III -IV 
 Cumulative incidence of acute GVHD will be estimated from the time of transplant using the cumulative incidence function, treating death prior to acute GVHD as the competing risk.  
Cumulative incidence of a cute GVHD will be compared between treatment arms using Gray’s 
test.  
 5.5.2.8. Chronic GVHD  
 Cumulative incidence of c hronic GVHD from the time of transplant will be estimated using the 
cumulative incidence function, treating death prior to c hronic GVHD as the competing risk.  
Cumulative incidence of chronic GVHD will be compared between treatment arms using Gray’s  
test.   5.5.2.9. Incidence of primary graft f ailure  
 The proportions of patients alive at D ay 56 but with primary graft failure will be described and 
compared between  the treatment arms using the chi -square test or Fisher’s exact test as 
appropriate.   
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-9 5.5.2.10. Incidence of s econdary graft f ailure  
 
The cumulative incidence of secondary graft failure out of those who had initial engraftment will 
be described using the cumulative incidence estimator, treating death and disease relapse/progression prior to secondary graft failure as a competing event.    
5.5.2.11. Incidence of t oxicities g rade ≥  3 per CTCAE v ersion 4.0 
 All Grade ≥  3 toxicities will be tabulated by grade for each treatment arm , by type of toxicity as 
well as the peak grade overall .  Toxicity frequencies will be described for each time interval as 
well as cumulative over time.   
 
The cumulative  incidence of Grade ≥ 3 toxicity will be compared between treatment arms at 
Days 28, 56, 180, 365, and 730.    
 5.5.2.12. Incidence of i nfections  
 The num ber of infections and the number of patients experiencing infections will be tabulated by 
type of infection, severity, and time period after transplant.  The cumulative incidence of severe, 
life-threatening, or fatal infections, treating death as a competi ng event, will be compared 
between the two treatment arms  at 6, 12, and 24  months .  A secondary analysis of infections 
requiring hospitalization will be conducted in a similar way.   
 5.5.2.13. Hospital admission and length of stay  
 
The number of hospital readmissions, the number of patients experiencing hospital readmissions, and the average length of stay for both hospital readmissions and the initial transplant hospitalization will be described.  The number of days alive and not hospitalized will be used to examin e the total duration of hospitalization in the first 6 months accounting for mortality.  
These distributions will be compared between the two groups using Mann- Whitney tests.   
 5.5.2.14. Health -Related Quality of l ife 
 HQL at each time point will be summarized using simple descr iptive statistics (mean, SD).  HQ L 
among survivors at each time point will be compared between treatment arms in an initial analysis using two sample t- statistics.  The missing data pattern of the HQL measurements will 
be examined using graphical techniques and logistic regression models conditional on survival.  
At each time point, estimates of the difference in HQ L between the treatments conditional on 
survival at that time point will be obtained using inverse probability of censoring we ighting with 
independent estimating equations
26 to account for missing data.     
 
5.6.Subgroup Analysis  
 
Subgroup analyses will be conducted for 2 year PFS according to disease, disease risk and age.  Interaction tests between treatment group and subgroup will be conducted using a logistic regression model with treatment, subgroup, and a treatment *subgroup interaction term.  If there 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
5-10 is censoring present prior to 2 years, a logistic regression model for 2 year PFS using 
pseudovalues will be used.  A Bonferroni a djusted significance level of 0.05/3=0.0167 will be 
used for each interaction test to account for multiple testing.  If a significant interaction is identified, plots of Kaplan- Meier estimates of PFS by treatment will be shown separately for 
each level of the subgroup.     
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
6-1 CHAPTER 6  
 
 6. ETHICS AND REGULATORY  
 6.1. Good Clinical Practice Guidelines  
 
The DCC  and the clinical investigators assure that the clinical study is performed in accordance 
with the protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996, the Declaration of Helsinki (Recommendations guiding physicians in Biomedical Research involving Human Subjects, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 
1989, Somerset West 1996, Edinburgh, 2000, Seoul 2008 , Fortaleza 2013) and applicable 
regulatory requirements.  
 6.1.1. Patient  Consent  
 
A conference will be held with the patient, donor and family to discuss this study and alternative treatments available for the treatment of the underlying disease.  The conference will be conducted by the principal investigator or other designated physici an.    
 6.1.2.  Patient  Withdrawal  
 6.1.2.1. Patient  withdrawal from intervention  
 Participation in the trial is voluntary. Patients will be advised that they may voluntarily withdraw from the study at any time and will be instructed to notify the investigator. Patients may choose to withdraw for any reason(s). Patients are not obligated to reveal their reason(s) for withdrawal to the DCC .  
 6.1.2.2. Patient  withdrawal from data collection  
 If a patient explicitly states they do not wish to contribute further data to the trial th eir decision 
must be respected and notified to the DCC  in writing.  In this event details should be recorded in 
the patient’s hospital records, no further CRFs must be completed and no further data sent to the sponsor. 
 
6.1.2.3. Patient  Removal From Study  
 
The investigator has the right to terminate the participation of any subject at any time, if s/he 
deems it in the partients ’s best interest. The reason and circumstances for study discontinuation 
will be documented by the site and sent to the DCC . 
 
Reasons for st udy discontinuation might be:  
• Intolerable side effects of the study product. 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
6-2 • Changes in medical status of the patient such that the Investigator believes that 
patient safety will be compromised or that it would be in the best interest of the 
patient to sto p  
treatment.  
• Pregnancy.  
• Withdrawal of consent.  
• Relevant non- compliance with the protocol.  
6.1.3. Confidentiality  
 
Confidentiality will be maintained by individual names being masked and assigned a patient 
identifier code  upon enrollment in AdvantageEDC .  The code relaying the patient’s identity with 
the ID code will be kept separately at the center.   
 
6.1.4. Participation of Women and Minorities  
 
Women and ethnic minorities and other populations will be included in this study.  Accrual of women and minorities  at each center will be monitored to determine whether their rates of 
enrollment are reflective of the distribution of potentially eligible women and minorities expected from data reported to the CIBMTR and from published data on incidence of leukemia and lymphoma in these groups.  Centers will be notified if their rates differ significantly from 
those expected and asked to develop appropriate recruitment reports.  
6.2. Protocol Amendments  
 
All protocol amendments containing substantive changes must be reviewe d and accepted by 
members of the DSMB before distribution to Clinical Centers.  The review may take place at a DSMB meeting, on an arranged conference call, or by ballot.   
 Once approved by the DSMB, participating centers (and the FDA if applicable) will be notified of approved protocol amendments by an e -mail announcement from the DCC.  Amendment 
documents may be included with the e -mail announcement and will be posted on the BMT CTN 
website.  The documents will include:  
1. A summary of protocol changes  
2. A revised protocol with changes highlighted  
3. A second version with the changes fully incorporated into the document  
4. A rationale for changes may be provided  
 Other types of amendments containing non -substantive changes may be released to Centers 
before DSMB notification or deliberation.  These changes will be reviewed at the next regularly scheduled DSMB meeting or conference call.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
6-3 The DCC PIs will determine the appropriate review process in collaboration with the NHLBI 
Project Officer.  
 Clinical Centers are r esponsible for implementing all amendments  according to institutional 
policy . 
 
6.3. Protocol Deviations  
 
Clinical centers should inform the DCC of any major protocol deviations.  These will be  
submitted to the DSMB on a semi -annual basis.  
 
6.4. Premature Terminat ion of the Trial  
 
The sponsor has the right to discontinue the study due to relevant medical or administrative reasons. Participants who still receive medication during the time of discontinuation will undergo a final visit which has to be documented in the CRF.  
Possible reasons for discontinuation by the sponsor are:  
• failure in recruiting participants,  
• data quality is insufficient,  
• unforeseen circumstances at the study site that make the continuation of the study 
impossible,  
• early prove of superiority or non- inferiority of a treatment group,  
• occurrence of unjustifiable risks or toxicity,  
• new scientific knowledge that does not justify continuation of the clinical study.  
6.5. Publication Policy  
 Manuscripts reporting the results of this trial will be prepared and submitted to a reputable peer -
reviewed medical journal in accordance with basic ethical principles, including preservation of the accuracy of the results and making both positive and nega tive results publicly available. In all 
publications the confidentiality of patients’ data will be ensured.  
 Data analysis and authorship will be conducted according to the BMT CTN MOP.  No clinical 
trial results are released, presented or published without approval from the Publications Committee, the BMT CTN DCC, NHLBI and NCI.  
 The study is  registered in the clinical trials database (www.clinicaltrials.gov) which is accessible 
to the public. The ClinicalTrials.gov number [STUDY_ID_REMOVED] allocated to this tri al will be quoted 
in any publications resulting from this trial.  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
6-4 By signing this study protocol, the investigators accept that the results of this clinical trial can be  
presented to national and international authorities. They also accept that in this context their 
name, address, qualification and grade of involvement in this trial will be published  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
A-1  
 
              
APPENDIX A  
 
ABBREVIATIONS  
       
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
A-2 APPENDIX A  
 
ABBREVIATIONS  
 
AdvantageEDCSM – Proprietary electronic data capture system  
AE – Adverse Event  
ALL – Acute Lymphoblastic Leukemia  
ALT – Alanine Aminotransferase  
AML – Acute Myeloid Leukemia  
ANC – Absolute Neutrophil Count  
AST – Aspartate Aminotransferase  
B-ALL – Acute B Lymphoblastic Leukemia  
BM – Bone Marrow  
BMT CTN – Blood and Marrow Transplant Clinical Trials Network  
RIC – Reduced Intensity Conditioning  
CBC – Complete Blood Count  
CCr – Creatinine Clearance Rate  
CD15 – Cluster of Differentiation 15  
CD3 -  Cluster of Differentiation 3  
CD33 -  Cluster of Differentiation 33  
CDC – Centers for Disease Control  
CEA – Cost Effectiveness Analysis  
cGVHD – Chronic Graft Versus Host Disease  
cGY -  Centigray 
CHOP±R  – Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone +/ - Rituximab  
CI – Confidence Interval  
CIBMTR – Center for International Blood and Marrow Transplant Research 
CMV -  Cytomegalovirus  
CNS – Central Nervous System  
CR -  Complete Remission  
CsA – Cyclosporin A  
CT – Computed Tomography  
CTCAE – Common Terminology Criteria for Adverse Events  
CVP±R – Cyclophosphamide/Vincristine Sulfate/Prednisone +/ - Rituximab  
DCC – Data and Coordinating Center  
DHAP±R – Dexamethasone/Cytarabine/Cisplatin +/ - Rituximab  
DLCO – Diffusing Capacity of the Lung for Carbon Monoxide  
DLI – Donor Lymphocyte Infus ion 
DMSO – Dimethyl Sulfoxide  
DNA – Deoxyribonucleic Acid  
DSMB – Data Safety Monitoring Board  
dUCB – Double Umbilical Cord Blood  
EBV – Epstein Barr Virus  
EKG -  Electrocardiogram  
ESHAP±R  – Etoposide, Methylprednisolone, Cytarabine, Cisplatin +/ - Rituximab  
FDA – Food and Drug Administration  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
A-3 FDG -  Flurodeoxyglucose  
FEV1 – Forced Expiratory Volume 1  
FHCRC – Fred Hutchinson Cancer Research Center  
FISH – Fluorescence In Situ Hybridization 
FK-506 -  Tacrolimus  
FLAG – Fludarabine+High -dose Cytarabine+G -CSF 
FLT3 -ITD – FLT3 -Internal  Tandem Duplication  
FLT3 -TKD – FLT3 - Tyrosine Kinase Domain  
FVC – Forced Vital Capacity  
G-CSF – Granulocyte Colony Stimulating Factor  
GFR – Glomerular Filtration Rate  
GI - Gastrointestinal  
GINA – Genetic Information Nondiscrimination Act  
GVHD – Graft versus Host Disease  
haplo- BM – Haploidentical Bone Marrow  
HCG – Human Chorionic Gonadotropin  
HCT -comorbidity – Hematopoietic Cell Transplant Comorbidity  
HepA – Hepatitis A  
HepB – Hepatitis B  
HepC – Hepatitis C  
HHV- 6 – Human Herpesvirus 6 
HiDAc – High Dose Intermittent Ara -C 
HIPAA – Health Insurance Portability and Accountability Act  
HIV – Human Immunodeficiency Virus  
HLA – Human Leukocyte Antigen  
HPLC – High Performance Liquid Chromatography  
HQL – Health -related Quality of Life  
HSCT – Hematopoietic Stem Cell Transplant HTLV1 – Human T -Lymphotrophic Virus 1  
IBW – Ideal Body Weight  
ICE±R – Ifosfamide+Carboplatin+Etoposide+/ - Rituximab  
IRBs – Institutional Review Boards  
ITT – Intension To Treat  
IUD – Intrauterine Device 
IV - Intravenous  
LDH – Lactate Dehydrogenase  
MDS – Myelodysplastic Syndrome  
MMF – Mycophenolate Mofetil  
MOP – Manual of Procedures  
MUD – Matched Unrelated Donor  
NCBI – National Center for Biotechnology Information NCCN – National Comprehensive Cancer Network  
NCI – National C ancer Institute  
NIH – National Institutes of Health  
NMDP – National Marrow Donor Program  
OHRP – Office for Human Research Protections  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
A-4 OS – Overall Survival  
PCR – Polymerase Chain Reaction  
PET – Positron Emission Tomography  
PFS – Progression Free Survival  
PI – Principal Investigator  
PO – Per Os (by mouth)  
PR – Partial Response  
QALY – Quality -adjusted Life Year  
RBC – Red Blood Cell  
SCTOD – Stem Cell Therapeutic Outcomes Database  
SD – Standard Deviation  
SPRT – Sequential Probability Ratio Test  
T-ALL – T -cell Acute Lymphoblastic Leukemia  
TBI – Total Body Irradiation  
TID – ter in die (three times/day)  
TRM – Treatment Related Mortality  
UCB – Umbilical Cord Blood  
ULN – Upper Limit of Normal WBC – White Blood Cell  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-1  
 
 
 
 
 
 
 
  
 
 
APPENDIX B  
 
CONSENT FORMS 
  
 
PATIENT INFORMED CONSENT 
 
DONOR INFORMED CONSENT  
 
DONOR ASSENT  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-2 Informed Consent to Participate in Research  
 
A M ulti-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) 
Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood 
(dUCB) versus HLA -Haploidentical Related Bone Marrow for Patients with 
Hematologic Malignancies  
 
Your Name:   ________________________________ 
Study Title :  A Multi- Center, Phase III, Randomized Trial of Reduced Intensity(RIC) 
Conditioning and Transplantation of Double Unrelated Umbilical Cord 
Blood (dUCB) versus HLA -Haploidentical Related Bone Marrow for 
Patients with Hematologic Malignancies  
Protocol:   BMT CTN #1101  
Co-Investigator:  Ephraim Fuchs, M.D.  
Johns Hopkins University 
488 Bunting- Blaustein Cancer Research Building, 1650 Orleans Street  
Baltimore, MD   21231  
Phone: 410-  955- 8143  Email: fuchsep@jhmi.edu  
 
Co-Invest igator:  Paul O’Donnell, M.D., Ph.D. 
Massachusetts General Hospital Cancer Center , 55 Fruit St. Boston, MA 
02141Phone: 508- 693-7430  Email: pvodonnell@mgh.harvard.edu   
 
Co-Investigator:  Claudio Brunstein, M.D.  
University of Minnesota  Medical Center  
420 Delaware Street SE, MMC  286, Minneapolis, MN 55455 
Phone: 612- 624-5620  Email: bruns072@umn.edu  
 
Transplant Center  
Investigator:   ________________________ 
(Insert contact  information for PI at your site)  
Sponsor:   The National Institutes of Health (NIH) is sponsoring this study by 
providing financial support through the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).  
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-3 1.  Introduction  
We invite you to join this clinical trial, also 
known as a research study. We are doing 
this research because we want to learn more 
about reduced- intensity transplants that use 
a mismatched donor. These results will help 
us understand if one kind of mismatched 
donor is better or if there is no difference at all. 
This study will take at least 4 years and will 
include about 400 participants . Your study 
participation will last for 3 years  after your 
transplant.  
This Consent Form will tell you about the 
purpose of the study, the  possible risks and 
benefits, other options available to you, and 
your rights as a participant in the study.  
Everyone who takes part in research at [insert facility name]  should know that:  
 Being in any research stu dy is voluntary.  
 You may or may not benefit from being in the study. Knowledge we gain from this study may benefit others.    If you join the study, you can quit the 
study at any time.  
 If you decide to quit the study, it will not 
affect your care at [insert name of 
facility or institution].  
 Please ask the study staff questions about anything that you do not 
understand, or if you would like to have 
more information.  
 You can ask questions now or any time 
during the study.  
 Please take the time you need to talk about the study with your doctor, study 
staff, and your family and friends. It is 
your decision to be in the study. If you decide to join, please sign and date the end of the Consent Form. 
You and your doctor will discuss other 
treatment choices if you do not want to 
participate in this study .
 
2.  Study Background  
The National Institutes of Health  (NIH), 
through the Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN), are providing staff support and money for this 
resea rch study. The BMT CTN will direct 
the research study. The BMT CTN and the NIH will make decisions about how to 
manage the study.  
A stem cell transplant is the only treatment at this time that may
 cure your disease. An 
allogeneic  transplant uses blood- maki ng 
cells from a family member or an unrelated 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-4 donor  to remove and replace your abnormal 
blood cells . Your doctor may recommend 
that you have a transplant that uses lower 
amounts of chemotherapy and radiation. 
This type of transplant is also called a 
reduced intensity , non -myeloablative , or 
“mini ” transplant. Because of your age or 
health problems and because you do not 
have a matched donor, you may have a higher chance of health problems from a 
standard stem cell transplant  that uses high 
doses of chemotherapy and/or radiation. Recent studies by the BMT CTN suggest the 
results are very similar for reduced -intensity 
transplants when they use either mismatched 
cord blood or use mismatched bone marrow from a family member.  
There is no guarantee or promise that this 
procedure will be successful .  
 
    
 
3. Study  Purpose  
We are inviting you to take part in this study 
because you have a cancer of the blood or 
lymph glands and a stem cell transplant is a 
treatment option.  
Tissue typing shows that you do not have a 
completely matched donor available in your family.  You also do not have a matched 
donor outside of your family who can donate when you need them to. However, you do have two other donor choices available for a transplant: (1) partially 
matched units of unrelated cord blood, and 
(2) a family donor who is a partial m atch.  
We are doing thi s research to learn more 
about reduced- intensity transplants that use 
a mismatched donor. We will use either cord blood from an unrelated donor or bone marrow from a family member, and then compare the transplant results.  
These resul ts will help us understand if one 
kind of mismatched donor is better or if there is no difference at all .   
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-5  
4.  Right to Ask Questions and/or Withdra w 
You have the right to ask questions about 
the study at any time. If you have questions 
about the study  or you want to leave the 
study, please contact:  
[insert contact info for site PI]  
Being in this study is voluntary . You can 
choose not to be in this study or leave this 
study at any time . If you choose not to take  part or leave this study, it will not affect 
your regular medical care in any way .  
Your study doctor and study staff will be 
available to answer any questions that you 
may have about taking part in or leaving this 
study. 
 
 
5.  Study Treatment and Tests  
We will check your health before you start 
treatment, while you receive treatment, and 
for several years after you finish your 
treatment.  
Before You Start Your Treatment  
We will ask you to  take quality of life 
surveys. The surveys will ask about:  
o Any side effects of your treatment  
o Any health problems  
o How well you can do things that are 
important to you  
o How you relate to other people  
o Your feelings.  
You may skip any questions you wish.   
We will also ask you to provide optional Blood Samples for Future Research (see 
Section 18:  Optional  Blood Samples for 
Future Research ).  
Randomization  
We will use a computer to randomly assign 
you to 1 of  2 study groups. One group will 
receive partially matched cord blood fro m 
an unrelated donor, and one group will 
receive bone marrow from a partially 
matched family member. You will have an equal chance of being placed in either group.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-6 During Your Treatment  
 Conditioning Regimen Before 
Transplant ( chemotherapy and 
radiation)  
You will be treated with a type of 
chemotherapy called fludarabine , which is 
given daily for 5 days. If you receive cord blood, you will also be given a type of chemotherapy called cyclophosphamide  for 
1 day . If you receive bone marrow, you will 
be given c yclophosphamide for 2 days.  
After the chemotherapy is completed, you 
will receive a small dose of radiation  to your 
whole body ( Total Body Irradiation ) in a 
single dose. The chemotherapy and radiation 
may cause side effects. Some of these side effects may be life -threatening (see Section 
6: Risks and Discomforts ). 
If you receive cord blood, and have not had 
cytotoxic chemotherapy within the last 3 
months or an autologous transplant within 
the last 2 years, you will receive a slightly 
higher dose of radiation (300 cGy instead of 
200 cGy ). This slightly higher dose of 
radiation has shown hematopoietic recovery is comparable to that seen with low dose 
radiation for patients who have had 
chemotherapy in the last 3 months or an autologous transplant in the last 2 years.
  
 Reinfusion of Stem Cells (Transplant)  
On your transplant day, if you receive cord 
blood, it will be given to you through your 
catheter like a blood transfusion. If you receive bone marrow, your family donor will have his or her marrow collected in the operating room. The donated marrow may 
be taken to a laboratory where red cells will 
be removed. The donor cells will be given to 
you through your catheter and will travel to your bone marrow where they will start to make healthy, new blood cells .  
If you receive cord blood you will start to take the immune suppressing drugs cyclosporine and mycophenolate m ofetil 
(MMF) for 3 days before transplant. These 
drugs may help prevent a complication called graft versus host disease  (GVHD; 
see Section 6: Risks and Discomforts ).    
If you receive bone marrow , you will be 
given another dose of cyclophosphamide  on 
Days 3 and 4 after your transplant. You will 
start to take the immune suppressing drugs tacrolimus  and MMF
 to help prevent 
GVHD on D ay 5 after your transplant.  
In both study groups (partially matched cord 
blood from an unrelated donor or bone marrow from a partially matched family 
member), you will continue to take MMF 
for about 5 weeks and cyclosporine or tacrolimus for up to 6 months.  
If you receive cord blood , you will be given 
filgrastim (G -CSF)  through your catheter 
or by injection under your skin beginning on 
day 1 after your transplant. If you receive 
bone marrow, you will be given filgrastim (G-CSF) beginning on D ay 5 after your 
transplant.  Filgrastim speeds up the recovery of white blood cells. In both study 
groups, y ou will receive filgrastim daily 
until your white blood cells have recovered.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-7 The immune suppressing drugs and filgrastim 
may cause side effects. These side effects 
may be life -threatening (see Section 6: Risks 
and Discomforts ).  
If needed, you will receive blood transfusions 
to maintain normal blood cell levels and antibiotics to treat or prevent infection. You 
may also receive extra nutrients and pain 
drugs during or after you r transplant. They 
will be given to you through your catheter .    
 Health  Evaluations  
We will test  (evaluate) your health during 
the study . These tests and how often they are 
scheduled are standard care for patients 
receiving an allogeneic transplant . They  
would be done even if you were not part of this study.  You will be watched closely for 
any signs and symptoms of GVHD.  
 
Health evaluations  after treatment :  
1) Physical exam  to assess toxicities, and 
infections  weekly until Day 56 and then 
at Days 180, 365, and  730. 
2) Physical exam  to assess GVHD weekly 
until Day 90 and then at Days 180, 365, 
and 730. 3) Routine blood tests ( cell counts and liver 
and kidney function)  weekly until Day 
56 and then at Days 180, 365, and  730. 
4) Blood or bone marrow tests to find the 
amount  of donor cells in your body on 
Days 28  and 56. This is  also called 
chimerism . 
5) Restaging tests to see how much cancer you have after treatment on Day  730.  
6) A quality of  life survey  (see Before You 
Start Your Treatment ) at Days 365 and 
730.  
7) Optional blood samples for future research (see Section 19: Blood 
Samples for Future Research ). 
 Long- term follow -up  
Data regarding your clinical situation after 2  
years may be obtained from the CIBMTR, which captures information on all US 
transplants. 
 
 
 
6.  Risks and Discomforts  
You will have side effects while on the 
study. Side effects can range from mild to very serious.  
The risks and discomforts in participating in this study will be similar to what you may have with blood or marrow  cell tr ansplant  if 
you do not participate in this trial. Other complications from transplants, such as graft -versus -host disease ( GVHD) and 
infections happen equally in patients who have either type of regimen.  
Your health care team will give you 
medicines to he lp lower side effects such as 
feeling sick to your stomach (nausea). In some cases, side effects can be long lasting or may never go away.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-8 Risks Related to Medications or Total Body 
Irradiation  Used in Conditioning Regimens  
All chemotherapy and radiation treatments 
used as conditioning regimens in this study are commonly used in allogeneic hematopoietic  cell transplantation .  
 
TABLE 1 – Risks and Side Effects  
 Likely  What it means: This type of side effect is expected to occur in more than 
20% of patients. This means t hat 21 or more patients out of 100 might get 
this side effect.  
Less Likel y What it means: This type of side effect is expected to occur in 20% of patients or fewer. This means that 20 patients or fewer out of 100 might get this side effect.  
Rare, but Serious  What it means: This type of side effect does not occur very often – in fewer than 2% of patients – but is serious when it occurs. This means that 1 or 2 patients (or fewer) out of 100 might get this side effect.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-9 Cyclophosphamide (Cytoxan®) 
Likely  Less Likely  Rare , but Serious  
 Decreased white blood cell 
count with increased risk of 
infection  
 Temporary hair loss  
 Nausea  
 Vomiting  
 Loss of appetite  
 Sores in mouth or on lips  
 Diarrhea  
 Stopping of menstrual periods in women 
 Decreased sperm production 
in men  
 Decreased platelet count 
(mild) with increased risk of bleeding 
 Blood in urine   Anemia  
 Temporary tiredness  
 Damage to the fetus if 
you become pregnant while taking drug 
  Scarring of lung 
tissue, with cough and shortness of breath 
 Severe heart muscle injury and death at very high doses  
 New (s econdary ) 
cancers  
 
 
Fludarabine (Fludara®) 
Likely  Less Likely  Rare, but Serious  
 Decreased white blood cell 
count with risk of infection 
 Decreased platelet count 
with increased risk of bleeding 
 Anemia  
 Tiredness  
 Nausea  
 Vomiting   Diarrhea  
 Numbness and tingling in hands and/or feet related to irritation of nerves of the hand and/or feet 
 Changes in vision   Pneumonia  
 Agitation or nervousness  
 Confusion 
 Cough  
 Difficulty breathing  
 Weakness  
 Severe brain injury and death  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-10 Filgrastim  (G -CSF; Neupogen) 
Likely  Less Likely  Rare, but Serious  
 Ache or pain inside the bones  
 Increased levels of liver 
enzymes and uric acid in the blood 
 Low number of platelets in the blood 
 Headache  
 Tiredness   Local irritation (skin) 
at the injection site  
 Nausea  
  Allergic reaction  
 Low fever  
 Enlargement or rupture of the spleen  
 Worsening of pre -
existing skin rashes  
 
Mycophenolate mofetil (MMF; CellCept) 
Likely  Less Likely  Rare, but Serious  
 Miscarriage  
 Birth defects  
 Diarrhea 
 Damage to unborn baby  
 Limited effectiveness of birth control  
 Stomach pain  
 Upset stomach  
 Vomiting  
 Headache 
 Tremors  
 Low white blood cell count with increased risk of infection  
 Increased blood cholesterols  
 Swelling of the hands, feet, 
ankles, or lower legs   Anemia  
 Rash  
 Difficulty falling asleep or staying asleep  
 Dizziness  
 Uncontrollable hand shakes   Difficulty breathing  
 Unusual bruising  
 Fast heartbeat  
 Excessive tiredness  
 Weakness  
 Blood in stool  
 Bloody vomit  
 Change in vision  
 Secondary cancers, such as lymphoproliferative disease or lymphoma   
 Progressive Multifocal Leukoencephalopathy  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-11 Total Body Irradiation  
Likely  Less Likely  Rare, but Serious  
 Fatigue  
 Hair loss  
 Infertility  
 Loss of 
appetite  
 Mouth sores  
 Nausea   Vomiting  
 Cataracts  
 Inflammation of the parotid glands  
 Skin pigmentation (reversible)  
 Stunt ed Growth  
 Low white blood cell count with increased risk of infection  
 Low platelet count with increased risk of bleeding 
 Anemia   Diarrhea  
 Lung fibrosis  
 Second cancers  
 
Tacrolimus (Prograf; FK -506)/Cyclosporine  
Likely  Less Likely  Rare, but Serious  
 Kidney problems  
 Loss of magnesium, calcium, potassium  
 High blood pressure  
 Tremors  
 Increases in cholesterol and triglyceride  
  Nausea  
 Vomiting  
 Liver problems  
 Changes in how clearly one can think 
 Insomnia  
 Unwanted hair growth  
 Confusion  Seizures  
 Changes in vision  
 Dizziness  
 Red blood cell destruction 
 
It is very important that you do not eat grapefruit or drink grapefruit juice  while taking 
Tacrolimus .  Grapefruit has an ingredient called bergamottin, which can affect some of the 
treatment drugs used in this study.  Common soft drinks that have bergamottin are Fresca , 
Squirt , and Sunny  Delight .  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-12   
Risks and Toxicities Related to Transplant  
The following problems may occur as a 
result of cord blood or marrow transplant. These risks may occur whether a transplant was done as part of the study or not:  
1. Slow r ecovery of b lood c ounts.  The red 
blood cells, white blood cells, and platelets can b e slow to recover after blood or 
marrow transplant. Until your blood counts recover, you will need blood and platelet transfusions, and will be at risk for bleeding and infections. To speed the recovery of the white cells as much as possible you will recei ve Filgrastim.   
2. Graft failure. The cord blood or bone marrow stem cells (the “graft”) may fail to grow inside your body. Past experience suggests that there can be up to a 10 -15% 
chance of graft failure. If graft failure occurs, this may result in low blood counts for a long 
period of time. If your counts do not recover, you may need to receive a second transplant. Graft failure can be fatal.  
3. Graft -Versus -Host Disease (GVHD).  
GVHD results from the bone marrow or cord blood cells in the graft recogniz ing your body 
as foreign and attacking it. In most cases, GVHD can be successfully treated. Sometimes GVHD is severe or difficult to treat and may lead to death. You will be watched closely for this complication and given drugs to prevent and/or treat it.  
Acute GVHD may produce skin rash, nausea, 
vomiting, diarrhea, abdominal pain, abnormalities of liver function, and an increased risk of infection. Chronic GVHD may produce skin rashes, hair loss, thickened dry skin, dry eyes, dry mouth, liver disease, weight loss, diarrhea, and an increased risk of 
infection. To confirm the diagnosis of acute or chronic GVHD, you may be asked to have a biopsy (a small sample of your tissue to look at under the microscope) of your skin, gut, or, rarely, your liver.  
4. Othe r complications. Other complications 
may include:  
a. Damage to the vital organs in your 
body. The transplant could cause 
problems in any body organ such as the 
heart, lungs, liver, gut, kidneys and 
bladder, or brain. The kidneys  and the 
liver are most likely to be damaged. Some 
patients will experience serious lung 
problems from infections or the 
chemotherapy and radiation.  
b. Serious infections. Full and complete 
recovery of your immune system may 
take many months.  During this time, there 
is an increased risk of infections. You will 
be prescribed certain drugs to reduce the chance of those infections. However, 
these treatments do not always work. If 
you have an infection, you may have to stay in the hospital longer or be re -
hospita lized after transplant. Although 
most infections can be successfully treated, some infections may result in 
death.  
c. Relapse of disease or a new blood 
cancer. Your leukemia or lymphoma may 
come back even if the transplant is 
initially successful. In rare cases, a new blood cancer may develop from the donor cells. Cyclophosphamide can cause 
damage to blood cells, which may result in a blood cancer such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The blood cancer usually develops 2- 10 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-13 years after treatment, or 6 years on 
average.  
The risk of developing a new blood cancer after allogeneic blood or marrow 
transplant is probably less than 2%. 
However, if you receive bone marrow, 
your donor’s marrow is exposed to the 
chemotherapy drug, cyclophosphamide, after the transplant. There is a risk that a 
blood cancer may develop in your 
donor’s blood cells. This risk is 
unknown, but it may be as high as  5%. If 
cancer develops in your donor’s blood cells, you may require additional treatment with chemotherapy or another blood or marrow transplant. 
d. Risk to the unborn. The treatments in this study have not
 been proven to be safe 
at any stage of pregnancy. T herefore, if 
you are pregnant or nursing, you are not eligible for this study. Women who can become pregnant must  refrain from all 
acts of vaginal sex (abstinence) or use two 
form s of effective birth control while 
receiving chemotherapy, TBI, and drugs to prevent GVHD. Effective birth control 
is defined as the following:  
1. Consistent use of birth control pills  
2. Injectable birth control methods (Depo -Provera, Norplant)  
3. Tubal sterilization or male partner who has undergone a vasectomy  
4. Placement of an  IUD (intrauterine 
device)  
5. Use of a diaphragm with contraceptive jelly and/or condoms with contraceptive foam every time you have sex.  
 Reproductive Risks   
The drugs used in thi s research study may  
damage your reproductive organs, affect your ability to  have children  or possibly 
cause birth defects if you take them while you are pregnant. I t is important that a 
woman is  not pregnant or breast -feeding and 
does not become pregnant during the course 
of the study.  
If you are a woman and can become pregnant , you will need to take a pregnancy 
test before you start the study . You should 
discuss ways to prevent pregnancy while you are in  the study. Women who have gone 
through puberty may find that their menstrual cycle becomes irregular or stops permanently. This  does not mean that you 
cannot become pregnant. You must still use two effective method s of birth control or 
abstinence during your transplant and continue until you are finished with your GVHD prevention treatment. 
If you are a man, your body may not be a ble 
to produce sperm (become sterile). You 
should talk with your doctor about banking 
your sperm before having a transplant.  
Please check with your doctor to understand more about these risks.  
Unforeseen Risks  
New risks might appear at any time during the study . These risks might be different 
from what is listed in this Consent Form. We will promptly tell you about  new 
information that may affect your decision to take part in the study . We may learn new 
things about reduced- intensity transplants that 
might make you want to stop being in the 
study. We will let you know if this happens and you can decide if you want to continue in the study .  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-14 Additional Information about MMF  
 MMF could be damaging to an unborn 
baby if you are pregnant or become pregnant while receiving the drug.  
 MMF can make birth control pills less effective and increase your chances of becoming pregnant while you are taking it. 
 If you could become pregnant, you must use 2 effective forms of birth control  or 
abstinence for 4 weeks before  starting 
MMF, during treatment, and for 6 weeks after stopping MMF.  
 In this study, you will be assigned to receive MMF for about 5 weeks, so you should not become pregnant during that time. If you think you might be pregnant or could be become pregnant during the upcoming 5 weeks, you should not join 
the study.  
Other Treatments or Drug s  
Some drugs  react with each other . It is 
important to  tell the study doctor or staff 
about any other drugs  or treatments you are 
taking. This includes over -the-counter  drugs , 
vitamins and herbal treatments.  
It is also important that you tell the study 
staff about changes to any of your drugs  
during the study.  
For more information about risks and side effects, ask your study doctor . 
 
 
7.  Alternative Treatments
Participation in this study is optional. If you 
choose not to take part,  you may still receive 
an allogeneic transplant to treat your disease. T he treatment and evaluations you 
would receive could be very similar to what would receive if you join this study .  
Your study doctor will talk with you about your options. If you decide not to participate in this study, your medical care will not be affected in any way.  
Your other choices may include:  
 Treatment with other drugs, radiation, or 
a combination of drugs and radiation without a transplant    An allogeneic blood or marrow  
transplant that is not part of the study , or 
another type of transplant  
 Participation in another clinical trial, if 
available ( check with your doctor)  
 No treatment for  your blood cance r at 
this time  
 Comfort care  
Every treatment option has benefits and risks . Talk with your doctor about your 
treatment choices before you decide if you will take part in this study . 
 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-15  
8.  Possible Benefits
Takin g part in this study may or may not 
make your health better. The information 
from this study will help doctors learn more about reduced- intensity transplant as a 
treatment for people with a blood cancer and who have a mismatched donor. This information could help people with a blood cancer who may need a transplant in the future . 
 
 
9.  New Information Available During the Study  
During this study, the study doctors may learn 
new information about the study drug or the 
risks and benefits of the study. If this happens, they will tell you about the new information. The new information may mean that you can no longer take part in the study, or that you 
may not want to continue in the study.  If this happens, the study doctor will stop 
your participation and will offer you all 
available care to meet your needs and 
medical conditions . 
 
 
 
10.  Privacy, Confidentiality and Use of Information  
Your confidentiality  is one of our main 
concerns . We will do our best to make sure 
that the personal information in your 
medical record is kept private . However, we 
cannot guarantee total privacy. A ll your 
medical and demographic (such as race and 
ethnicity, gender and household income) 
information will be kept private and confidential. (Name of Transplant Center)  
and the organizations listed below will not 
disclose your participation by any means of  
communication to any person or 
organization, except by your written request, or permission, or unless required by federal, state or local laws, or regulatory agencies.  
Individuals authorized by the organizations below will have access to your research an d 
medical information. They may use this information for inspections or audits to 
study the outcomes of your treatment. In 
agreeing to participate, you consent to such inspections and to the copying of parts of your records, if required by these 
organizati ons. 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-16 We may give out your personal information 
if required by law . If information from this 
study is published or presented at scientific 
meetings, your name and other personal 
information will not be used.  
Information about your transplant from your 
original medical records may be seen or sent 
to national and international transplant 
registries, including:  
 
 /Institution/ 
 The National Institutes of Health (NIH)  
 The National Heart, Lung, and Blood 
Institute (NHLBI)  
 The National Cancer Institute (NCI)  
 Office of Human Research Protection (OHRP)  
 The Food and Drug Administration (FDA)  
 Institutional Review Boards (IRBs) 
responsible for this study   Data and Safety Monitoring Board (DSMB), not part of /Institution/  
 Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN), including the Center for International Blood and Marrow Transplant Research (CIBMTR), 
the National Marrow Donor Program 
(NMDP) and the EMMES Corporation who are coordinating the studies of the BMT CTN  
 Study investigators  
A description of  this clinical trial will be 
available on http://www.ClinicalTrials.gov , 
as required by U.S. Law. This Web site will 
not include information that can identify 
you. At most, the Web site will include a summary of the results. You can search this Web site at  any time.  
  
For questions about access to your medical records, please contact /name/ at /number . 
 
 
11.  Ending Your Participation  
The study doctor or the study sponsor may 
stop the study at any time, and we may ask 
you to leave the study. If we ask you to leave the study, the reasons will be discussed with you. Possible reasons to end 
your participation in this study include:  
 You do not meet the study 
requirements.   You need a medical treatment not 
allowed in this study.  
 The study doctor decides that it 
would be harmful to you to stay in the study.  
 You are having serious side effects.  
 You become pregnant . 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-17  You cannot keep appointments or 
take study drugs as directed.  
 The study is stopped for any reason.  
You could have serious health risks if 
you stop treatment during the  
conditioning process before you receive 
your transplant. If you stop taking the  
immune suppressing drugs (see Section 
6: Risks and Discomforts ) too soon 
after transplant, your body could reject 
the donor stem cells or  you could 
develop serious complications and 
possibly die.  
We ask that you talk with the research 
doctor and your regular doctor before you leave the study. Your doctors will tell you how to stop safely and talk with 
you about other treatment choices .  
 If you decide to leave this study after 
the start of treatment, or your doctor 
asks you to leave the study for medical reasons, you will need to 
come back to the doctor’s office for 
tests for your safety. Even if you leave the study, the information collected from your participation will 
be included in the study results, unless 
you specifically ask that it not be included . 
 
 
 
 
12.  Physical Injury as a Result of Participation  
It is important to  tell your study doctor, 
__________________ [investigator's 
name(s)]  or study staff if you feel that you 
have been injured from  taking part in this 
study. You can tell the doctor in person or 
call him/her at __________________ 
[telephone number] . 
You will get all available medical treatment if you are injured from taking part in this study. You and/or your health plan will be charged for this treatment. The study will not pay for medical treatment.  
In case you are injur ed in  this study, you do 
not lose any of your legal rights to receive 
payment by signing this Consent F orm.
 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-18  
13.  Compensation or Payment
You will not be paid for taking part  in this 
study . You will not be compensat ed or 
reimburse d for any ex tra costs (for example, travel  and meals) from taking part  in this 
study .
 
14.  Costs and Reimbursements  
Most of the visits for this study are standard 
medical care for your allogeneic transplant 
and will be billed to your insurance company . 
You and/or your health plan/insurance 
company will need to pay for the costs of standard treatment in this study .  
Some health plans will not pay these costs for people taking part in studies. Check with 
your health plan or insurance company to 
find out if they will pay.  
You or your insurance will not  be charged for 
tests that are only done  for research on this 
study.  
 For questions about your costs, financial responsibilities, and/or medical insurance coverage for your transplant and this study, 
please contact /Center/ Financial Counselor 
at /Number/.  
For more information on clinical trials and 
insurance coverage, you can visit the National Cancer Institute’s Web site at 
http://cancer.gov/clinicaltrials/understanding
/insurance -coverage . You can print a copy 
of the “Clinical Trials and Insurance Coverage” information from this Web site.  
Another way to get the information is to call 1-800-4-CANCER (1 -800-422-6237) and 
ask them to send you a free copy . 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-19  
15.  For More Information  
If you need more information about this 
study, or if you have problems while taking  
part in this study, you can contact the  study doctor or his/her staff . They can be reached at 
the telephone numbers listed here:    
[Insert name and contact detail]  
 
 
16.  Contact Someone about Your Rights  
If you wish to speak to someone not directly involved in the study, or if you have any complaints about the project, or any questions 
about your rights as a research participant, 
then you may contact:  
[Insert appropriate contact details]  The ethical aspects of this research study have been reviewed and approved by [name of IRB].  
 For questions about your rights while taking part in this study, call the __________[name of center] Institutional Review Board (a  
group of people who review the research to 
protect your rights) a t __________________ 
(telephone number) .  
 
 
17. Cost -effectiveness Research  
Study purpose:  The study doctors want to 
learn more about the costs of the two types of 
transplant that are being tested in the larger 
transplant study: 1) partially matched units of 
unrelated cord blood and 2) family donor s 
who are a partial match.  This research will 
help doctors know which type of transplant is 
more cost effective.  
Lead study doctor : Scott Ramsey of the 
Fred Hutchinson Cancer Research Center in Seattle is the lead study doctor for the cost -
effectiveness research. Dr. Ramsey is a 
medical doctor and well -known health 
economist.  
Your health insurance and out -of-pocket 
medical costs: If you agree to join this study, 
we will ask for the following information 
about your health insurance:  
1) Type 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-20 2) Provider  
3) Policy  number  
4) Group number  
5) Policy holder’s name and date of birth  
We will also want to know about your out -of-
pocket transplant costs (costs not covered by 
your insurance). The out -of-pocket costs you 
and your family have to cover are important 
in understanding the overall cost of transplant, so we want to colle ct information 
this information as well. For example, we want to know how much you spend on:  
1) Medical costs (for example, co -pays, 
prescriptions)  
2) Travel and lodging  
3) Cost of time away from work for both you and your caregivers (family and friends).  
Your health insurance and out -of-pocket 
information is called the ‘study data’ in this consent form.  
How we will use your health insurance 
information:  After you have finished the 
transplant study, we will use your insurance 
information to learn about the reimb ursements your health insurer made and 
calculate the cost of your transplant. Illness and transplant -related costs happen before the 
transplant and go on for many years after, so we want to collect reimbursement information for the 12 months before your 
transplant, and for the 2 years following.   Privacy, c onfidentiality  and use of 
information : Only the study doctors at the 
Fred Hutchinson Cancer Research Center 
will have access to your health insurance and out-of-pocket cost information (study data). 
To maintain your confidentiality, we will not 
link your name to the study data. Also, all of 
the study doctors signed a confidentiality 
agreement and promised to keep electronic data protected under passwords and physical 
data (paper or other media such as CDs) in 
secure facilities (for example, on -campus 
locked offices and locked filing cabinets).   
Collecting the study data: W e will collect 
your health insurance and out -of-pocket 
information using an online questionnaire 
and diary.  You will get a  user ID number and 
password to log on to  the system . The system 
was designed to be very user friendly, but w e 
will help you with the online questionnaire and diary over the phone  if needed . We will 
also send email reminders . The option to 
complete a mail -out survey will also be 
available.  
As stated above, we will collect 
reimbursement information starting  12 
months before your transplant  until 2 years 
after.    
We will collect out -of-pocket costs 1 month 
after your transplant, and again 4 and 7 
months after your transplant date . We think 
each online entry will take between 5 and 25 minutes, but this depends on how much 
information there is to enter.  
Help from your caregiver(s): We ask that 
you give us the name(s) and contact 
information of your main caregiver(s). This 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-21 may be your spouse, partner, parent, adult 
child or sibling, and friends.  You may not 
feel like using the online  diary when you’re 
recovering from your transplant , so we ask 
that your  caregiver(s) help enter this 
information    
We also  want to know  the time your 
caregiver(s)  spend caring for you after your 
transplant and the time they spend away  from 
work or school .   
Be sure to talk to your caregiver(s) about this 
study and get their permission before giving 
us their name and contact information.  If you 
give us the name of your caregiver(s), we 
will explain the study to them and what they 
would need to do. They will also get their own consent form to participate in this study.   
Risks to participating: The risks to 
participating in the cost- effecti veness study 
are small. We will make every effort to keep 
your health insurance and out -of-pocket cost 
information private. We will only use this 
data to get reimbursement information. A possible risk is the loss of confidentiality 
about your medical infor mation , but t he 
chance of this happening  is very small.   
Payment and costs: Y ou will not get paid 
for participating in this study. You will not 
be charged for taking part in this study.   
If you provide out -of-pocket costs, we will 
give you a summary of th ese costs at the end 
of the study. This may be helpful information for tax reporting.   
Right to ask questions and/or withdraw: 
You do not have to be part of the cost -
effectiveness research study. Your 
involvement is totally  voluntary  and 
deciding not to be part of this study will not affect the medical care or services you are receiving. You can also leave the study at any time.  
For more information:  Jordan Steelquist , 
Fred Hutchinson Cancer Research Center, Seattle (206) -267-7438 or 
email:jsteelqu@fredh utch.org . 
 
18.  Blood Samples for Research (Optional)  
This section of the informed consent form is about future research studies that will use  
blood samples from people who are taking 
part i n the main study . You may choose to 
give blood samples for these future research 
studies if you want to. You can still be a part of the main stud y even if you say 'no' to give  
blood samples for future research studies.  
There are no major risks  associated with 
drawing blood. Having your blood drawn 
can be uncomfortable an d can sometimes 
cause a bruise.  In rare cases, a blood draw 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-22 can cause fainting. Only trained people will 
draw your blood.  
 
If you agree to provide blood samples, here 
is what will happen:  
a.) We will collect five extra blood samples 
at the same time you have routine blood 
tests done . The amount of blood 
collected from you is about 4 
tablespoons (50 mL) each time. If you 
weigh less than 50 kg, the amount of 
blood collected will be based on your 
weight (1 mL  per kg).   
b.) We wi ll collect samples at five different 
dates in the study: Prior to transplant , 
Day 28, Day 56, Day 180, and Day 365.  
c.) The blood samples will be sent to the 
BMT CTN Repository for processing 
and storage . A repository is a place that 
protects, stores and sends  out samples 
for approved research studies. All 
research samples will be given a bar 
code that cannot be linked to your name or other identifying information  by 
future researchers testing your samples.  
d.) Samples  stored in the Repository will be 
used mainly by clinicians and researchers in the BMT CTN network. In the future, the unused research 
samples and clinical information  will be 
made available outside of this network.  
e.) Researchers can apply to study the mate rials stored in the Repository. The 
BMT CTN Steering Committee and/or 
the BMT CTN Executive Committee 
must approve each request  before they will share samples or information with 
researchers. This is to make sure that the 
investigators requesting the samples are qualified, and that the research is of high quality . 
f.) DNA from your stored blood samples 
might be used in genome -wide 
association (GWA) studies for a future 
project either done or supported by the National Institutes of Health (NIH). 
Genome -wide asso ciation studies are a 
way for scientists to find  genes that have 
a role in human disease or treatment. 
Each study can look at hundreds of thousands of genetic changes at the same 
time 
If your coded samples are used in such a study, the researcher is 
requir ed to add your test results and 
sample information into a shared, 
public research database. This public database is called the NIH Genotype 
and Phenotype Database and it is 
managed by the National Center for Biotechnology Information (NCBI). The NCBI will never have any 
information that would identify you, 
or link you to your information or research samples.  
Some general things you should know about letting us store your blood samples for 
research are:  
 We will only store samples from people 
who give us per mission.  
 Research is meant to gain knowledge that 
my help people in the future. You will not 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-23 get any direct benefit from taking part.  
Additionally, you or your doctor will not 
be given results and they will not be 
added to your medical record.  
 A possible r isk is the loss of 
confidentiality about your medical 
information. We will use safety measures 
with both your samples and clinical information  to make sure that your 
personal information will be kept private. 
The chance that this information will be 
given to someone else is extremely  small.  
 Your blood will be used only for research 
and will not be sold. The research done 
with your blood may help to develop new 
products in the future. You will not get paid for any samples or for any products 
that may be dev eloped from current or 
future research.  
You can change your mind at any time 
about allowing us to use your samples and 
health information for research .  
We ask that you contact [Principal 
Investigator] in writing and let him/her know you do not want us to use your research samples or health information for 
research. His/her mailing address is on the 
first page of this form . However, samples 
and information that have already been 
shared with other researchers cannot be 
taken back or destroyed.  
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-24  
Health Insurance Portability and 
Accountability Act 1 (HIPAA1) 
Authorization to use and disclose 
research purpose  
A. Purpose :   
As a research participant, I authorize the 
Principal Investigators and the researcher’s staff to use and disclose my individual health information for the purpose of 
conducting the research study:  
A Multi- Center, Phase III, Randomized 
Trial of Reduced Int ensity (RIC) 
Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) 
versus HLA -Haploidentical Related Bone 
Marrow for Patients with Hematologic Malignancies  
B. Individual Health Information to be Used or Disclosed :  
My individual health information that may be used or disclosed to do this research includes:  
 Demographic information (for example: date of birth, sex, weight) .  
 Medical history (for example: diagnosis, complications with prior treatment) . 
 Findings from physical exams . 
                                                 
1 HIPAA is the Health Insurance Portability and 
Accountability Act of 1996, a federal law related to 
privacy of health information   Laboratory test results obtained at the 
time of work up and after transplant (for 
example: blood tests, biopsy results) .  
C. Parties Who May Disclose My Individual Health Information :  
The researcher and the researcher’s staff 
may collect my individual health 
information from:  
[List hospitals, clinics or providers from 
which health care information can be 
requested ]. 
D. Parties Who May Receive or Use My 
Individual Health Information :  
The individual health information disclosed 
by parties listed in item c and information 
disclosed by me during the course of the research may be received and used by the following parties: 
Principal Investigator and the researcher’s staff 
Study S ponsors  
 National Heart, Lung, and Blood 
Institute (NHLBI) and the National 
Cancer Institute (NCI), both of the National Institutes of Health (NIH),  
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN), data and 
coordinating center  
 U.S. government agencies that are 
responsible for overseeing research  such 
as the Food and Dru g Administration 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-25 (FDA) and the Office of Human 
Research Protections (OHRP)  
U.S. government agencies that are 
responsible for overseeing public health 
concerns  such as the Centers for Disease 
Control (CDC) and federal, state and local 
health departments.   
E. Right to Refuse to Sign this 
Authorization :  
I do not have to sign this Authorization. If I 
decide not to sign the Authorization, I will not be allowed to participate in this study or receive any treatment related to research that is provided through the  study .  
My decision not to sign this authorization will not affect any other treatment, payment, or enrollment in health plans or eligibility for benefits .  
F. Right to Revoke :   
I can change my mind and withdraw this authorization at any time by sending a written notice to the Principal Investigator to 
inform the researcher of my decision.  
If I withdraw this authorization, the 
researcher may only use and disclose the 
protected he alth information already 
collected for this research study . No further 
health information about me will be collected by or disclosed to the researcher for this study.  G. Potential for Re -disclosure:  
My individual health information disclosed under this authorization may be subject to re-disclosure outside the research study and 
no longer protected.  
Examples include potential disclosures for 
law enforcement purposes, mandated 
reporting or abuse or neglect, judicial 
proceedings, health oversight activities a nd 
public health measures.  
H. Genetic Information 
Nondiscrimination Act (GINA)  
A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health 
insurance companies, group health plans, and employe rs of 15 or more persons to 
discriminate against you based on your 
genetic information.  
Health insurance companies and group 
health plans may not request your genetic 
information that we get from this research. 
This means that they must not use your 
genet ic information when making decisions 
regarding insurability. Be aware that this 
new federal law will not protect you against 
genetic discrimination by companies that 
sell life insurance, disability insurance, or long-term care insurance.  
I. This authorizat ion does not have an 
expiration date . 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-26 TITLE: A Multi- Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning 
and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA -
Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies  
PROTOCOL NUMBER: BMT CTN # 1101  
CO-INVESTIGATOR :  
Ephraim Fuchs, M.D.  
Johns Hopkins University 
488 Bunting- Blaustein Cancer Research B ldg 
1650 Orleans Street , Baltimore, MD   21231 
Phone: 410-  955- 8143   
Email: fuchsep@jhmi.edu  CO-INVESTIGATOR :  
Paul O’Donnell, M.D., Ph.D. 
Massachusetts General Hospital Cancer 
Center  
55 Fruit St , Boston, MA 02141 
Phone:  508- 274-7430   
Email: pvodonnell@mgh.harvard.edu  
CO-INVESTIGATOR:   
Claudio Brunstein, M.D.  
University of Minnesota Medical Center  
420 Delaware Street SE, MMC 286 
Minneapolis, MN  55455 Phone: 612- 624-5620  
Email: bruns072@umn.edu   
 
I have read and understood this Consent Form . The nature and purpose of the research study has 
been explained to me.  
 I have had the chance to ask questions, and understand the answers I have been given. I 
understand that I may ask questions a t any time during the study.  
 I freely agree to be a participant in the study.  
 I understand that I may not directly benefit from taking part in the study.  
 I understand that, while information gained during the study may be published, I will not be 
identifie d and my personal results will stay confidential.  
 I have had the chance to discuss my participation in this research study with a family member or friend.  
 I understand that I can leave this study at any time, and doing so will not affect my current care 
or prevent me from receiving future treatment.  
 I understand that I will be given a copy of this signed consent form .
              
Participant Name        Date  
              
Signature         Date  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-27  
Statement of Consent for Cost Effectiveness Research  
The purpose of the cost effectiveness research , the procedures involved, and the risks and 
benefits have been explained to me. I have asked all the questions I have at this time and I have 
been told whom to contact if I have more questions. I have been told that I will be given a signed copy of this consent form to keep.  
I understand that I do not have to participate in the cost effectiveness research . If I decide to not 
participate , it will not affect my medical care in any way.  
 I agree  to be part of the cost -effectiveness research.  
 I do not agree to be part of the cost -effectiveness research.  
              
Signature         Date 
 
Statement of Consent for Research Samples  
The purpose of storing blood samples, the procedures involved, and the risks and benefits have 
been explained to me. I have asked all the questions I have at this time and I have been told whom to contact if I have more questions. I have been told that I will be given a signed copy of this consent form to keep. 
I understand that I do not have to allow the use of my blood for research. If I decide to not let 
you store research samples now or in the future, it will not affect my medical care in any way.  
I voluntarily agree that my blood and information can be stor ed indefinitely by the BMT CTN 
and/or NHLBI Repositories for research to learn about, prevent, or treat health problems. I also understand that my DNA and clinical  information may or may not be used in genome -wide 
association studies. 
 I agree to allow my b lood samples to be stored for research. 
 I do not agree to allow my blood samples to be stored for research.  
              
Signature         Date 
I certify that I have provided a verbal explanation of the details of the research study, including the procedures and risks . I believe the participant has understood the information provided. 
              
Name of Counseling Physician      Date  
 
              
Signature of Counseling Physician         Date  
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-28 Donor Informed Consent to Participate in Research 
 
 
A M ulti-Center, Phase III, Randomized Trial of Reduced Intensity ( RIC) Conditioning and 
Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA -
Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies  
 
 
Your name: _________________________________________________   
 
Study Title:  Reduced Intensity (RIC) Conditioning and Transplantation of Double 
Unrelated Umbilical Cord Blood (dUCB) versus HLA -Haploidentical 
Related Bone Marrow for Patients with Hematologic Malignancies   
 Protocol:   BMT CTN #1101  
 Co-Investigator:  Ephraim Fuchs, M.D.  
Johns Hopkins University 488 Bunting- Blaustein Cancer Research Building, 1650 Orleans Street  
Baltimore, MD   21231  
Phone: 410-  955- 8143  Email: 
fuchsep@jhmi.edu  
 
Co-Investigator:  Paul O’Donnell, M.D., Ph.D. 
Massachusetts General Hospital Cancer Center 55 Fruit St, Boston, MA 
012141Phone: 508- 274-7430Email: pvodonnell@mgh.harvard.edu   
 
Co-Investigator:  Claudio Brunstein, M.D.  
University of Minnesota  Medical Center  
420 Delaware Street SE, MMC  286, Minneapolis, MN 55455 
Phone: 612- 624-5620  Email: bruns072@umn.edu  
 
Transplant Center  
Investigator:   ________________________ 
(Insert contact information for PI at your site)  
 
Sponsor:   The National Institutes of Health (NIH) is sponsoring this study by providing 
financial support through the Blood and Marrow Transplant Clinical Trials Network (BMT 
CTN).  
   
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-29  
1.  Introduction  
This informed consent form is about future 
research studies . These studies  will use  
blood and bone marrow samples from 
people who take part i n the main study titled 
BMT CTN #1101. You must be 18 years of 
age or older to give  bone marrow samples 
for future research . 
You may choose to give blood and marrow  
samples for these future research studies if you want to. You r family member  can still 
be a part of the main stud y even if you say 
'no' to giving  blood and marrow samples for  
future research.  
The main study will use either umbilical 
cord blood (cord blood) from an unrelated donor or bone marrow from a family member (you), and then compare the 
transplant results. These results will help us 
understand if one kind of mismatched donor is better or if there is no difference at all.  
If you agree to give blood and marrow samples  (marrow from donors 18 and older  
only) , we will collect the  blood sample  at 
the same time you have routine blood tests done  and the marrow sample at the same 
time you donate marrow . We hope to collect 
samples from 200 bone marrow donors who are a part of the main BMT CTN #1101 study.  
This Consent Form will tell you about the 
purpose of the samples for future research , 
the poss ible risks and benefits, other options available to you, and your rights as a research participant.  
Everyone who takes part in research at 
[insert facility name]  should know that:  
 Being in any research study is voluntary.  
 You will not directly  benefit fro m being 
in the study. Knowledge we gain from this study may benefit others.  
 If you give blood and marrow samples 
for future research , you can change your 
mind  at any time.  
 If you decide to quit the study, it will not affect your care or the care of your 
family member at [insert name of facility 
or institution].  
 Please ask the study staff questions 
about anything that you do not 
understand, or if you would like to have 
more information.  
 You can ask questions now or any time during the study.  
 Please take the time you need to talk 
about the study with your doctor, study 
staff, and your family and friends. It is your decision to provide blood and marrow samples for future research . If 
you decide to join, please sign and date the end of the Consent Form . 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-30 The Nat ional Institutes of Health  (NIH), 
through the Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN), are 
giving  staff support and money for this 
research study. The BMT CTN will lead the research study and, along with the NIH, will 
make decisions about how to manage the 
study.  We wish to collect blood and marrow 
samples from donors (marrow from donors 
age 18 and older  only)  to be used in future 
research. The research that may be done with your blood and marrow  is not designed 
to help you but it may help people who have 
cancer or other diseases in the future  
 
 
2.  Study  Purpose  
 
We are collecting extra blood and marrow 
samples for future research because we want 
to learn more about reduced -intensity 
transplants that use a mismatched donor.   Samples may also be used in the future by 
researchers with the BMT CTN and other 
organizations  
 
 
 
3.  Right to Ask Questions and/or Withdra w 
You have the right to ask questions about the study at any time. If you have questions 
about your rights as a participant or you want to leave the study, please contact:  
[insert  contact info]  
Giving blood and marrow samples for future 
research  is voluntary . You can choose not to 
give samples , or change your mind at any 
time. If you choose not to take part or 
change your mind, it will not affect your donation process or the treatment of your 
family member in the main study in any way.  
If you change your mind, your blood and 
marrow samples will not be used for other 
research studies or tested further.  
Your study doctor and study staff wi ll be 
available to answer any questions that you 
may have about giving samples for future research .
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-31  
4.  Study Treatments and Tests   
If you agree to give blood and marrow 
samples  (marrow from donors  age 18 and 
older  only) , here is what will happen:  
a.) We will collect 1 extra blood sample 
at the same time you have routine 
blood tests done. The amount of 
blood collected from you is about 4 tablespoons (50 mL ).  If you weigh 
less than 50 kg, the amount of blood 
collected will be based on your 
weight (1 mL  per kg).   
b.) If you are age 18 or older, w e will 
also collect  up to 1 tablespoon (10 
mL) of bone marrow  when you 
donate for your family member. 3- 5 
mL will be saved for future research.    
c.) The blood and marrow samples will 
be sent to the BMT CTN Repository 
for processing and storage. A repository is a place that protects, 
stores , and sends out samples for 
approved studies. All samples will be 
given a unique bar code that cannot 
be linked to you by researchers 
testing your samples.  
d.) Samples  stored in the Repository 
will be used mainly by clinicians and researchers in the BMT CTN network. In the future, the unused research samples and clinical data 
will b e made available outside of this 
network.  e.) Researchers can apply to study the samples  stored in the Repository. 
The BMT CTN Steering Committee 
and/or the BMT CTN Executive 
Committee must approve each 
request  before they will share 
samples or information wi th 
researchers. This is to make sure that 
the investigators  who  request the 
samples are qualified, and that the 
research is of high quality . 
f.) DNA from your stored samples 
might be used in genome -wide 
association (GWA) studies for a future project either don e or 
supported by the NIH. Genome -wide 
association studies are a way for 
scientists to find  genes th at have a 
role in human disease or treatment. 
Each study can look at hundreds of 
thousands of genetic changes at the same time . 
If your coded samples are used in 
such a study, the researcher is 
required to add your test results and sample information to a shared, 
public research database. This public 
database is called the NIH Genotype and Phenotype Database and it is managed by th e National Center for 
Biotechnology Information (NCBI). The NCBI will never have any information that would identify you, 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-32 or link you to your information or 
research samples .    
 
 
5.  Risks and Discomforts  
There are no major risks  to having your 
blood drawn. It can be uncomfortable to 
have your blood taken and it can sometimes 
leave a bruise. In rare cases, you might  faint . 
Only trained people will take your blood.   
 
There is not a major risk to give extra 
research samples of bone marrow when the 
samples are collected at the same time you donate bone marrow.  
Information about the bone marrow 
donation process for this study can be found in a separate consent form. Your transplant 
doctor or study coordinator w ill give you a 
copy of the donation consent form.  
The donation consent form has more information about the steps to donate, and the risks and side effects of the donation process. Only trained people will collect 
your bone marrow.  
 
  
 
 
 
6.  Possible Benefits
You will not directly benefit from taking 
part in this study. The information from this 
study will help doctors le arn more about 
reduced -intensity transplant as a treatment 
for people with a blood cancer and who have a mismatched donor. This information could help people with blood cancer s who may need a transplant in the 
future.  
 
 
7.  Privacy, Confidentiality and Use of Information  
Your confidentiality is one of our main concerns . We will do our best to make sure 
that the personal information in your medical record is kept private . However, we cannot guarantee total privacy. All your 
medical and demographic (such as race and 
ethnicity, gender and household income) 
information will be kept private and 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-33 confidential. (Name of Transplant Center)  
and the organizations listed below will not 
disclose your participation by any means of 
communication to any person or 
organization, except by your written request, or permission, or unless required by federal, 
state or local laws, or regulatory agencies.  
Individuals authorized by the organizations 
below will have access to your research and medical information. They may use this 
information for inspections or audits to 
study the outcomes of your treatment. In 
agreeing to participate, you consent to such inspections and to the copying of parts of 
your records, if required by these 
organizations . We may give out your personal information 
if required by law . If information from this 
study is published or presented at scientific 
meetings, your name and other personal information will not be used.  
A description of this clinical trial will be 
available on http://www.ClinicalTrials.gov , 
as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can se arch this 
Web site at any time.   
 For questions about access to your medical records, please contact / name/ at /number/.  
 
 
8.  Ending Your Participation  
The study doctor or the study sponsor may 
stop the study at any time, and we may ask you to leave the study. We may ask you to 
leave the study if you do not follow 
directions or if you suffer from side effects of the blood draw or the marrow collection. 
The study sponsor may decide to end the 
study at any time. If we ask you to leave the study, the reasons will be discussed with you.  Possible reasons to end your participation in this study include: 
 You do not meet the study requirements.  
 You become unable  to donate bone 
marrow to your family member.  
 The study is stopped for any reason.  
 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-34  
9.  Physical Injury as a Result of Participation  
It is important that you tell your doctor, 
__________________ [investigator's 
name(s)]  or study staff if you feel that you 
have been injured because you provided 
blood and marrow samples for future 
research . You can tell the doctor in person 
or call him/her at __________________ 
[telephone number ]. 
You will get all available medical treatment 
if you are injured as a result providing blood and marrow samples for future research . 
You, or your health plan, or your family 
member’s health plan  will be charged for 
this treatment. The study will not pay for 
medical treatment.  
In case of in jury resulting from this study, 
you do not lose any of your legal rights to 
seek payment by signing this Consent F orm. 
 
 
10.  Payment and Study Costs  
You will not be paid for your participation in 
the research stud y or for providing blood and 
marrow samples for future research. You will 
not be compensated or reimbursed for any 
extra costs (for example, travel and   meals) 
from taking part in this study.  
The visits  to collect these samples  are 
standard for bone marrow donors and will be billed to your family member’s insurance company.  
Your family member’s insurance will not be 
charged for tests that are only done for research on this study. The costs of shipping and storing your blood and bone marrow samples will be paid by the BMT CTN.  
For questions about your costs, financial  
responsibilities, and/or medical insurance coverage for your transplant and this study, please contact /Center/ Financial Counselor 
at /Number /.
 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-35  
11.  For More Study Information  
If you need m ore information about providing 
blood and marrow samples for future 
research , or if you have problems while you 
are participating in this study, you can contact the study doctor or his/her staff . They can be 
reached at the telephone numbers listed here:  
[Insert name and contact details] . 
 
 
12.  Contact Someone About Your Rights  
If you wish to speak to someone not di rectly 
involved in the study, if you have any  
complaints about the project, or would like more information  about your rights as a 
research participant, you may contact:  
[Insert appropriate contact details] . The ethical aspects of this research study have 
been reviewed and approved by [name of 
IRB].  
 
For more information  about your rights 
about providing blood and marrow samples 
for future research , call the 
__________[name of center]  Institutional 
Review Board (a group of people who 
review the research to protect your rights) at 
__________________ (telephone number).  
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-36 Health Insurance Portability and 
Accountability Act (HIPAA )2 
Authorization to us e and disclose 
research purpose  
A.  Purpose :   
As a research participant, I authorize the 
Principal Investigators and the researcher’s staff to use and disclose my individual 
health information for the purpose of 
conducting the research study:  
A Multi- Center, Phase III, Randomized 
Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double 
Unrelated Umbilical Cord Blood (dUCB) 
versus HLA -Haploidentical Related Bone 
Marrow for Patients with Hematologic Malignancies  
B. Individual Health Infor mation to be 
Used or Disclosed :  
My individual health information that may be used or disclosed to do this research 
includes:  
 Demographic information (for example: 
date of birth, sex, weight) .  
 Medical history (for example: diagnosis, 
complications with prior treatment) . 
 Findings from physical exams . 
                                                 
2 HIPAA is the Health Insurance Portability and 
Accountability Act of 1996, a federal law related to 
privacy of health information   Laboratory test results obtained at the 
time of work up and after transplant (for 
example: blood tests, biopsy results) .  
C. Parties Who May Disclose My Individual Health Information :  
The researcher and the researcher’s staff may collect my individual health information from:  
[List hospitals, clinics or providers from 
which health care information can be requested ]. 
D. Parties Who May Receive or Use My Individual Health Information :  
The individual health inf ormation disclosed 
by parties listed in item c and information disclosed by me during the course of the research may be received and used by the 
following parties: 
Principal Investigator and the researcher’s 
staff 
 
Study S ponsors  
 National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), both of the National Institutes of Health (NIH),  
 Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN), data coordinating center
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-37  
 U.S. government agencies that are 
responsible for overseeing research  such 
as the Food and Drug Administration 
(FDA) and the Office of Human Research Protections (OHRP)  
U.S. government agencies that are 
responsible for overseeing public health 
concerns  such as the Centers for Disease 
Control (CDC) and federal, state , and local 
health departments.   
E. Right to Refuse to Sign this Authorization :  
I do not have to sign this Authorization. If I 
decide not to sign the Authorization, I will 
not be allowed to participate in this study or 
recei ve any treatment related to research that 
is provided through the study .  
My decision not to sign this authorization 
will not affect any other treatment, payment, 
or enrollment in health plans or eligibility for benefits .  
F. Right to Revoke :   
I can chang e my mind and withdraw this 
authorization at any time by sending a written notice to the Principal Investigator to inform the researcher of my decision.  
If I withdraw this authorization, the 
researcher may only use and disclose the 
protected health inform ation already 
collected for this research study . No further 
health information about me will be collected by or disclosed to the researcher 
for this study.  G. Potential for Re -disclosure:  
My individual health information disclosed under this authorization may be subject to re-disclosure outside the research study and 
no longer protected.  
Examples include potential disclosures for law enforcement purposes, mandated reporting or abuse or neglect, judicial proceedings, health oversight activities and 
public health measures.  
H. Genetic Information 
Nondiscrimination Act (GINA)  
A new federal law (2009), called the Genetic 
Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and employers of 15 o r more persons to 
discriminate against you based on your genetic information.  
Health insurance companies and group health plans may not request your genetic information that we get from this research. 
This means that they must not use your 
genetic informa tion when making decisions 
regarding insurability. Be aware that this new federal law will not protect you against 
genetic discrimination by companies that 
sell life insurance, disability insurance, or 
long-term care insurance.  
I. This authorization does n ot have an 
expiration date. 
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-38 TITLE: Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated 
Umbilical Cord Blood (dUCB) versus HLA -Haploidentical Related Bone Marrow for 
Patients with Hematologic Malignancies   
 
PROTOCOL NUMBER: BMT CTN # 1101  
CO-INVESTIGATOR :  
Ephraim Fuchs, M.D.  
Johns Hopkins University 
488 Bunting- Blaustein Cancer Research B ldg 
1650 Orleans Street , Baltimore, MD   21231 
Phone: 410-  955- 8143   
Email: fuchsep@jhmi.edu  CO-INVESTIGATOR :  
Paul O’Donnell, M.D., Ph.D. 
Massachusetts General Hospital  Cancer 
Center  
55 Fruit St, Boston MA, 02151  
Phone: 508- 274-7430 
Email:  pvodonnell@mgh.harvard.edu  
CO-INVESTIGATOR:   
Claudio Brunstein, M.D.  
University of Minnesota Medical Center  
420 Delaware Street SE, MMC 286 
Minneapolis, MN  55455 Phone: 612- 624-5620  
Email: 
bruns072@umn.edu  
  
I have read and understood this Consent Form . The nature and purpose of providing blood and 
marrow samples for future research  has been explained to me.  
 
 I have had the chance to ask questions, 
and understand the answers I have been 
given . I understand that I may ask 
questions at any time during the study.  
 I freely agree to give blood and marrow 
samples  (marrow samples from donors  
age 18 and older  only)  for future 
research . 
 I understand that I may not directly benefit from providing samples for 
future research . 
 I understand that, whil e information 
gained dur ing research may be published, I will not be identified and 
my personal results will stay  
confidential.  
 I have had the chance to discuss giving 
blood and marrow samples for future research with a family member or friend.  
 I understand that I can change my mind  
at any time, and doing so will not affect my current care or prevent me from receiving future treatment.  
 I understand that I will be given a copy of this signed consent form. 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-37  
 
Complete Appropriate Item Below, A or B  
 
A. Adult Donor’ s Consent  
I have read the explanation about this study 
and have been given the opportunity to discuss 
it and to ask questions. I hereby consent to 
give blood and marrow samples for this study.  
 
 
____________________________________ 
Signature of Adult Donor  & Date Signed  
THIS CONSENT DOCUMENT HAS BEEN 
APPROVED FOR USE FROM _________ 
THROUGH __________. B. Parent 's Permission for Minor Donor  
I have read the explanation about this study and have been given the opportunity to discuss it and to ask questions. I hereby give permission 
for my child to  give a blood sample for this  
study.  
 
______________________________________ 
Signature of Parent(s)/Guardian & Date 
Signed  
If other than parent, specify relationship: ___________________________________ 
  
 
_____________________________________ 
Signature of Investigator & Date Signed   
______________________________________ 
Signature of Witness & Date Signed  
 
 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-40 Pediatric Assent to Provide Extra Samples for Research  
 
Study Title : A Multi -Center, Phase III, Randomized Trial of Reduced Intensity(RIC) 
Conditioning and Transplantation of Double Unrelated Umbilical Cord 
Blood (dUCB) versus HLA -Haploidentical Related Bone Marrow for 
Patients with Hematologic Malignancies  
Protocol : BMT CTN  1101 
 
A. Why am I here ? 
Your bone marrow is a match for a person in your family who needs a transplant. Your bone 
marrow grows inside your bones. It helps your body make blood and keeps you healthy. A 
transplant will collect some of your marrow and give it to a person who needs it to make new, healthy cells. Your body will make more marrow afterwards.  
If you give us your permission, we would like t o have  an extra sample of your blood. We 
would collect the extra sample at the same time you have other blood tests done. We want to save the samples and use them for research in the future.  
 
B. Why are you collecting an extra sample of blood ? 
Research with blood samples will help us learn more about transplant and other diseases. We 
will keep all of the extra samples private and store them in a place called a Repository. Your 
name will not be on the samples. Doctors and other researchers can ask to use the s amples in 
the Repository as a part of their research.  
 
C. What will happen to me? 
If you say it is OK for us to collect an  extra blood sample for research , we will ask you for:  
 An e xtra blood sample. We would collect the extra sample at the same time as you 
have other blood tests done .  
We will watch you carefully for side effects, fevers, infections or other problems.  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
B-41  
D. Will it hurt?  
When you have your blood taken with a needle, it may feel like a pinch. It will hurt for a 
minute and sometimes the place where the needle went might be red and sore. You might get 
a little bruise from the needle but it goes away in a few days.  
 
E. Will the study  help me?  
Giving the blood sample for research will not help you.  
 
F. What if I have questions ? 
You can ask an y questions that you have about giving an extra blood sample . If you forget to 
ask a question and thi nk of it later, you can call [ insert office number ].   
  
G. Do I have to be in this study?  
If you do not want to give an extra blood sample, you need to tell us and your parent or 
guardian. Your doctor will not be angry or upset if you do not w ant to join. You can still give 
bone marrow to the person in your family who needs it. They will still get the exact same care.  
You can say yes now and change your mind at any time.   
Please talk this over with your parents before you decide if you want to give an extra blood 
sample for research . We will also ask your parents to give their permission for you to give an 
extra sample for research .  
 
Writing your name on this page means that you agree to give an extra blood sample and know 
what will happen to you. If you change your mind, all you have to do is tell the person in charge.  
You and your parent or guardian will get a copy of this form after  you sign it. 
             
Signature  of Child        Date   
 
             
Signature of Researcher       Date  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
C-1  
               
 
 
APPENDIX C  
 
LABORATORY PROCEDURES  
 
OPTIONAL RESEARCH SPECIMENS 
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
C-2 APPENDIX C  
 
LABORATORY PROCEDURES  
 
OPTIONAL RESEARCH SPECIMENS  
 
Patients consenting to the optional future research will have samples collected for future, 
undefined research supporting the protocol.  All research sample aliquots  will be given unique 
bar code designations that cannot be linked back to the participant ’s name or other identifying 
information .  Laboratory test results, clinical information, etc., associated with the coded samples 
are provided to the Investigator  only after completion of the protocol.  Samples sent to 
researchers cannot be linked with any remaining sample s at the repository.  
 Patient samples will be collected both prior to the initiation of treatment and at four post-treatment time points as specified  in the table  below.  Peripheral blood and bone marrow product 
samples w ill also be collected from HLA -haploindentical related donors and stored to support 
future research studies.  All research samples will be collected and shipped same- day to the BMT 
CTN Repository for processing and sample aliquot storage.  Sample collectio n and shipping 
procedures are detailed in the BMT CTN 1101 Laboratory Sample Guide.  
 
Optional  Research Samples  
Subject  Research 
Sample Type  Time Points  Sample 
Quantity  Sample 
Processing & 
Storage Site  Stored 
Material  Purpose  
HLA -
Haploidentical 
Related Donor  Peripheral 
Blood Pre-BM 
Donation  50 mL  
(donors 
<50kg 1 
mL/kg up to 
50kg)  BMT CTN 
Repository  Plasma  
Undefined 
Future 
Research  Viable PBMC  
Stem Cell 
Product  
(BM)  
(Donors ≥18 
only)  Product to 
be Infused  3-5 mL  BMT CTN 
Repository  Viable BMMC  
Patient  Peripheral 
Blood Pre-
conditioning  50 mL    
(patients 
<50kg 1 
mL/k g up to 
50 Kg  BMT CTN 
Repository  Plasma  
Undefined 
Future 
Research  Viable PBMC  
Granulocytes  
Post-
transplant          
Day 28, 56, 
180, 365  50 mL    
(patients 
<50kg 1 
mL/kg up to 
50 kg) BMT CTN Repository  Plasma  
Viable PBMC  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
D-1  
        
 
         
APPENDIX D  
 
APPROVED CYTOTOXIC CHEMOTHERAPY REGIMENS  
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
D-2 APPENDIX D  
 
APPROVED CYTOTOXIC CHEMOTHERAPY REGIMENS  
 
Patients must have received either  
a. At least one cycle of at least one of the following cytotoxic chemotherapy regimens 
(or regimen of similar intensity) within 3 months of enrollment (measured from the start date of chemotherapy)  
i. Multi- agent chemotherapy (e.g. CVP±R, CHOP±R, ICE±R, DHAP±R, 
ESHAP±R, …)  
ii. Chemotherapy regimens like those that are given as i nduction or 
consolidation of acute leukemia  (7+3, HiDAc, mitoxantrone+etoposide, 
FLAG, FLIG, and others)  
iii. Single drug alkylator agent (cyclophosphamide ≥1.5 g/m
2 or equivalent ) 
iv. Bendamustine   
v. Single agent alemtuzumab or brentuximab vedotin 
Antineoplasti c agents that are  not considered adequate cytotoxic chemotherapy 
include:  
i. Single agent steroids  
ii. Single agent monoclonal antibody ± steroids with the exception of 
alemtuzumab  
iii. Single  agent hypomethylating agent (e.g. azacytidine)  
iv. Single agent antimetabolite ± steroids (e.g. low dose methotrexate, low dose cytarabine)  
v. Single agent proteasome inhibitor ± monoclonal antibody  (except for 
alemtuzumab or brentuximab vedotin)  ± steroids  
vi. Hydr oxyurea  
vii. Localized radiation therapy   
viii. Interferon
 
b.  Autologous hematopoietic stem cell transplantation < 2 years prior to enrollment.   
Please consult with the protocol chairs for any drugs or regimens not listed above .
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
E-1  
                  
APPENDIX E  
 
REFERENCES  
  
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
E-2 APPENDIX E  
 
REFERENCES  
 
                                                 
1 Giralt S, Logan B, Rizzo D et al. Reduced -intensity conditioning for unrelated donor progenitor 
cell transplantation: long -term follow -up of the first 285 reported to the national marrow 
donor program. Biol.Blood Marrow Transplant. 2007;13:844- 852. 
2 Platzbecker U, Thiede C, Fussel M et al. Reduced intensity conditioning allows for up- front 
allogeneic hematopoietic stem cell transplantation after cytoreductive induction  therapy in 
newly -diagnosed high- risk acute myeloid leukemia. Leukemia 2006;20:707- 714. 
3 Popat U, Heslop HE, Durett A et al. Outcome of reduced- intensity allogeneic hematopoietic 
stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high -risk 
acute myeloid leukemia (AML). Bone Marrow Transplant 2006;37:547- 552. 
4 Grigg AP, Gibson J, Bardy PG et al. A Prospective Multicenter Trial of Peripheral Blood Stem 
Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remis sion Using 
Fludarabine -Cyclophosphamide Reduced Intensity Conditioning. Biol.Blood Marrow 
Transplant. 2007;13:560- 567. 
5 Oran B, Giralt S, Saliba R et al. Allogeneic Hematopoietic Stem Cell Transplantation for the 
Treatment of High -Risk Acute Myelogenous L eukemia and Myelodysplastic Syndrome Using 
Reduced -Intensity Conditioning with Fludarabine and Melphalan. Biol.Blood Marrow 
Transplant. 2007;13:454- 462. 
6 Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell 
transplantation: Marro w or umbilical cord blood? Blood 2003;101:4233- 4244. 
7 Ballen KK, Spitzer TR, Yeap BY et al. Double unrelated reduced -intensity umbilical cord 
blood transplantation in adults. Biol.Blood Marrow Transplant. 2007;13:82- 89. 
8 Barker JN, Weisdorf DJ, Defor TE et al. Rapid and complete donor chimerism in adult 
recipients of unrelated donor umbilical cord blood transplantation after reduced -intensity 
conditioning. Blood 2003;102:1915- 1919. 
9 Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transpl antation after 
nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with 
hematologic disease. Blood 2007;110:3064- 3070. 
10 Misawa M, Kai S, Okada M et al. Reduced -intensity conditioning followed by unrelated 
umbilical cord blood t ransplantation for advanced hematologic malignancies: rapid 
engraftment in bone marrow. Int.J Hematol. 2006;83:74- 79. 
11 Miyakoshi S, Yuji K, Kami M et al. Successful Engraftment After Reduced- Intensity 
Umbilical Cord Blood Transplantation for Adult Patient s with Advanced Hematological 
Diseases. Clin Cancer Res 2004;10:3586- 3592. 
12 Luznik L, O'Donnell PV, Symons HJ et al. HLA -Haploidentical Bone Marrow Transplantation 
for Hematologic Malignancies Using Nonmyeloablative Conditioning and High- Dose, 
Posttranspl antation Cyclophosphamide. Biol.Blood Marrow Transplant. 2008;14:641- 650. 
BMT CLINICAL TRIALS NETWORK   RIC dUCB versus Haplo BM –  Protocol # 1101  
  Version 8.0 dated January 18, 2017  
 
 
E-3                                                                                                                                                              
13 Salit, RB, Milano F, Gutman JA, Maris MB, Chauncey T, Peterson F, Delaney C.  Umbilical 
Cord Blood Transplant Patients At High Risk of Graft Rejection Achieve Early Full Donor 
Chim erism When 200 cGy Is Used In The Reduced Intensity Conditioning Regimen. Blood 
November 15, 2013. Vol 122 no. 21 Abstract #697  
14 Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Peterson FB, Sandmaier BM, 
Storb R, Delaney C. Bone Marrow Transplant ation. 2013;48:782- 786. 
15 Eapen M, O’Donnell P, Brunstein C, Wu J, Barowski K, Mendizabal A, Fuchs E.  Mismatched 
Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplant; In Press, Corrected Proof.  
16 Brown JA, Boussiotis VA. Umbilical cord blood transplantation: Basic biology and clinical 
challenges to immune reconstitution. Clinical Immunology;In Press, Corrected Proof.  
17 Komanduri KV, John LS, de Lima M  et al. Delayed immune reconstitution after cord blood 
transplantation is characterized by impaired thymopoiesis and late memory T -cell skewing. 
Blood 2007;110:4543- 4551. 
18 Safdar A, Rodriguez GH, De Lima MJ et al. Infections in 100 cord blood transplantat ions: 
spectrum of early and late posttransplant infections in adult and pediatric patients 1996- 2005. 
Medicine (Baltimore) 2007;86:324- 333. 
19 Confer D, Robinett P. The US National Marrow Donor Program role in unrelated donor 
hematopoietic cell transplantation. Bone Marrow Transplant 2008;42 Suppl 1:S3- S5. 
20 Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers M E, 
Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ.  Blood. 2011 Oct 13;118(15):4242- 9.  
21 Gu M, Follmann D, Geller NL. Monitoring a general class of two- sample survival statistics 
with applications. Biometrika 1999, 86: 45- 57. 
22 Jennison C, Turnbull BW.  Group sequential methods with applications to clinical trials.  
Chapman and Hall/CRC, Boca Raton, 2000. 
23 Logan, B.R., Klein, J.P., and Zhang, M.- J.  Comparing treatments in the presence of crossing 
survival curves: an application to bone marrow transplantation.  Biometrics, 64: 733- 740, 
2008. 
24 Zhang X, Loberiza FR, Klein JP, Zhang M -J. A SAS macro for estimation of direct adjusted 
survival curves based on a s tratified Cox regression model.  Computer methods and programs 
in biomedicine 2007; 88: 95- 101. 
25 Gray RJ.  A class of K -sample tests for comparing the cumulative  incidence of a competing 
risk. Annals of Statistics 1988, 16: 1141- 1154. 
26 Kurland BF, Heagerty PJ Directly parameterized regression conditioning on being alive: 
analysis of longitudinal data truncated by deaths, Biostatistics 6: 241 -258, 2005.)  